---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence. Covers COMP005, COMP006, COMP001, COMP004, COMP003, PsiDeR, and 1 further heading. 370 evidence topics quoted from 66 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 COMP005

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Primary aim: single dose of COMP360 25 mg versus placebo with psychological support

> “Efficacy, Safety, and Tolerability of a single administration of COMP360 in participants with treatment-resistant depression (TRD)”
> “In this study, the primary aim is to assess the efficacy and safety of a single dose of COMP360 25 mg versus placebo for reducing symptom severity in TRD, when administered with psychological support.”

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

<a id="topic-3.1.1.1-2"></a>

###### Secondary aims: durability, long-term safety, and retreatment

> “Durability of efficacy and long-term safety, and the efficacy and safety of re-treatment will be assessed in a 20-week single-dose, double-blind re-treatment part (Part B), and a 26-week open-label treatment part (Part C).”

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

> “We believe that this design will enable us to appropriately characterize the efficacy, safety and durability of COMP360 administration.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Study dates in the registry record

| Milestone | Registry entry |
| --- | --- |
| Study start (actual) | “2023-01-24” |
| Primary completion (actual) | “2025-05-28” |
| Study completion (actual) | “2026-04-15” |

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

<a id="topic-3.1.1.2-2"></a>

###### Number of sites: registry and Form 10-K

> “This study has 40 locations”

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

> “The first pivotal trial, COMP005, is a randomized, double-blind, placebo-controlled study, with 258 dosed participants across 40 trial sites in the United States”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.1.2-3"></a>

###### Number of sites: June 2025 Form 8-K

> “The ongoing COMP005 trial is a randomized, double-blinded, placebo-controlled study, which has dosed 258 participants with moderate-to-severe depression across 32 sites in the United States”

Source: [COMPASS Pathways Form 8-K COMP005 topline (2025)](https://www.sec.gov/Archives/edgar/data/1816590/000181659025000085/cmps-20250623.htm)

<a id="topic-3.1.1.2-4"></a>

###### Timing of Part A completion

> “Part A, which concluded during the second quarter of 2025, and was blinded through 6 weeks”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Phase 3 randomized, double-blind, placebo-controlled, parallel-group design

> “This is a phase III, international, multi-centre, randomised, parallel group, fixed single-dose, double-blind, placebo-controlled study.”
> “The study comprises three parts (A, B, and C) and will last approximately 62 weeks including a three- to ten-week Screening Period.”
> “Part A will include a six-week follow-up from initial investigational product (IP) administration.”

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

| Design element | Registry entry |
| --- | --- |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple” |
| Primary purpose | “Treatment” |

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

<a id="topic-3.1.1.3-2"></a>

###### Parts A, B, and C as described in the 52-week release

> “In Part A, blinded through Week 6, eligible participants were randomized (2:1) to receive a single dose of 25 mg of COMP360 or placebo”
> “In Part B, blinded from Weeks 6 to 26, eligible participants could receive an additional dose of the same treatment to which they were originally randomized”
> “In Part C, open-label from Week 26 to 52, eligible participants from both dosing arms could receive a single dose of 25 mg”
> “There was a potential for a total of 3 doses of COMP360 across a 52-week period.”

Source: [COMPASS Pathways COMP005 52-week release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-New-52-Week-Topline-Open-Label-Data-from-Phase-3-COMP005-Trial-Demonstrates-Additional-Benefit-from-Another-COMP360-Dose-in-Part-C-Extending-Durability-Out-to-1-Year/default.aspx)

<a id="topic-3.1.1.3-3"></a>

###### Retreatment criteria in Parts B and C

> “In Part B (20 weeks), participants could receive a second administration if they did not achieve remission at Week 6 or subsequently met criteria for relapse.”

Source: [Psych Congress Elevate COMP005 26-week abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378888)

> “During Part B, based on pre-specified criteria, participants were eligible either for a second administration of the treatment to which they were randomized or to resume antidepressants.”
> “Participants who complete part B and go into Part C during which participants who meet criteria for re-treatment may receive a 25mg dose of COMP360 psilocybin.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

> “COMP360 25mg treatment (one dose only after relapse or for non-remitters from Part B)”
> “Re-dosing for non-remitters from Part A or Part B could occur several weeks after transition to Part B or Part C, respectively, due to scheduling requirements.”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.1.3-4"></a>

###### Concomitant antidepressants permitted after Part A

> “Participants were permitted to take protocol-allowed antidepressant treatments in Part B and C of the study.”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.1.3-5"></a>

###### Timing of the 26-week data disclosure

> “Compass Pathways anticipates sharing 26-week data for COMP005 once all participants in the COMP006 trial have completed part A of the COMP006 trial.”

Source: [COMPASS Pathways Form 8-K COMP005 topline (2025)](https://www.sec.gov/Archives/edgar/data/1816590/000181659025000085/cmps-20250623.htm)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Population described by the company

> “Adults with TRD (2-4 inadequate prior treatment responses) were randomized 2:1 to single administration of COMP360 25 mg or placebo in Part A (6 weeks).”

Source: [Psych Congress Elevate COMP005 26-week abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378888)

<a id="topic-3.1.1.4-2"></a>

###### Key inclusion criteria

> “Aged ≥18 years at Screening”
> “Major depression without psychotic features (single or recurrent episode as informed by the Diagnostic and Statistical Manual of Mental Disorders, 5th edition”
> “If the current major depressive episode is the participant's first lifetime episode of depression, the length of the current episode must be ≥3 months and ≤2 years at Screening”
> “MADRS total score ≥20 at Screening and Baseline to ensure at least moderate severity of depression”
> “TRD, defined as failure to respond to an adequate dose and duration of two, three, or four different pharmacological treatments for the current episode as determined through the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and using the supplementary advice on additional antidepressants not included in MGH-ATRQ.”
> “At Screening, agreement to discontinue all prohibited medications.”

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

<a id="topic-3.1.1.4-3"></a>

###### Key psychiatric exclusion criteria

> “Prior or ongoing bipolar disorder, any psychotic disorder, including schizophrenia, schizophreniform disorder, schizoaffective disorder, brief psychotic disorder (unless substance induced or due to a medical condition), antisocial personality disorder as assessed by a structured clinical interview (MINI 7.0.2)”
> “Lifetime paranoid, schizoid, schizotypal, histrionic, narcissistic personality disorder, or any ongoing serious psychiatric comorbidity based on medical history and clinical judgement”
> “Borderline personality disorder as demonstrated by medical history or the Mini International Neuropsychiatric Interview Plus (MINI plus) - borderline personality disorder module”
> “Ongoing post-traumatic stress disorder, obsessive-compulsive disorder, or anorexia nervosa as assessed by medical history and a structured clinical interview (MINI 7.0.2)”
> “Psychiatric inpatient within the past 12 months prior to Screening”

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

<a id="topic-3.1.1.4-4"></a>

###### Exclusions for prior neuromodulation, psychotherapy, and psilocybin exposure

> “Use of electroconvulsive therapy, deep brain stimulation, or vagus nerve stimulation during the current depressive episode”
> “Transcranial magnetic stimulation within the past six months prior to Screening”
> “Current enrolment in a psychological therapy programme that will not remain stable for the duration of the study. Psychological therapies cannot have been initiated within 30 days prior to Screening”
> “Exposure to COMP360 psilocybin therapy prior to Screening”

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Study arms

| Arm | Registry description |
| --- | --- |
| Experimental | “25 mg COMP360 Psilocybin” |
| Placebo comparator | “Matched placebo” |
| Intervention | “COMP360 Psilocybin administered under supportive conditions” |

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

<a id="topic-3.1.1.5-2"></a>

###### Dosing by study part

> “Overall, 255 participants will be randomised in a 2:1 ratio to receive COMP360 25 mg or placebo.”

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

> “In Part B, participants who complete Part A will be followed for 20 weeks and those who meet criteria for re-treatment will have the option to receive an additional treatment dose according to their assigned dose.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.1.5-3"></a>

###### Psychological support and monitoring model in the trials

> “Our trial protocols provide that such support is delivered over three different phases: preparation, the COMP360 administration session, and post-administration follow-up.”
> “A COMP360 administration session lasts approximately six to eight hours and at least one healthcare professional is present throughout the session to monitor and safeguard participants in our clinical trials.”
> “Patients wear eye shades to help them focus internally, lie on a bed, and listen to a carefully curated music playlist through a high-quality sound system and earphones.”
> “In our clinical trials, healthcare professionals refrain from intervening with the patient’s experience, unless required for safety reasons.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Montgomery-Åsberg Depression Rating Scale Total Score as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Primary endpoint as defined by the sponsor

> “The primary endpoint is the difference in change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) scores between the active treatment group and the placebo group at week 6.”

Source: [COMPASS Pathways Form 8-K COMP005 topline (2025)](https://www.sec.gov/Archives/edgar/data/1816590/000181659025000085/cmps-20250623.htm)

> “COMP360 25 mg versus placebo for the change from baseline in MADRS total score”
> “Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item clinician rated scale measuring depression severity”

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

<a id="topic-3.1.1.6.1-2"></a>

###### Key secondary endpoint: Sheehan Disability Scale at Week 6

> “COMP360 25 mg versus placebo for the change from baseline in SDS total score”
> “Sheehan Disability Scale (SDS) is a brief, five-item self report inventory that assesses functional impairment in work/school, social life, and family life.”

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

<a id="topic-3.1.1.6.1-3"></a>

###### Development and validation of the MADRS

> “The construction of a depression rating scale designed to be particularly sensitive to treatment effects is described.”
> “The inner-rater reliability of the new depression scale was high. Scores on the scale correlated significantly with scores on a standard rating scale for depression, the Hamilton Rating Scale (HRS), indicating its validity as a general severity estimate. Its capacity to differentiate between responders and non-responders to antidepressant treatment was better than the HRS, indicating greater sensitivity to change.”

Source: [Montgomery and Asberg (1979)](https://pubmed.ncbi.nlm.nih.gov/444788/)

<a id="topic-3.1.1.6.1-4"></a>

###### FDA guidance on primary and secondary endpoints in MDD trials

> “Clinician-rated outcome measures are the current standard for assessing efficacy in”
> “To date, the FDA has accepted the following as primary endpoints in phase”
> “Montgomery Asberg Depression Rating Scale”
> “Secondary endpoints assess other domains of symptom improvement relevant for labeling.”
> “Sheehan Disability Scale”

Source: [FDA (2018)](https://www.fda.gov/media/113988/download)

<a id="topic-3.1.1.6.1-5"></a>

###### FDA guidance on the timing of the primary endpoint and durability

> “Thus, we consider 6 to 8 weeks an appropriate study”
> “Efficacy generally should be demonstrated within 1 week for a rapid-acting”
> “Durability of effect beyond the initial response should be characterized.”

Source: [FDA (2018)](https://www.fda.gov/media/113988/download)

<a id="topic-3.1.1.6.1-6"></a>

###### European Medicines Agency guidance on rating scales

> “Acceptable scales to determine symptomatic improvement include the Hamilton Rating Scale of Depression (HDRS), preferably the 17-item scale, and the Montgomery-Asberg Depression Rating Scale (MADRS), however other validated scales might be acceptable as well.”
> “For rapid acting antidepressants it is anticipated that specific scales, other than the most commonly used MADRS, will be developed and validated, in order to be able to fully capture the rapid onset of effect.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

<a id="topic-3.1.1.6.1-7"></a>

###### MADRS total score as the primary efficacy measure in FDA-approved labeling for esketamine in TRD

> “In Study 1, the primary efficacy measure was change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at the end of the 4-week double-blind induction phase. The MADRS is a ten-item, clinician-rated scale used to assess severity of depressive symptoms. Scores on the MADRS range from 0 to 60, with higher scores indicating more severe depression.”

Source: [Spravato prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s019lbl.pdf)

<a id="topic-3.1.1.6.1-8"></a>

###### Outcomes named in the ICER draft scope

> “Depressive symptom improvement (e.g., Montgomery–Åsberg Depression Rating Scale [MADRS])”
> “Rate of response, remission, and relapse”
> “Improvements in functional outcomes (e.g., Sheehan Disability Scale [SDS])”

Source: [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_TRD_Draft-Scope_For-Publication_102126-1.pdf)

<a id="topic-3.1.1.6.1-9"></a>

###### Minimal clinically important difference on the MADRS

> “To identify the minimal clinically important difference (MCID) for the Montgomery-Asberg Depression Rating Scale (MADRS) in randomised studies of depression, and to cross-validate the estimated MCID.”
> “MCID estimates for MADRS ranged from 1.6 to 1.9.”

Source: [Duru and Fantino (2008)](https://pubmed.ncbi.nlm.nih.gov/18377706/)

<a id="topic-3.1.1.6.1-10"></a>

###### Clinically meaningful change on the MADRS and SDS in TRD

> “Clinically meaningful changes in CGI‐S scores after 28 days corresponded to 6‐, 4‐, and 3‐point changes from baseline on the MADRS, SDS, and PHQ‐9, respectively. Similarly, a 2‐point CGI‐S score change (clinically substantial change) corresponded to a 12‐, 8‐, and 6‐point change on the MADRS, SDS, and PHQ‐9, respectively.”
> “The relationships between the CGI‐S and the MADRS, SDS and PHQ‐9 were established in a moderately severe TRD population and may not be generalizable to severely ill subjects.”

Source: [Turkoz et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7986932/)

<a id="topic-3.1.1.6.1-11"></a>

###### Clinical meaning of MADRS response and remission thresholds

> “Our results confirm the validity of the commonly used measures for response in MDD trials: a CGI-I score of 2 ('much improved') corresponded to a percentage MADRS reduction from baseline of 48-57%, and a CGI-I score of 1 ('very much improved') to a reduction of 80-84%.”
> “If a state of almost complete absence of symptoms were required for a definition of remission, a MADRS total score would be <8, because such scores corresponded to a CGI-S score of 2 ('borderline mentally ill').”

Source: [Leucht et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28068617/)

> “No consensus has emerged regarding an appropriate cutoff for defining remission on the Montgomery-Asberg Depression Rating Scale (MADRS).”
> “On the basis of a narrow definition of remission, which requires a complete absence of clinically significant symptoms of depression, the optimal MADRS cutoff was < or = 4. On the basis of a broader definition, the optimal cutoff was < or = 9.”

Source: [Zimmerman et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15003068/)

<a id="topic-3.1.1.6.1-12"></a>

###### Response and remission definitions used by the company

> “Responder: ≥50% decrease in total score from baseline”
> “Remitter: ≤12 MADRS total score and no single item ≥4”

Source: [COMPASS Pathways COMP005 52-week release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-New-52-Week-Topline-Open-Label-Data-from-Phase-3-COMP005-Trial-Demonstrates-Additional-Benefit-from-Another-COMP360-Dose-in-Part-C-Extending-Durability-Out-to-1-Year/default.aspx)

> “Clinically meaningful reduction in MADRS defined as a >25% reduction from baseline in MADRS total score at Week 6. This graph is a post hoc analysis.”
> “Remitters (n=11) = MADRS ≤12 and no single item ≥4; Responders and Partial Responders (n=31) = % CFB in MADRS ≥ 25% and do not meet remission criterion; Non-Responder (n=115) = % CFB in MADRS ≤ 25%”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Planned enrollment

> “Overall, 255 participants will be randomised in a 2:1 ratio to receive COMP360 25 mg or placebo.”

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

<a id="topic-3.1.1.7.1-2"></a>

###### Participants dosed in Part A

> “The ongoing COMP005 trial is a randomized, double-blind, placebo-controlled study, with 258 dosed participants across the United States and is assessing the efficacy and safety of a single dose of 25 mg COMP360 versus placebo for reducing symptom severity in TRD (COMP360 25 mg: n=171; placebo: n=87).”

Source: [COMPASS Pathways Form 8-K COMP006 topline (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm)

> “A total of 258 participants received COMP360 (n=171) or placebo (n=87) in Part A.”

Source: [Psych Congress Elevate COMP005 26-week abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378888)

<a id="topic-3.1.1.7.1-3"></a>

###### Participants analyzed at Week 6 in the 25 mg arm

> “Total n at 6 weeks = 157 (based on ITT)”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.1.7.1-4"></a>

###### Participants dosed in open-label Part C

> “Response/remission rates based on the 142 participants (n=90 from 25mg arm, n=52 from original Placebo arm) who received a 25mg dose in Part C.”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Safety analysis set

> “N=number of participants in the treatment group in the Safety Analysis Set by administration; n = number of participants; TEAE = treatment emergent adverse event”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.1.7.2-2"></a>

###### Efficacy analyses by study part

> “Least square mean in Part A. Observed mean in Part B and C”
> “No statistical analyses performed after the primary analysis at Week 6”
> “COMP 005 Part B (post Week 6) and COMP 006 Part B (post Week 9) results are based on observed data only (CFB Mean ± 95% CI).”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

> “Descriptive statistics for MADRS change were assessed through Week 26.”

Source: [Psych Congress Elevate COMP005 26-week abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378888)

<a id="topic-3.1.1.7.2-3"></a>

###### Post hoc responder analysis and Part C percentages

> “This graph is a post hoc analysis. Total n at 6 weeks = 157 (based on ITT)”
> “Percentages are based on the number of observed participants at the visit”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Randomized and dosed participants

> “A total of 258 participants received COMP360 (n=171) or placebo (n=87) in Part A.”

Source: [Psych Congress Elevate COMP005 26-week abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378888)

<a id="topic-3.1.1.8.1-2"></a>

###### Participants in the 25 mg arm at Week 6

> “Total n at 6 weeks = 157 (8% dropout)”

Source: [COMPASS Pathways COMP006 topline presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/exhibit991investorpresen.htm)

<a id="topic-3.1.1.8.1-3"></a>

###### Second administration in Part B

> “Second dosing occurred in 70% (COMP360) and 53% (placebo).”

Source: [Psych Congress Elevate COMP005 26-week abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378888)

<a id="topic-3.1.1.8.1-4"></a>

###### Entry into and dosing in open-label Part C

> “Approximately 70% of the study participants continued beyond Week 26 and entered Part C”
> “25 mg Arm: Approximately 80% (n=90) who entered Part C received an additional open-label dose; this was their second or third dose depending on whether they received an additional dose in Part B”
> “Placebo Arm: Approximately 90% (n=52) who entered Part C received an open-label 25 mg dose; this was their first dose of COMP360 25 mg given they received placebo in parts A and B”

Source: [COMPASS Pathways COMP005 52-week release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-New-52-Week-Topline-Open-Label-Data-from-Phase-3-COMP005-Trial-Demonstrates-Additional-Benefit-from-Another-COMP360-Dose-in-Part-C-Extending-Durability-Out-to-1-Year/default.aspx)

> “118 participants from 25mg arm entered Part C and 113 of those met eligibility criteria for open-label treatment of which 90 (80%) were dosed”
> “61 participants from Placebo arm entered Part C and 58 of those met eligibility criteria for open-label treatment of which 52 (90%) were dosed”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Demographics

| Characteristic | COMP360 25 mg (N=171) | Placebo (N=87) |
| --- | --- | --- |
| Female, n (%) | “93 (54.4)” | “47 (54.0)” |
| White, n (%) | “149 (87.1)” | “78 (89.7)” |
| Asian, n (%) | “11 (6.4)” | “4 (4.6)” |
| Black or African American, n (%) | “6 (3.5)” | “2 (2.3)” |
| American Indian or Alaska Native, n (%) | “0” | “1 (1.1)” |
| Other race, n (%) | “5 (2.9)” | “2 (2.3)” |
| Age, years, mean (SD) | “45.9 (13.4)” | “45.3 (14.4)” |
| Age, years, minimum and maximum | “19, 77” | “22, 72” |
| Age ≥65 years, n (%) | “15 (8.8)” | “11 (12.6)” |
| Prior psilocybin experience, n (%) | “5 (2.9)” | “5 (5.7)” |
| Prior psychedelic experience including psilocybin, n (%) | “8 (4.7)” | “6 (6.9)” |
| BMI, kg/m2, mean (SD) | “28.4 (6.2)” | “27.7 (6.1)” |

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.1.8.2-2"></a>

###### Treatment history and baseline MADRS

| Characteristic | COMP360 25 mg (N=171) | Placebo (N=87) |
| --- | --- | --- |
| Failed treatments in current episode: 1, n (%) | “2 (1.2)” | “1 (1.1)” |
| Failed treatments in current episode: 2, n (%) | “114 (66.7)” | “62 (71.3)” |
| Failed treatments in current episode: 3, n (%) | “45 (26.3)” | “19 (21.8)” |
| Failed treatments in current episode: 4, n (%) | “10 (5.8)” | “4 (4.6)” |
| Failed treatments in current episode: 5, n (%) | “0” | “1 (1.1)” |
| Treatments withdrawn in screening: 0, n (%) | “58 (33.9)” | “26 (29.9)” |
| Treatments withdrawn in screening: 1, n (%) | “38 (22.2)” | “32 (36.8)” |
| Treatments withdrawn in screening: 2, n (%) | “50 (29.2)” | “21 (24.1)” |
| Treatments withdrawn in screening: more than 2, n (%) | “25 (14.6)” | “8 (9.2)” |
| MADRS total score at baseline, mean (SD) | “31.5 (5.5)” | “31.5 (5.9)” |
| Mild (11-19), n (%) | “1 (0.6)” | “2 (2.3)” |
| Moderate (20-30), n (%) | “73 (42.7)” | “33 (37.9)” |
| Severe (≥31), n (%) | “97 (56.7)” | “52 (59.8)” |

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.1.8.2-3"></a>

###### Depression diagnosis history

| Characteristic | COMP360 25 mg (N=171) | Placebo (N=87) |
| --- | --- | --- |
| Length of current episode, months, mean (SD) | “34.1 (29.1)” | “38.6 (33.0)” |
| Current episode less than 1 year, n (%) | “30 (17.5)” | “20 (23.0)” |
| Current episode 1-2 years, n (%) | “52 (30.4)” | “19 (21.8)” |
| Current episode more than 2 years, n (%) | “89 (52.0)” | “48 (55.2)” |
| Lifetime depressive episodes, mean (SD) | “7.7 (10.9)” | “7.2 (7.6)” |
| Lifetime episodes 2-5, n (%) | “107 (62.6)” | “54 (62.1)” |
| Lifetime episodes 6-10, n (%) | “40 (23.4)” | “21 (24.1)” |
| Lifetime episodes more than 10, n (%) | “23 (13.5)” | “12 (13.8)” |

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### Part A: primary endpoint, change in MADRS total score at Week 6

> “A single dose of COMP360 25 mg versus placebo demonstrated a highly statistically significant reduction in symptom severity with a p-value of p<0.001 and a clinically meaningful difference of -3.6 in change at the primary endpoint.”
> “Efficacy Data (MADRS): Single dose of COMP360 25 mg versus placebo with a mean treatment difference of -3.6 points, 95% CI[ -5.7, -1.5]; p<0.001”

Source: [COMPASS Pathways Form 8-K COMP005 topline (2025)](https://www.sec.gov/Archives/edgar/data/1816590/000181659025000085/cmps-20250623.htm)

> “In COMP005, COMP360 25 mg significantly reduced MADRS scores versus placebo at Week 6 (LSMD: -3.6; 95% CI: -5.7, -1.5;”

Source: [Psych Congress Elevate phase 3 primary endpoint abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378891)

<a id="topic-3.1.1.8.3-2"></a>

###### Part A: least squares mean differences in MADRS by visit

| Visit | COMP360 25 mg vs placebo, LS mean difference (95% CI), p-value |
| --- | --- |
| Day 2 | “-4.7 (-7.0, -2.3), p<0.001” |
| Week 1 | “-7.2 (-9.6, -4.8), p<0.001” |
| Week 3 | “-5.2 (-7.4, -2.9), p<0.001” |
| Week 6 (primary) | “-3.6 (-5.7, -1.5), p<0.001” |

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

> “Statistical significance at all timepoints beginning the day after administration (Day 2) demonstrates rapid onset of action”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.1.8.3-3"></a>

###### Part A: post hoc analysis of participants with at least 25% MADRS reduction at Week 6

> “For participants who had a clinically meaningful reduction in MADRS (≥ 25%), a statistically significant rapid onset from the day following administration was maintained at all measured timepoints through Week 6 in the 25 mg arm”
> “25% of participants in the 25 mg arm achieved a clinically meaningful reduction in MADRS (≥ 25%) at Week 6 with durability lasting out through 26 weeks after just one or two doses of 25 mg”

Source: [COMPASS Pathways Form 8-K COMP006 topline (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm)

> “Remitters (n=11) = MADRS ≤12 and no single item ≥4; Responders and Partial Responders (n=31) = % CFB in MADRS ≥ 25% and do not meet remission criterion; Non-Responder (n=115) = % CFB in MADRS ≤ 25%”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.1.8.3-4"></a>

###### Part B: blinded follow-up and retreatment through Week 26

> “During Part B, numerical separation from placebo was maintained through Week 26.”
> “Reductions in MADRS total scores following one or two administrations of COMP360 25 mg were observed to be rapid and sustained for at least 26 weeks.”

Source: [Psych Congress Elevate COMP005 26-week abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378888)

> “Through the randomized and blinded Part B up to week 26, the results show that there was a consistent separation between 25 mg of COMP360 and placebo.”
> “During Part B, 70% of participants in the 25mg arm and 53% of participants in the placebo arm received a second administration.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.1.8.3-5"></a>

###### Part B: remission after a second dose among Week 6 responders who had not remitted

> “Over 40% of those who achieved a clinically meaningful reduction in MADRS but had not remitted by 6 weeks went into remission after the second dose in Part B”

Source: [COMPASS Pathways Form 8-K COMP006 topline (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm)

<a id="topic-3.1.1.8.3-6"></a>

###### Part C: open-label 25 mg dose in participants originally randomized to 25 mg

> “Notable additional benefit observed at all Part C timepoints through Week 52, with additional meaningful reduction in MADRS beyond what had been observed in Parts A and B, with an average 13-point reduction from baseline at Week 52”

Source: [COMPASS Pathways COMP005 52-week release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-New-52-Week-Topline-Open-Label-Data-from-Phase-3-COMP005-Trial-Demonstrates-Additional-Benefit-from-Another-COMP360-Dose-in-Part-C-Extending-Durability-Out-to-1-Year/default.aspx)

> “Additional benefit observed after another Part C dose, for those in the 25mg arm, with average 13-point MADRS reduction from baseline at Week 52”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.1.8.3-7"></a>

###### Part C: first 25 mg dose in participants originally randomized to placebo

> “Meaningful average reduction of 10 points from baseline in MADRS at end of Part C from one dose”

Source: [COMPASS Pathways COMP005 52-week release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-New-52-Week-Topline-Open-Label-Data-from-Phase-3-COMP005-Trial-Demonstrates-Additional-Benefit-from-Another-COMP360-Dose-in-Part-C-Extending-Durability-Out-to-1-Year/default.aspx)

<a id="topic-3.1.1.8.3-8"></a>

###### Part C: response and remission after the open-label 25 mg dose

> “40%-45% response rates (Responder: ≥50% decrease in total score from baseline) were observed between Day 1 and Week 6 following COMP360 25 mg Part C treatment”
> “Approximately 30% remission rates (Remitter: ≤12 MADRS total score and no single item ≥4) were observed between Day 1 and Week 6 following COMP360 25 mg Part C treatment”

Source: [COMPASS Pathways COMP005 52-week release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-New-52-Week-Topline-Open-Label-Data-from-Phase-3-COMP005-Trial-Demonstrates-Additional-Benefit-from-Another-COMP360-Dose-in-Part-C-Extending-Durability-Out-to-1-Year/default.aspx)

> “Response/remission rates based on the 142 participants (n=90 from 25mg arm, n=52 from original Placebo arm) who received a 25mg dose in Part C.”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### Safety summary through Week 26

> “Most TEAEs occurred on the days of study drug administration (66%), with the vast majority (88%) resolving within a day”
> “Most common TEAEs reported were headache, nausea and visual hallucination”
> “There were 11 treatment-emergent serious adverse events (SAEs) from 8 participants (5%) overall”

Source: [COMPASS Pathways Form 8-K COMP006 topline (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm)

> “Common TEAEs included headache, nausea, and visual hallucination, primarily on dosing days and resolving within 24 hours. Eleven SAEs occurred in 8 participants (4.7%).”

Source: [Psych Congress Elevate COMP005 26-week abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378888)

<a id="topic-3.1.1.8.5-2"></a>

###### Treatment-emergent adverse events in Part A, through Week 6

| Event | COMP360 25 mg (N=171), n (%) | Placebo (N=87), n (%) |
| --- | --- | --- |
| Any TEAE up to Week 6 | “120 (70.2)” | “34 (39.1)” |
| Any serious TEAE up to Week 6 | “4 (2.3)” | “1 (1.1)” |
| Any TEAE with onset on day of dosing | “118 (69.0)” | “23 (26.4)” |
| Resolved within 1 day | “111 (64.9)” | “22 (25.3)” |
| Resolved after more than 1 and up to 2 days | “15 (8.8)” | “2 (2.3)” |
| Resolved after more than 2 days | “22 (12.9)” | “5 (5.7)” |

Source: [COMPASS Pathways COMP006 topline presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/exhibit991investorpresen.htm)

<a id="topic-3.1.1.8.5-3"></a>

###### Treatment-emergent adverse events in Part A with incidence above 5%

| MedDRA preferred term | COMP360 25 mg (N=171), n (%) | Placebo (N=87), n (%) |
| --- | --- | --- |
| Any TEAE | “86 (50.3)” | “12 (13.8)” |
| Headache | “42 (24.6)” | “10 (11.5)” |
| Nausea | “35 (20.5)” | “3 (3.4)” |
| Hallucination, visual | “24 (14.0)” | “0” |
| Anxiety | “14 (8.2)” | “2 (2.3)” |
| Dizziness | “10 (5.8)” | “2 (2.3)” |
| Illusion | “9 (5.3)” | “1 (1.1)” |

Source: [COMPASS Pathways COMP006 topline presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/exhibit991investorpresen.htm)

<a id="topic-3.1.1.8.5-4"></a>

###### Treatment-emergent serious adverse events in Part A

| MedDRA preferred term | COMP360 25 mg (N=171), n (%) | Placebo (N=87), n (%) |
| --- | --- | --- |
| Any SAE | “4 (2.3)” | “1 (1.1)” |
| Suicidal ideation | “2 (1.2)” | “0” |
| Depression suicidal | “1 (0.6)” | “0” |
| Major depression | “0” | “1 (1.1)” |
| Cellulitis | “1 (0.6)” | “0” |
| Diverticulitis | “1 (0.6)” | “0” |

Source: [COMPASS Pathways COMP006 topline presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/exhibit991investorpresen.htm)

<a id="topic-3.1.1.8.5-5"></a>

###### Treatment-emergent adverse events through Week 26

| Event | COMP360 25 mg (N=171), n (%) | Placebo (N=87), n (%) |
| --- | --- | --- |
| Any TEAE up to Week 26 | “145 (84.8)” | “52 (59.8)” |
| Any serious TEAE up to Week 26 | “8 (4.7)” | “2 (2.3)” |
| Any TEAE with onset on day of dosing | “121 (70.8” | “25 (28.7)” |
| Resolved within 1 day | “115 (67.3)” | “24 (27.6)” |
| Resolved after more than 1 and up to 2 days | “16 (9.4)” | “2 (2.3)” |
| Resolved after more than 2 days | “22 (12.9)” | “5 (5.7)” |

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

| MedDRA preferred term (incidence above 10% in the 25 mg arm) | COMP360 25 mg (N=171), n (%) | Placebo (N=87), n (%) |
| --- | --- | --- |
| Any TEAE | “145 (84.8)” | “52 (59.8)” |
| Headache | “61 (35.7)” | “16 (18.4)” |
| Nausea | “44 (25.7)” | “5 (5.7)” |
| Hallucination, visual | “27 (15.8)” | “0” |
| Anxiety | “22 (12.9)” | “3 (3.4)” |

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.1.8.5-6"></a>

###### Treatment-emergent serious adverse events through Week 26

| MedDRA preferred term | COMP360 25 mg (N=171), n (%) | Placebo (N=87), n (%) |
| --- | --- | --- |
| Any TESAE | “8 (4.7)” | “2 (2.3)” |
| Suicidal ideation | “4 (2.3)” | “0” |
| Depression suicidal | “1 (0.6)” | “0” |
| Major depression | “0” | “1 (1.1)” |
| Cellulitis | “1 (0.6)” | “0” |
| Diverticulitis | “1 (0.6)” | “0” |
| Urinary tract infection bacterial | “0” | “1 (1.1)” |
| Clavicle fracture | “1 (0.6)” | “0” |
| Rib fracture | “1 (0.6)” | “0” |
| Pneumothorax | “1 (0.6)” | “0” |
| Anaphylactic reaction | “1 (0.6)” | “0” |

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.1.8.5-7"></a>

###### Suicidality: data safety monitoring board statement, June 2025

> “Based on the latest review of the data for the 005 and 006 studies, safety findings are consistent with previous studies of COMP360 and there are no new or unexpected safety findings. From this review of the data, there is no evidence of a clinically meaningful imbalance between treatment arms in suicidality in either study.”

Source: [COMPASS Pathways Form 8-K COMP005 topline (2025)](https://www.sec.gov/Archives/edgar/data/1816590/000181659025000085/cmps-20250623.htm)

<a id="topic-3.1.1.8.5-8"></a>

###### Suicidality: serious adverse events across COMP005 and COMP006

> “Across both trials, for the data available to date, the rate for SAE suicidal ideation was less than 1%. There was only one event of SAE suicidal behavior, which occurred in the 1 mg arm in COMP006.”

Source: [COMPASS Pathways Form 8-K COMP006 topline (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm)

<a id="topic-3.1.1.8.5-9"></a>

###### Safety in open-label Part C

> “COMP360 safety profile in Part C is consistent with Parts A and B. COMP360 continues to demonstrate a generally well-tolerated and safe profile, with no new safety signals observed.”

Source: [COMPASS Pathways COMP005 52-week release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-New-52-Week-Topline-Open-Label-Data-from-Phase-3-COMP005-Trial-Demonstrates-Additional-Benefit-from-Another-COMP360-Dose-in-Part-C-Extending-Durability-Out-to-1-Year/default.aspx)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary: functional unblinding, placebo comparator, observed-case and open-label follow-up, preliminary data

COMP005 compared COMP360 25 mg with a matched placebo, and the company states that concerns about functional unblinding and expectancy bias could hinder the interpretability or regulatory acceptability of its trial data. A systematic review reports that psychedelic trials have generally not reported pre-trial expectancy or blinding success and argues that their effect sizes are likely over-estimated. No statistical analyses were performed after the Week 6 primary analysis: Part B and Part C results are observed data, the responder analysis is post hoc, and protocol-allowed antidepressants were permitted in Parts B and C. Part C was open-label and was entered by approximately 70% of participants. The results are preliminary, had not been reviewed by the FDA at the 2025 topline announcement, and are reported in company documents and congress abstracts.

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268); [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm); [Muthukumaraswamy et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34038314/); [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf); [COMPASS Pathways COMP005 52-week release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-New-52-Week-Topline-Open-Label-Data-from-Phase-3-COMP005-Trial-Demonstrates-Additional-Benefit-from-Another-COMP360-Dose-in-Part-C-Extending-Durability-Out-to-1-Year/default.aspx); [COMPASS Pathways Form 8-K COMP005 topline (2025)](https://www.sec.gov/Archives/edgar/data/1816590/000181659025000085/cmps-20250623.htm); [Psych Congress Elevate COMP005 26-week abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378888)

<a id="topic-3.1.1.9-2"></a>

###### Company-stated risks of functional unblinding and expectancy bias

> “For example, concerns about functional unblinding, expectancy bias or the impact of our model for supporting and monitoring participants in our clinical trials evaluating COMP360 could hinder interpretability or regulatory acceptability of data from clinical trials of our investigational COMP360 psilocybin treatment.”
> “In addition, our later stage clinical trials may present challenges related to conducting adequate and well-controlled clinical trials, including designing an appropriate comparator arm in trials given the potential difficulties related to maintaining the blinding during the trial or placebo or nocebo effects.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.1.9-3"></a>

###### Regulatory scrutiny of functional unblinding in the phase 3 program

> “In addition, as a result of the increased regulatory scrutiny on functional unblinding, the company has decided to shift the data release for COMP006 until after the 26-week time point and the completion of the blinded portion has been reached for all patients to protect against the risk of unblinding.”

Source: [COMPASS Pathways third quarter 2024 results (2024)](https://www.sec.gov/Archives/edgar/data/1816590/000162828024044400/q32024pressrelease.htm)

<a id="topic-3.1.1.9-4"></a>

###### Preliminary topline data not yet reviewed by FDA or published

> “The Company plans to discuss these preliminary COMP005 data with the U.S. Food and Drug Administration (FDA) which has not yet reviewed the data.”

Source: [COMPASS Pathways Form 8-K COMP005 topline (2025)](https://www.sec.gov/Archives/edgar/data/1816590/000181659025000085/cmps-20250623.htm)

> “Based on preliminary clinical data that are subject to change as data collection, validation, and analysis continue.”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.1.9-5"></a>

###### Descriptive, observed-case, and post hoc analyses after Week 6

> “No statistical analyses performed after the primary analysis at Week 6”
> “COMP 005 Part B (post Week 6) and COMP 006 Part B (post Week 9) results are based on observed data only (CFB Mean ± 95% CI).”
> “This graph is a post hoc analysis.”
> “Participants were permitted to take protocol-allowed antidepressant treatments in Part B and C of the study.”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.1.9-6"></a>

###### Open-label design of Part C

> “In Part C, open-label from Week 26 to 52, eligible participants from both dosing arms could receive a single dose of 25 mg”
> “Approximately 70% of the study participants continued beyond Week 26 and entered Part C”

Source: [COMPASS Pathways COMP005 52-week release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-New-52-Week-Topline-Open-Label-Data-from-Phase-3-COMP005-Trial-Demonstrates-Additional-Benefit-from-Another-COMP360-Dose-in-Part-C-Extending-Durability-Out-to-1-Year/default.aspx)

<a id="topic-3.1.1.9-7"></a>

###### European Medicines Agency guidance on comparators, expectancy, and unblinding in psychedelic trials

> “Due to the obvious and easily detectable subjective effects induced by an active dose of a psychedelic substance the choice of appropriate comparator while maintaining the blinding can be challenging.”
> “Positive expectancy might lead to overestimation bias while disappointment with treatment (negative expectancy) might lead to symptom worsening or safety issues (nocebo effect).”
> “The use of independent and blinded external raters could help to mitigate the effects of unblinding and expectancy.”
> “Trials need to be able to demonstrate that the effect of the psychedelic assisted therapy is not due to the psychological intervention alone.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

<a id="topic-3.1.1.9-8"></a>

###### Blinding and expectancy confounds in psychedelic trials

> “We conduct systematic reviews of psychedelic RCTs using Medline, PsychInfo and EMBASE (Jan 1990 - Nov 2020) and show that currently reported psychedelic RCTs have generally not reported pre-trial expectancy, nor the success of blinding procedures.”
> “While psychedelic RCTs have generally shown promising results, with large effect sizes reported, we argue that treatment effect sizes in psychedelic RCTs are likely over-estimated due to de-blinding of participants and high levels of response expectancy.”

Source: [Muthukumaraswamy et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34038314/)

> “Of studies with a drug control condition (80), 49 (61.2%) used an inert placebo control, 16 (20.0%) used active comparators, 12 (15.0%) used both, and 3 (3.8%) used only different active psychedelic doses as a control.”
> “The majority (81/86; 94%) of studies were blinded, though only 14 (17.3%) included blind assessment; only 8 of these 14 studies assessed participants' blinding. Blinding success, assessed in highly varied ways, was generally poor.”

Source: [Nayak et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37167563/)

> “Blinding integrity may be compromised by perceived treatment efficacy and adverse effects, introducing bias into outcome assessments.”
> “We recommend collecting data on treatment expectations alongside monitoring blinding integrity to more accurately interpret study results.”

Source: [Huneke et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40072447/)

<a id="topic-3.1.1.9-9"></a>

###### Low control-group response in psilocybin depression trials

> “In this meta-analysis of 17 acute-phase randomized clinical trials of psilocybin (n = 373), esketamine (n = 573), or SSRIs (n = 4014), patients receiving control treatments in psilocybin trials had significantly worse depression outcomes compared with those receiving control treatments in trials of esketamine or SSRIs.”
> “Psilocybin in trials for depression has been given in psychedelic doses, which risks making functional unblinding both immediate and prevalent.”
> “Furthermore, since administration is usually supervised, unblinding may also extend to study personnel.”

Source: [Hieronymus et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12311713/)

<a id="topic-3.1.1.9-10"></a>

###### Comparison with open-label antidepressants under equal unblinding conditions

> “Psychedelic-assisted therapy (PAT) trials have high levels of functional unblinding, which biases results when comparing PAT with blinded interventions.”
> “Contrary to the first of 3 hypotheses, PAT (8 trials; 249 patients) was no more effective than open-label TAD treatment (16 open-label TAD trials; 7921 patients), with an estimated difference of 0.3 favoring open-label TADs (95% CI, -1.39 to 1.98; P = .73).”

Source: [Williams et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41848744/)

<a id="topic-3.1.1.9-11"></a>

###### Guideline and systematic review assessments of psilocybin trial methods

> “Small sample sizes and functional unblinding were major limitations in all studies.”

Source: [Rosenblat et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9720483/)

> “Future trials should publish trial protocol and SAPs, use clinician-rated outcomes accessed by a blinded rater, evaluate blinding of intervention, and consider measuring expectancy and therapeutic fidelity.”

Source: [Hovmand et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10350724/)

<a id="topic-3.1.1.9-12"></a>

###### Uncertainty in durability noted in the ICER draft scope

> “The base-case analysis will use a five-year time horizon, reflecting uncertainty in the durability of treatment effects and the limited evidence available to support longer-term extrapolation.”

Source: [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_TRD_Draft-Scope_For-Publication_102126-1.pdf)

<a id="topic-3.1.1.9-13"></a>

###### Limited long-term evidence on retreatment with psychedelics

> “The experience and the available information on the sustainability of the action and the long-term effects, both desirable and undesirable of psychedelics and the efficacy of re-treatment are very limited.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

<a id="heading-3.1.2"></a>

#### 3.1.2 COMP006

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Registered objective

> “Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)”
> “In this study, the aim is to assess the efficacy of COMP360, administered with psychological support in adult participants with TRD, in improving symptoms of depression.”

Source: [ClinicalTrials.gov NCT05711940](https://clinicaltrials.gov/study/NCT05711940)

<a id="topic-3.1.2.1-2"></a>

###### Objective of the second dose and the 10 mg arm

> “This trial is designed to investigate if a second dose can increase the number of responders and/or improve response seen in the Company’s Phase 2b study and explore the potential for a meaningful treatment response from repeat administration of COMP360 10mg.”

Source: [COMPASS Pathways phase 3 design release (2022)](https://ir.compasspathways.com/News--Events-/news/news-details/2022/COMPASS-Pathways-Announces-Phase-3-Pivotal-Program-Design-for-COMP360-in-Treatment-Resistant-Depression-at-Capital-Markets-Day/default.aspx)

> “Pivotal trial 2 (COMP006) (n=581): a fixed repeat dose monotherapy using three dose arms: 25mg, 10mg and 1mg. This trial is designed to investigate whether a second dose can increase therapeutic response.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Study dates

> “Study Start (Actual) 2023-02-14”
> “Primary Completion (Actual) 2025-11-13”
> “Study Completion (Estimated) 2026-12”

Source: [ClinicalTrials.gov NCT05711940](https://clinicaltrials.gov/study/NCT05711940)

<a id="topic-3.1.2.2-2"></a>

###### Sites and countries

> “This study has 116 locations”

Source: [ClinicalTrials.gov NCT05711940](https://clinicaltrials.gov/study/NCT05711940)

> “The second pivotal trial, COMP006, is a randomized, double-blind study with 581 dosed participants across 116 trial sites in the United States, Canada and Europe”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.2.2-3"></a>

###### Completion of enrollment

> “Company accelerating commercialization readiness plans by 9-12 months, following completion of COMP006 trial enrollment and positive meeting with FDA on NDA submission strategies for COMP360 in TRD, including potential rolling submission”

Source: [COMPASS Pathways third quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1816590/000181659025000149/q32025pressrelease.htm)

<a id="topic-3.1.2.2-4"></a>

###### Dates of the Part A and Part B results announcements

> “On February 17, 2026, the Company announced the successful achievement of the primary endpoint in the ongoing Phase 3 COMP006 trial, the second of two Phase 3 trials”

Source: [COMPASS Pathways Form 8-K COMP006 topline (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm)

> “On July 7, 2026, the Company announced the 26-week results (Part B) from its second ongoing Phase 3 COMP006 trial of COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression, or TRD”

Source: [COMPASS Pathways Form 8-K COMP006 26-week results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/cmps-20260707.htm)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Phase 3, randomized, double-blind, dose-controlled parallel-group design

> “This is a phase III, international, multi-centre, randomised, parallel group, fixed repeat dose, double-blind, controlled study.”
> “Allocation : Randomized Interventional Model : Parallel Assignment Masking : Quadruple”

Source: [ClinicalTrials.gov NCT05711940](https://clinicaltrials.gov/study/NCT05711940)

> “In COMP006, participants were randomized 2:1:1 to two doses (3 weeks apart) of COMP360 25 mg, 10 mg, or 1 mg.”

Source: [Psych Congress Elevate phase 3 primary endpoint abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378891)

<a id="topic-3.1.2.3-2"></a>

###### Three study parts over 52 weeks

> “The study comprises three parts (A, B, and C) and will last approximately 62 weeks including a three- to ten-week screening period. Part A will include a nine-week follow-up from initial investigational product (IP) administration. Part B will include a further 17 weeks follow-up out to 26 weeks from initial IP administration. Part C will include a further 26 weeks follow-up out to 52 weeks from initial IP administration.”

Source: [ClinicalTrials.gov NCT05711940](https://clinicaltrials.gov/study/NCT05711940)

> “The trial is comprised of three parts: Part A, which was blinded through 9 weeks, Part B which recently concluded and remained blinded through week 26, and Part C, which contains an open-label treatment part from week 26 to 52.”
> “There is a potential for a total of 4 doses of COMP360 across a 52-week period.”

Source: [COMPASS Pathways Form 8-K COMP006 26-week results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/cmps-20260707.htm)

<a id="topic-3.1.2.3-3"></a>

###### Retreatment and concomitant antidepressants in Parts B and C

> “Part A (blinded) 9 weeks Part B (blinded) 17 weeks Part C (open label) 26 weeks”
> “COMP360 25mg treatment (one dose only after relapse or for non-remitters from Part B)”
> “Re-dosing for non-remitters from Part A or Part B could occur several weeks after transition to Part B or Part C, respectively, due to scheduling requirements. Participants were permitted to take protocol-allowed antidepressant treatments in Part B and C of the study.”
> “retreatment based on pre-specified criteria and receive either what they were randomized into or antidepressant”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.2.3-4"></a>

###### Protocol amendments discussed with FDA

> “We have Breakthrough Therapy Designation and have had dialogue with the FDA regarding our Phase 3 trial design, including certain protocol amendments that we implemented in the first half of 2023.”

Source: [COMPASS Pathways Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000076/cmps-20260930.htm)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Key inclusion criteria

> “Aged ≥18 years at Screening”
> “Major depression without psychotic features (single or recurrent episode as informed by the Diagnostic and Statistical Manual of Mental Disorders, 5th edition [DSM-5])”
> “If the current major depressive episode is the participant's first lifetime episode of depression, the length of the current episode must be ≥3 months and ≤2 years at Screening”
> “MADRS total score ≥20 at Screening and Baseline to ensure at least moderate severity of depression”
> “TRD, defined as failure to respond to an adequate dose and duration of two, three, or four different pharmacological treatments for the current episode as determined through the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and using the supplementary advice on additional antidepressants not included in MGH-ATRQ”
> “At Screening, agreement to discontinue all prohibited medications”

Source: [ClinicalTrials.gov NCT05711940](https://clinicaltrials.gov/study/NCT05711940)

> “Adults with TRD (2-4 inadequate prior treatment responses) were enrolled.”

Source: [Psych Congress Elevate phase 3 primary endpoint abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378891)

<a id="topic-3.1.2.4-2"></a>

###### Key exclusion criteria

> “Prior or ongoing bipolar disorder, any psychotic disorder, including schizophrenia, schizophreniform disorder, schizoaffective disorder, brief psychotic disorder (unless substance induced or due to a medical condition), antisocial personality disorder as assessed by a structured clinical interview (MINI 7.0.2)”
> “Borderline personality disorder as demonstrated by medical history or the Mini International Neuropsychiatric Interview Plus (MINI plus) - borderline personality disorder module”
> “Ongoing post-traumatic stress disorder, obsessive-compulsive disorder, or anorexia nervosa as assessed by medical history and a structured clinical interview (MINI 7.0.2)”
> “Psychiatric inpatient within the past 12 months prior to Screening”
> “Use of electroconvulsive therapy, deep brain stimulation, or vagus nerve stimulation during the current depressive episode”
> “Transcranial magnetic stimulation within the past six months prior to Screening”
> “Exposure to COMP360 psilocybin therapy prior to Screening”

Source: [ClinicalTrials.gov NCT05711940](https://clinicaltrials.gov/study/NCT05711940)

<a id="topic-3.1.2.4-3"></a>

###### Planned limit on prior psychedelic experience

> “planned limit for prior psychedelic experience in trial was 15%”

Source: [COMPASS Pathways COMP006 26-week presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/a8-kdated7july2026ex991.htm)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Study arms

> “Experimental: 25 mg COMP360 Psilocybin”
> “Experimental: 10 mg COMP360 Psilocybin”
> “Active Comparator: 1 mg COMP360 Psilocybin”
> “COMP360 Psilocybin administered under supportive conditions”

Source: [ClinicalTrials.gov NCT05711940](https://clinicaltrials.gov/study/NCT05711940)

<a id="topic-3.1.2.5-2"></a>

###### Two fixed doses three weeks apart in Part A

> “is comparing the efficacy and safety of two fixed doses, taken three weeks apart, of 25 mg COMP360 to 10 mg COMP360 and 1 mg COMP360”

Source: [COMPASS Pathways Form 8-K COMP006 26-week results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/cmps-20260707.htm)

<a id="topic-3.1.2.5-3"></a>

###### Retreatment doses in Parts B and C

> “those who meet criteria for re-treatment will have the option to receive an additional treatment dose according to their assigned dose”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

> “COMP360 25mg treatment (one dose only after relapse or for non-remitters from Part B)”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.2.5-4"></a>

###### Psychological support model

> “In contrast to psychedelic-assisted psychotherapy, COMP360 psilocybin is administered with non-directive psychological support rather than directive psychotherapy.”
> “The Compass Psychological Support Model (CPSM) has been designed as a manualized standard of care in clinical research with COMP360 psilocybin, not to support efficacy, but to safeguard study participants and ensure consistency across multi-site trials.”

Source: [Young et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Caroline-Hostetler-ASCP-2025.pdf)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Montgomery-Åsberg Depression Rating Scale Total Score as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Primary endpoint: change from baseline in MADRS total score at Week 6, 25 mg versus 1 mg

> “COMP360 25 mg versus COMP360 1 mg for the change from baseline in MADRS total score. Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item clinician rated scale measuring depression severity”

Source: [ClinicalTrials.gov NCT05711940](https://clinicaltrials.gov/study/NCT05711940)

> “The primary endpoint was the difference in change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) scores between the 25 mg and 1 mg groups at Week 6.”

Source: [COMPASS Pathways Form 8-K COMP006 topline (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm)

<a id="topic-3.1.2.6.1-2"></a>

###### Key secondary endpoint at Week 9

> “Week 9 Key secondary endpoint”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.2.6.1-3"></a>

###### Registered secondary endpoints

> “COMP360 25 mg versus COMP360 1 mg for the change from baseline in Sheehan Disability Scale (SDS) total score. Sheehan Disability Scale (SDS) is a brief, five-item self report inventory that assesses functional impairment in work/school, social life, and family life.”
> “COMP360 25 mg versus COMP360 10 mg for the change from baseline in MADRS total score.”
> “COMP360 25 mg versus COMP360 10 mg for the change from baseline in Sheehan Disability Scale (SDS) total score.”

Source: [ClinicalTrials.gov NCT05711940](https://clinicaltrials.gov/study/NCT05711940)

<a id="topic-3.1.2.6.1-4"></a>

###### Sponsor's stated rationale for the MADRS

> “For the MADRS – a more widely used and accepted clinician-rated scale which Compass is using as the primary endpoint in their clinical trials”
> “MADRS, as assessed by independent raters in native language, is a widely accepted assessment of mood disorders.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.2.6.1-5"></a>

###### FDA guidance on primary endpoints in depression trials

> “Clinician-rated outcome measures are the current standard for assessing efficacy in”
> “To date, the FDA has accepted the following as primary endpoints in phase”
> “Montgomery Asberg Depression Rating Scale”

Source: [FDA (2018)](https://www.fda.gov/media/113988/download)

<a id="topic-3.1.2.6.1-6"></a>

###### MADRS total score as the primary efficacy measure in FDA-approved labeling for esketamine in treatment-resistant depression

> “In Study 1, the primary efficacy measure was change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at the end of the 4-week double-blind induction phase. The MADRS is a ten-item, clinician-rated scale used to assess severity of depressive symptoms. Scores on the MADRS range from 0 to 60, with higher scores indicating more severe depression.”

Source: [Spravato prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s019lbl.pdf)

<a id="topic-3.1.2.6.1-7"></a>

###### Development and sensitivity to change of the MADRS

> “Ratings on these 17 items for 64 patients participating in studies of four different antidepressant drugs were used to create a depression scale consisting of the 10 items which showed the largest changes with treatment and the highest correlation to overall change.”
> “Its capacity to differentiate between responders and non-responders to antidepressant treatment was better than the HRS, indicating greater sensitivity to change.”

Source: [Montgomery and Asberg (1979)](https://pubmed.ncbi.nlm.nih.gov/444788/)

<a id="topic-3.1.2.6.1-8"></a>

###### Clinically meaningful change in MADRS total score in treatment-resistant depression

> “Clinically meaningful changes in CGI‐S scores after 28 days corresponded to 6‐, 4‐, and 3‐point changes from baseline on the MADRS, SDS, and PHQ‐9, respectively. Similarly, a 2‐point CGI‐S score change (clinically substantial change) corresponded to a 12‐, 8‐, and 6‐point change on the MADRS, SDS, and PHQ‐9, respectively.”

Source: [Turkoz et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7986932/)

> “MCID estimates for MADRS ranged from 1.6 to 1.9.”

Source: [Duru and Fantino (2008)](https://pubmed.ncbi.nlm.nih.gov/18377706/)

<a id="topic-3.1.2.6.1-9"></a>

###### Response and remission definitions on the MADRS

> “Our results confirm the validity of the commonly used measures for response in MDD trials: a CGI-I score of 2 ('much improved') corresponded to a percentage MADRS reduction from baseline of 48-57%, and a CGI-I score of 1 ('very much improved') to a reduction of 80-84%.”

Source: [Leucht et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28068617/)

> “On the basis of a narrow definition of remission, which requires a complete absence of clinically significant symptoms of depression, the optimal MADRS cutoff was < or = 4. On the basis of a broader definition, the optimal cutoff was < or = 9.”

Source: [Zimmerman et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15003068/)

<a id="topic-3.1.2.6.1-10"></a>

###### Sponsor's definitions of remission and clinically meaningful reduction in COMP006

> “Remitters (n=48) = MADRS ≤12 and no single item ≥4; Responders and Partial Responders (n=68) = % CFB in MADRS ≥ 25% and do not meet remission criterion; Non-Responder (n=153) = % CFB in MADRS ≤ 25%”
> “Clinically meaningful reduction in MADRS defined as a ≥25% reduction from baseline in MADRS total score at Week 6. This graph is a post hoc analysis.”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.2.6.1-11"></a>

###### Rationale for the 1 mg active control and the 10 mg arm

> “COMP006 addresses some of the functional unblinding risks of an inert placebo-control by comparing the safety and efficacy of 25 mg COMP360 to a low active control dose of COMP360 (1 mg), while also including a moderately psychoactive active treatment arm (10 mg COMP360 psilocybin).”
> “Ongoing trials with investigational COMP360 psilocybin (COMP005 and COMP006) include several design elements to help address these considerations and align with FDA draft guidance on clinical trials with psychedelics.”

Source: [Young et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Caroline-Hostetler-ASCP-2025.pdf)

<a id="topic-3.1.2.6.1-12"></a>

###### FDA guidance on control groups in psychedelic drug trials

> “Given concerns for functional unblinding, the use of a traditional placebo as a control can be problematic for assessing efficacy even though it provides better contextualization for safety findings.”
> “Alternatives to an inert placebo (e.g., lower doses of a psychedelic, other psychoactive drugs that mimic some aspects of the subjective experience associated with psychedelic drugs) may be considered as well.”
> “For example, a trial using a low, middle, and high dose without a placebo could be paired with a placebo-controlled trial. The trial without a placebo could provide information about dose-response with less risk of functional unblinding.”
> “Sponsors should incorporate the use of central raters blinded to treatment allocation and visit number.”

Source: [FDA psychedelic drugs guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="topic-3.1.2.6.1-13"></a>

###### Use of a 1 mg psilocybin dose as an active control in earlier trials

> “In previous clinical trials, a dose of 1 mg of psilocybin or a dose range of 1-3 mg/70 kg were used as an active control because these doses were believed not to produce significant psychedelic effects.”

Source: [Hsu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11337322/)

> “we randomly assigned adults with treatment-resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control), along with psychological support.”

Source: [Goodwin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36322843/)

> “Active placebos, either low-dose psychedelics or alternative psychoactive medications (particularly those which induce a distinct but similarly profound psychoactive effect), likely provide a means of mitigating the expectancy effects”

Source: [Butler et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9481484/)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Planned enrollment

> “Overall, 568 participants are to be randomised in a 2:1:1 ratio to receive COMP360 25 mg, 10 mg or 1 mg.”

Source: [ClinicalTrials.gov NCT05711940](https://clinicaltrials.gov/study/NCT05711940)

> “Pivotal trial 2 (COMP 006) (n= 568): a fixed repeat dose monotherapy using three dose arms: 25mg, 10mg and 1mg.”

Source: [COMPASS Pathways phase 3 design release (2022)](https://ir.compasspathways.com/News--Events-/news/news-details/2022/COMPASS-Pathways-Announces-Phase-3-Pivotal-Program-Design-for-COMP360-in-Treatment-Resistant-Depression-at-Capital-Markets-Day/default.aspx)

<a id="topic-3.1.2.7.1-2"></a>

###### Actual enrollment in the registry record

> “Enrollment (Actual) 572”

Source: [ClinicalTrials.gov NCT05711940](https://clinicaltrials.gov/study/NCT05711940)

<a id="topic-3.1.2.7.1-3"></a>

###### Participants dosed, as reported by the company

> “is a randomized, double-blind study with 581 dosed participants across North America and Europe and is comparing the efficacy and safety of two fixed doses, taken three weeks apart, of 25 mg COMP360 to 10 mg COMP360 and 1 mg COMP360 (25 mg: n=296; 10 mg: n=142; 1 mg: n=143).”

Source: [COMPASS Pathways Form 8-K COMP006 topline (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm)

> “In COMP006 (n=581), two doses of 25 mg significantly reduced MADRS scores at Week 6 versus 1 mg”

Source: [Psych Congress Elevate phase 3 primary endpoint abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378891)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Safety analysis set

> “N=number of participants in the treatment group in the Safety Analysis Set by administration; n = number of participants.”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

> “Note: COMP006 safety includes 2 dose administrations and goes out to 9 weeks vs. 1 administration out to 6 weeks for COMP005”

Source: [COMPASS Pathways COMP006 topline presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/exhibit991investorpresen.htm)

<a id="topic-3.1.2.7.2-2"></a>

###### Efficacy analyses: least squares means in Part A and observed data in Part B

> “Change from baseline (Least square mean in Part A, Observed mean in Part B) +95% CIs”
> “COMP 006 Part B results (post Week 9) are based on observed data only (CFB Mean ± 95% CI)”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.2.7.2-3"></a>

###### Responder analysis population

> “This graph is a post hoc analysis. Total n at 6 weeks = 269 (based on ITT)”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Participants dosed by arm

> “(25 mg: n=296; 10 mg: n=142; 1 mg: n=143)”

Source: [COMPASS Pathways Form 8-K COMP006 26-week results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/cmps-20260707.htm)

<a id="topic-3.1.2.8.1-2"></a>

###### Participants in the 25 mg arm assessed at Week 6 and retreated in Part B

> “Total n at 6 weeks = 269 (based on ITT)”
> “58% of patients in 25mg arm received retreatment after Week 9”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.2.8.1-3"></a>

###### Results posting status in the registry

> “No Results Posted”

Source: [ClinicalTrials.gov NCT05711940](https://clinicaltrials.gov/study/NCT05711940)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Demographics

| Characteristic | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
| --- | --- | --- | --- |
| Female, n (%) | “160 (54.1)” | “68 (47.9)” | “69 (48.3)” |
| White, n (%) | “255 (86.1)” | “123 (86.6)” | “129 (90.2)” |
| Asian, n (%) | “14 (4.7)” | “6 (4.2)” | “6 (4.2)” |
| Black or African American, n (%) | “8 (2.7)” | “3 (2.1)” | “4 (2.8)” |
| American Indian or Alaska Native, n (%) | “0” | “0” | “1 (0.7)” |
| Other/not reported, n (%) | “19 (6.4)” | “10 (7.0)” | “3 (2.1)” |
| Age, years, mean (SD) | “46.2 (13.7)” | “42.9 (12.8)” | “45.5 (13.1)” |
| Age, min, max | “18, 79” | “19, 73” | “20, 75” |
| Age ≥65 years, n (%) | “29 (9.8)” | “9 (6.3)” | “13 (9.1)” |
| Prior psilocybin experience, n (%) | “12 (4.1)” | “5 (3.5)” | “5 (3.5)” |
| Prior psychedelic experience including psilocybin, n (%) | “20 (6.8)” | “8 (5.6)” | “9 (6.3)” |
| BMI, kg/m2, mean (SD) | “28.0 (6.2)” | “28.4 (6.4)” | “28.0 (6.5)” |

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.2.8.2-2"></a>

###### Treatment history and baseline MADRS

| Characteristic | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
| --- | --- | --- | --- |
| Failed treatments in current episode: 1, n (%) | “1 (0.3)” | “1 (0.7)” | “0” |
| Failed treatments in current episode: 2, n (%) | “190 (64.2)” | “105 (73.9)” | “98 (68.5)” |
| Failed treatments in current episode: 3, n (%) | “74 (25.0)” | “32 (22.5)” | “34 (23.8)” |
| Failed treatments in current episode: 4, n (%) | “29 (9.8)” | “4 (2.8)” | “11 (7.7)” |
| Failed treatments in current episode: 5, n (%) | “2 (0.7)” | “0” | “0” |
| Treatments withdrawn in screening: 0, n (%) | “68 (23.0)” | “30 (21.1)” | “36 (25.2)” |
| Treatments withdrawn in screening: 1, n (%) | “127 (42.9)” | “62 (43.7)” | “62 (43.4)” |
| Treatments withdrawn in screening: 2, n (%) | “68 (23.0)” | “34 (23.9)” | “31 (21.7)” |
| Treatments withdrawn in screening: more than 2, n (%) | “33 (11.1)” | “16 (11.3)” | “14 (9.8)” |
| MADRS total score at baseline, mean (SD) | “32.0 (5.8)” | “32.1 (5.8)” | “32.5 (5.4)” |
| Baseline MADRS subthreshold (≤10), n (%) | “2 (0.7)” | “0” | “0” |
| Baseline MADRS mild (11-19), n (%) | “0” | “0” | “0” |
| Baseline MADRS moderate (20-30), n (%) | “115 (38.9)” | “54 (38.0)” | “49 (34.3)” |
| Baseline MADRS severe (≥31), n (%) | “179 (60.5)” | “88 (62.0)” | “94 (65.7)” |

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.2.8.2-3"></a>

###### Depression diagnosis history

| Characteristic | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
| --- | --- | --- | --- |
| Length of current episode, months, mean (SD) | “45.5 (42.7)” | “37.7 (38.8)” | “38.4 (45.0)” |
| Length of current episode less than 1 year, n (%) | “53 (17.9)” | “37 (26.1)” | “30 (21.0)” |
| Length of current episode 1-2 years, n (%) | “73 (24.7)” | “35 (24.6)” | “41 (28.7)” |
| Length of current episode more than 2 years, n (%) | “170 (57.4)” | “70 (49.3)” | “72 (50.3)” |
| Lifetime depressive episodes, mean (SD) | “6.3 (7.4)” | “5.4 (6.6)” | “7.0 (12.5)” |
| Lifetime depressive episodes: 1, n (%) | “1 (0.3)” | “0” | “0” |
| Lifetime depressive episodes: 2-5, n (%) | “199 (67.2)” | “109 (76.8)” | “99 (69.2)” |
| Lifetime depressive episodes: 6-10, n (%) | “61 (20.6)” | “21 (14.8)” | “30 (21.0)” |
| Lifetime depressive episodes: more than 10, n (%) | “29 (9.8)” | “10 (7.0)” | “10 (7.0)” |

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.2.8.2-4"></a>

###### Chronicity of the enrolled population

> “In COMP006, participants had current depressive episodes lasting on average over three years and an average of more than six lifetime depressive episodes.”

Source: [COMPASS Pathways Form 8-K COMP006 26-week results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/cmps-20260707.htm)

<a id="topic-3.1.2.8.2-5"></a>

###### Baseline values that differ in the February 2026 presentation

| Characteristic | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
| --- | --- | --- | --- |
| Prior psilocybin experience, n (%) | “13 (4.4)” | “5 (3.5)” | “5 (3.5)” |
| Prior psychedelic experience including psilocybin, n (%) | “19 (6.4)” | “7 (4.9)” | “9 (6.3)” |
| BMI, kg/m2, mean (SD) | “28.0 (6.2)” | “28.6 (7.1)” | “27.8 (6.7)” |
| Failed treatments in current episode: 2, n (%) | “190 (64.2)” | “105 (73.9)” | “99 (69.2)” |
| Failed treatments in current episode: 3, n (%) | “74 (25.0)” | “32 (22.5)” | “33 (23.1)” |
| Treatments withdrawn in screening: 0, n (%) | “68 (23.0)” | “31 (21.8)” | “36 (25.2)” |
| Treatments withdrawn in screening: 1, n (%) | “127 (42.9)” | “61 (43.0)” | “62 (43.4)” |
| Treatments withdrawn in screening: 2, n (%) | “68 (23.0)” | “35 (24.6)” | “31 (21.7)” |
| Treatments withdrawn in screening: more than 2, n (%) | “33 (11.1)” | “15 (10.6)” | “14 (9.8)” |
| Lifetime depressive episodes: 2-5, n (%) | “198 (66.9)” | “109 (76.8)” | “99 (69.2)” |

Source: [COMPASS Pathways COMP006 topline presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/exhibit991investorpresen.htm)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Part A primary endpoint: MADRS change at Week 6, 25 mg versus 1 mg

> “Two fixed doses – administered 3 weeks apart – of COMP360 25 mg versus 1 mg demonstrated a highly statistically significant reduction in symptom severity with a p-value of <0.001 and a clinically meaningful difference of -3.8 points in change at the primary endpoint.”
> “Primary endpoint of Part A: Two doses of COMP360 25 mg versus 1 mg with a mean treatment difference of -3.8 points, 95% CI [-5.8, -1.8]; p<0.001 at Week 6”

Source: [COMPASS Pathways Form 8-K COMP006 topline (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm)

> “two doses of 25 mg significantly reduced MADRS scores at Week 6 versus 1 mg (LSMD: -3.8; 95% CI: -5.8, -1.8;”

Source: [Psych Congress Elevate phase 3 primary endpoint abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378891)

<a id="topic-3.1.2.8.3-2"></a>

###### Part A: MADRS least squares mean differences by visit through Week 6, November 2026 presentation

| Visit | 25 mg vs 1 mg, LS mean difference (95% CI) | 25 mg vs 1 mg, P-value | 10 mg vs 1 mg, LS mean difference (95% CI) | 10 mg vs 1 mg, P-value |
| --- | --- | --- | --- | --- |
| Day 2 | “-2.9 (-4.6, -1.2)” | “<0.001” | “-3.0 (-5.0, -1.0)” | “0.002” |
| Week 1 | “-5.0 (-7.0, -3.0)” | “<0.001” | “-3.5 (-5.9, -1.2)” | “0.001” |
| Week 3 | “-4.4 (-6.3, -2.5)” | “<0.001” | “-3.4 (-5.6, -1.2)” | “0.001” |
| Day 24 | “-5.0 (-7.1, -2.9)” | “<0.001” | “-4.9 (-7.4, -2.5)” | “<0.001” |
| Week 4 | “-4.8 (-6.9, -2.7)” | “<0.001” | “-4.9 (-7.3, -2.5)” | “<0.001” |
| Week 6 (primary) | “-3.8 (-5.8, -1.8)” | “<0.001” | “-2.5 (-4.8, -0.2)” | “0.017” |

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

> “Statistically significant treatment differences in 25mg vs 1mg and 10mg vs 1 mg found at all timepoints post administration”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.2.8.3-3"></a>

###### Part A: 10 mg versus 1 mg at Week 6, as reported in February and September 2026

> “the 10 mg dose showed a smaller effect (LSMD: -2.5; 95% CI: -4.9, -0.2; p=0.016)”

Source: [Psych Congress Elevate phase 3 primary endpoint abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378891)

<a id="topic-3.1.2.8.3-4"></a>

###### Part A key secondary endpoint: MADRS change at Week 9

| Visit | 25 mg vs 1 mg, LS mean difference (95% CI) | 25 mg vs 1 mg, P-value | 10 mg vs 1 mg, LS mean difference (95% CI) | 10 mg vs 1 mg, P-value |
| --- | --- | --- | --- | --- |
| Week 6 (primary) | “-3.8 (-5.8, -1.8)” | “<0.001” | “-2.5 (-4.9, -0.2)” | “0.016” |
| Week 9 (secondary) | “-2.9 (-5.0, -0.9)” | “0.002” | “-2.6 (-5.0, -0.2)” | “0.016” |

Source: [COMPASS Pathways COMP006 topline presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/exhibit991investorpresen.htm)

> “Statistical significance maintained through Week 9”

Source: [COMPASS Pathways COMP006 topline presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/exhibit991investorpresen.htm)

<a id="topic-3.1.2.8.3-5"></a>

###### Part A post hoc responder analysis at Week 6, 25 mg arm

> “39% of participants in the 25 mg arm achieved a clinically meaningful reduction in MADRS (≥ 25%) at Week 6”

Source: [COMPASS Pathways Form 8-K COMP006 topline (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm)

> “Remitters (n=48) = MADRS ≤12 and no single item ≥4; Responders and Partial Responders (n=68) = % CFB in MADRS ≥ 25% and do not meet remission criterion; Non-Responder (n=153) = % CFB in MADRS ≤ 25%”
> “This graph is a post hoc analysis. Total n at 6 weeks = 269 (based on ITT)”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.2.8.3-6"></a>

###### Part B: MADRS change through Week 26

> “Rapid onset of effect was observed, with consistent separation between the 25 mg and the 1 mg arm maintained through the randomized, blinded Part B period to Week 26”
> “39% of participants in the 25 mg arm achieved a clinically meaningful reduction in MADRS (≥ 25%) at Week 6, maintaining benefit, on average, through at least Week 26”

Source: [COMPASS Pathways Form 8-K COMP006 26-week results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/cmps-20260707.htm)

> “Persistent treatment effect of 25mg arm over full 26 weeks”
> “COMP 006 Part B results (post Week 9) are based on observed data only (CFB Mean ± 95% CI)”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.2.8.3-7"></a>

###### Part B: retreatment and remission after retreatment

> “58% of patients in 25mg arm received retreatment after Week 9”
> “28% of those who achieved clinically meaningful reduction in MADRS but had not remitted by 6 weeks went into remission after additional dose in Part B”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

> “Retreatment in Part B further enhanced benefit: nearly 30% of participants who achieved a clinically meaningful response at Week 6 later went into remission”

Source: [COMPASS Pathways Form 8-K COMP006 26-week results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/cmps-20260707.htm)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Part A safety summary

> “Most TEAEs occurred on the days of study drug administration (73%) with the vast majority (83%) resolving within a day”
> “Most common TEAEs were headache, nausea, anxiety and visual hallucination”
> “There were 6 treatment-emergent serious adverse events (SAEs) from 6 participants (2%) overall”
> “Across both trials, for the data available to date, the rate for SAE suicidal ideation was less than 1%. There was only one event of SAE suicidal behavior, which occurred in the 1 mg arm in COMP006.”

Source: [COMPASS Pathways Form 8-K COMP006 topline (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm)

> “To date there have been no attempted or completed suicides”
> “The DSMB noted that there is no evidence of a clinically meaningful imbalance between treatment arms in suicidality in either study”

Source: [COMPASS Pathways COMP006 topline presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/exhibit991investorpresen.htm)

<a id="topic-3.1.2.8.5-2"></a>

###### Part A treatment-emergent adverse events through Week 9

| Measure | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
| --- | --- | --- | --- |
| Any TEAE up to Week 9, n (%) | “274 (92.6)” | “125 (88.0)” | “116 (81.1)” |
| Any serious TEAE up to Week 9, n (%) | “6 (2.0)” | “1 (0.7)” | “5 (3.5)” |
| Any TEAE with onset on day of dosing, n (%) | “260 (87.8)” | “114 (80.3)” | “80 (55.9)” |
| Resolved ≤1 day, n (%) | “244 (82.4)” | “107 (75.4)” | “71 (49.7)” |
| Resolved >1 and ≤2 days, n (%) | “52 (17.6)” | “16 (11.3)” | “9 (6.3)” |
| Resolved >2 days, n (%) | “71 (24.0)” | “26 (18.3)” | “20 (14.0)” |

Source: [COMPASS Pathways COMP006 topline presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/exhibit991investorpresen.htm)

<a id="topic-3.1.2.8.5-3"></a>

###### Part A TEAEs with incidence above 10%

| MedDRA preferred term | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
| --- | --- | --- | --- |
| Any TEAE, n (%) | “254 (85.8)” | “111 (78.2)” | “80 (55.9)” |
| Nausea, n (%) | “118 (39.9)” | “42 (29.6)” | “15 (10.5)” |
| Headache, n (%) | “108 (36.5)” | “43 (30.3)” | “41 (28.7)” |
| Anxiety, n (%) | “62 (20.9)” | “28 (19.7)” | “21 (14.7)” |
| Hallucination, visual, n (%) | “46 (15.5)” | “24 (16.9)” | “3 (2.1)” |
| Illusion, n (%) | “41 (13.9)” | “16 (11.3)” | “3 (2.1)” |
| Dizziness, n (%) | “41 (13.9)” | “21 (14.8)” | “9 (6.3)” |
| Fatigue, n (%) | “41 (13.9)” | “23 (16.2)” | “16 (11.2)” |
| Crying, n (%) | “35 (11.8)” | “13 (9.2)” | “4 (2.8)” |
| Blood pressure increased, n (%) | “31 (10.5)” | “6 (4.2)” | “4 (2.8)” |

Source: [COMPASS Pathways COMP006 topline presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/exhibit991investorpresen.htm)

<a id="topic-3.1.2.8.5-4"></a>

###### Part A treatment-emergent serious adverse events

| MedDRA preferred term | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
| --- | --- | --- | --- |
| Any SAE, n (%) | “6 (2.0)” | “1 (0.7)” | “5 (3.5)” |
| Suicidal ideation, n (%) | “0” | “1 (0.7)” | “2 (1.4)” |
| Suicidal behaviour, n (%) | “0” | “0” | “1 (0.7)” |
| Syncope, n (%) | “1 (0.3)” | “0” | “1 (0.7)” |
| Major depression, n (%) | “1 (0.3)” | “0” | “0” |
| Anxiety, n (%) | “1 (0.3)” | “0” | “0” |
| Flashback, n (%) | “1 (0.3)” | “0” | “0” |
| Cervical spinal stenosis, n (%) | “1 (0.3)” | “0” | “0” |
| Renal neoplasm, n (%) | “0” | “0” | “1 (0.7)” |
| Pelvic pain, n (%) | “1 (0.3)” | “0” | “0” |

Source: [COMPASS Pathways COMP006 topline presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/exhibit991investorpresen.htm)

<a id="topic-3.1.2.8.5-5"></a>

###### Safety summary through Week 26

> “Majority of TEAEs were transient and predominantly occurring on day of dosing”
> “Most common adverse events were nausea, headache, anxiety and visual hallucination”
> “Serious adverse events (SAEs) were similar across arms (6.3% in the 1 mg arm and 5.7% in the 25 mg arm) over 26 weeks but low overall across the trial”

Source: [COMPASS Pathways Form 8-K COMP006 26-week results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/cmps-20260707.htm)

<a id="topic-3.1.2.8.5-6"></a>

###### Treatment-emergent adverse events through Week 26

| Measure | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
| --- | --- | --- | --- |
| Any TEAE up to Week 26, n (%) | “280 (94.6)” | “132 (93.0)” | “124 (86.7)” |
| Any serious TEAE up to Week 26, n (%) | “17 (5.7)” | “5 (3.5)” | “9 (6.3)” |
| Any TEAE with onset on day of dosing, n (%) | “265 (89.5)” | “119 (83.8)” | “88 (61.5)” |
| Resolved ≤1 day, n (%) | “255 (86.1)” | “113 (79.6)” | “78 (54.5)” |
| Resolved >1 and ≤2 days, n (%) | “60 (20.3)” | “22 (15.5)” | “12 (8.4)” |
| Resolved >2 days, n (%) | “80 (27.0)” | “32 (22.5)” | “21 (14.7)” |
| Nausea, n (%) | “133 (44.9)” | “50 (35.2)” | “18 (12.6)” |
| Headache, n (%) | “118 (39.9)” | “53 (37.3)” | “49 (34.3)” |
| Anxiety, n (%) | “83 (28.0)” | “38 (26.8)” | “29 (20.3)” |
| Hallucination, visual, n (%) | “51 (17.2)” | “27 (19.0)” | “5 (3.5)” |
| Fatigue, n (%) | “49 (16.6)” | “26 (18.3)” | “19 (13.3)” |
| Illusion or perceptual disturbance, n (%) | “48 (16.2)” | “19 (13.4)” | “4 (2.8)” |
| Dizziness, n (%) | “47 (15.9)” | “25 (17.6)” | “9 (6.3)” |
| Crying, n (%) | “41 (13.9)” | “15 (10.6)” | “6 (4.2)” |
| Blood pressure increased, n (%) | “35 (11.8)” | “10 (7.0)” | “4 (2.8)” |

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

> “Illusion and Perceptual Disturbance categories have been combined in this presentation due to some recent changes in MedDRA classification”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.2.8.5-7"></a>

###### Treatment-emergent serious adverse events through Week 26

| MedDRA preferred term | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
| --- | --- | --- | --- |
| Any TESAE, n (%) | “17 (5.7)” | “5 (3.5)” | “9 (6.3)” |
| Suicidal ideation, n (%) | “4 (1.4)” | “2 (1.4)” | “4 (2.8)” |
| Suicidal behaviour, n (%) | “0” | “0” | “1 (0.7)” |
| Suspected suicide, n (%) | “1 (0.3)” | “0” | “0” |
| Suicide attempt, n (%) | “0” | “0” | “1 (0.7)” |
| Syncope, n (%) | “1 (0.3)” | “0” | “1 (0.7)” |
| Major depression, n (%) | “1 (0.3)” | “0” | “0” |
| Anxiety, n (%) | “1 (0.3)” | “0” | “0” |
| Flashback, n (%) | “1 (0.3)” | “0” | “0” |
| Cervical spinal stenosis, n (%) | “1 (0.3)” | “0” | “0” |
| Renal neoplasm, n (%) | “0” | “0” | “1 (0.7)” |
| Pelvic pain, n (%) | “1 (0.3)” | “0” | “0” |
| Adjustment disorder with mixed disturbance of emotion and conduct, n (%) | “1 (0.3)” | “0” | “0” |
| Pneumonia, n (%) | “0” | “1 (0.7)” | “0” |
| Radius fracture, n (%) | “1 ( 0.3)” | “1 (0.7)” | “0” |
| Road traffic accident, n (%) | “1 ( 0.3)” | “0” | “0” |
| Tibia fracture, n (%) | “1 ( 0.3)” | “0” | “0” |
| Ulna fracture, n (%) | “1 ( 0.3)” | “0” | “0” |
| Alanine aminotransferase increased, n (%) | “1 ( 0.3)” | “0” | “0” |
| Aspartate aminotransferase increased, n (%) | “1 ( 0.3)” | “0” | “0” |
| Brain neoplasm, n (%) | “1 (0.3)” | “0” | “0” |
| Thyroid neoplasm, n (%) | “1 (0.3)” | “0” | “0” |
| Cerebrovascular accident, n (%) | “0” | “0” | “1 (0.7)” |
| Toxic encephalopathy, n (%) | “0” | “1 (0.7)” | “0” |
| Tremor, n (%) | “1 (0.3)” | “0” | “0” |

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

> “Suspected Suicide determined by the investigator as not related to the treatment, based on the specific circumstances and timing”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary: functional unblinding, low-dose comparator, post hoc and observed-case analyses, preliminary data

COMP006 used COMP360 1 mg as the comparator to address “some of the functional unblinding risks of an inert placebo-control”. FDA guidance states that functional unblinding can lead to expectation bias and that enrolling participants with prior psychedelic exposure raises the possibility of expectation bias; the planned limit for prior psychedelic experience in COMP006 was 15%. One analysis found that outcomes with extremely low dose psilocybin were better than placebo response in psychedelic trials (mean difference 3.96), and a review reported that psilocybin, LSD, and ayahuasca studies “frequently reported blinding failure values of more than 90%” among participants and raters. The responder analysis is post hoc, Part B results after Week 9 are observed data, and protocol-allowed antidepressants were permitted in Parts B and C. The company describes the 26-week results as preliminary and states that full results may not be consistent with them; the registry shows no results posted.

Source: [Young et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Caroline-Hostetler-ASCP-2025.pdf); [FDA psychedelic drugs guidance (2026)](https://www.fda.gov/media/169694/download); [COMPASS Pathways COMP006 26-week presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/a8-kdated7july2026ex991.htm); [Hsu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11337322/); [Orsini et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41984443/); [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf); [COMPASS Pathways Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000076/cmps-20260930.htm); [ClinicalTrials.gov NCT05711940](https://clinicaltrials.gov/study/NCT05711940)

<a id="topic-3.1.2.9-2"></a>

###### Functional unblinding and expectancy bias, as stated by the company

> “For example, concerns about functional unblinding, expectancy bias or the impact of our model for supporting and monitoring participants in our clinical trials evaluating COMP360 could hinder interpretability or regulatory acceptability of data from clinical trials of our investigational COMP360 psilocybin treatment.”

Source: [COMPASS Pathways Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000076/cmps-20260930.htm)

<a id="topic-3.1.2.9-3"></a>

###### Release of Part A results while Part B remained blinded

> “In addition, as a result of the increased regulatory scrutiny on functional unblinding, the company has decided to shift the data release for COMP006 until after the 26-week time point and the completion of the blinded portion has been reached for all patients to protect against the risk of unblinding.”

Source: [COMPASS Pathways third quarter 2024 results (2024)](https://www.sec.gov/Archives/edgar/data/1816590/000162828024044400/q32024pressrelease.htm)

> “Company now plans to disclose 9-week data (Part A) from COMP006 together with 26-week data (Part B) from COMP005 in Q1 2026”

Source: [COMPASS Pathways third quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1816590/000181659025000149/q32025pressrelease.htm)

> “The trial is comprised of three parts: Part A, which has recently concluded and was blinded through 9 weeks, Part B which remains blinded through week 26, and Part C, which contains an open-label treatment part from week 26 to 52.”

Source: [COMPASS Pathways Form 8-K COMP006 topline (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm)

<a id="topic-3.1.2.9-4"></a>

###### Preliminary, unpublished data

> “For example, in the first quarter of 2026, we reported preliminary results from our Phase 3 trials in TRD and in the third quarter of 2026, we reported preliminary 26-week results from our Phase 3 COMP006 trial and 52-week results from our Phase 3 COMP005 trial, and the full results and safety data from our Phase 3 clinical trials in TRD may not be consistent with the preliminary results to date.”

Source: [COMPASS Pathways Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000076/cmps-20260930.htm)

<a id="topic-3.1.2.9-5"></a>

###### Post hoc responder analyses, observed-case Part B data, and concomitant antidepressants

> “This graph is a post hoc analysis.”
> “COMP 006 Part B results (post Week 9) are based on observed data only (CFB Mean ± 95% CI)”
> “Participants were permitted to take protocol-allowed antidepressant treatments in Part B and C of the study.”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.2.9-6"></a>

###### Cross-trial comparisons with COMP005

> “Cross-trial comparisons should be interpreted with caution. Differences between trials, including but not limited to study designs, protocols, and timing of assessments. number or timing of doses and participant populations can meaningfully influence outcomes and limit the validity of any comparison.”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.2.9-7"></a>

###### FDA guidance on functional unblinding and prior psychedelic exposure

> “Functional unblinding can lead to expectation bias in the patients who experience perceptual disturbances, or in those who observe them, which may lead to an expectation that the participant will experience clinical benefit;”
> “Study results should be strongly persuasive and robust across study endpoints to overcome biases that may be introduced by functional unblinding.”
> “enrolling individuals with prior psychedelic drug exposure raises the possibility of expectation bias given that participants who have prior experience with psychedelic drugs are more likely to recognize their subjective effects (i.e., leading to functional unblinding) and anticipate a treatment benefit.”

Source: [FDA psychedelic drugs guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="topic-3.1.2.9-8"></a>

###### Blinding failure in psychedelic trials: systematic reviews

> “Functional unblinding was substantial: psilocybin, LSD, and ayahuasca studies frequently reported blinding failure values of more than 90% among participants and raters, inert placebo-controlled MDMA trials exceeded 85%, and ketamine trials rarely assessed blinding (17.9%) but showed improved preservation with midazolam vs saline controls. No control strategy consistently achieved ideal blinding.”

Source: [Orsini et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41984443/)

> “While psychedelic RCTs have generally shown promising results, with large effect sizes reported, we argue that treatment effect sizes in psychedelic RCTs are likely over-estimated due to de-blinding of participants and high levels of response expectancy.”

Source: [Muthukumaraswamy et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34038314/)

<a id="topic-3.1.2.9-9"></a>

###### Low-dose psilocybin as a comparator: response relative to inert placebo

> “Notably, placebo response in antidepressant trials (3.79 (95% credibile interval 0.77 to 6.80)) and extremely low dose psilocybin (3.96 (0.61 to 7.17)) were better than placebo response in the psychedelic trials, with mean differences exceeding 3 and 95% credibile intervals that did not cross zero.”

Source: [Hsu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11337322/)

> “However, the effect size (standardised mean difference) of high dose psilocybin decreased from large (0.88) to small (0.31) when the reference arm changed from placebo response in the psychedelic trials to antidepressant trials.”

Source: [Hsu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11337322/)

<a id="topic-3.1.2.9-10"></a>

###### Mitigation measures proposed in the literature

> “We suggest that simple practical measures may be (and indeed already are) taken in psychedelic trials to partially mitigate the effects of expectancy and unblinding, such as independent raters and active placebos.”

Source: [Butler et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9481484/)

<a id="heading-3.1.3"></a>

#### 3.1.3 COMP001

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Registered study purpose

> “The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression - a dose-ranging study”

Source: [ClinicalTrials.gov NCT03775200](https://clinicaltrials.gov/study/NCT03775200)

<a id="topic-3.1.3.1-2"></a>

###### Protocol objectives: dose selection and superiority over 1 mg

> “The main purpose of this study is to allow COMPASS to determine the optimal dose of psilocybin, either 10 mg or 25 mg.”
> “The primary objective of this study is to evaluate the efficacy of psilocybin (25 mg or 10 mg) compared to 1 mg, administered under supportive conditions to adult participants with TRD, in improving depressive symptoms, as assessed by the change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from Baseline.”

Source: [COMPASS Pathways COMP001 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf)

<a id="topic-3.1.3.1-3"></a>

###### Company statement of the trial objective

> “The objective of the randomised, controlled, double-blind phase 2b study was to understand the efficacy and safety of a single dose of investigational COMP360 psilocybin (25mg or 10mg), compared to 1mg, in patients with TRD.”
> “The objective of the trial was to find the appropriate dose for a larger, pivotal phase 3 programme, which COMPASS expects to begin in 2022.”

Source: [COMPASS Pathways NEJM publication release (2022)](https://ir.compasspathways.com/News--Events-/news/news-details/2022/COMPASS-Pathways-announces-publication-of-phase-2b-study-of-COMP360-psilocybin-therapy-for-treatment-resistant-depression-in-The-New-England-Journal-of-Medicine/default.aspx)

<a id="topic-3.1.3.1-4"></a>

###### Role in the new drug application

> “Robust NDA submission supported by data from two highly statistically significant Phase 3 trials and a Phase 2b study that each met its primary endpoint and involved a total of more than 1,000 participants living with highly chronic TRD”

Source: [COMPASS Pathways NDA submission release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Completes-COMP360-Psilocybin-New-Drug-Application-to-U-S--FDA-for-Treatment-Resistant-Depression/default.aspx)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Study dates and identifiers

| Item | Registry record |
| --- | --- |
| Other study ID | “COMP001” |
| Study start (actual) | “2019-03-01” |
| Primary completion (actual) | “2021-07-30” |
| Study completion (actual) | “2021-09-27” |
| Results first posted | “2023-04-24” |

Source: [ClinicalTrials.gov NCT03775200](https://clinicaltrials.gov/study/NCT03775200)

<a id="topic-3.1.3.2-2"></a>

###### First and last participant visits

> “First patient first visit: 1 March 2019”
> “Last patients last visit: 27 September 2021”

Source: [ClinicalTrials.gov NCT03775200 results](https://clinicaltrials.gov/study/NCT03775200?tab=results)

<a id="topic-3.1.3.2-3"></a>

###### Sites and countries: company statement

> “In 2021, we completed a Phase 2b international multi-site, randomized, controlled, double-blind, dose-finding clinical trial to assess the safety and efficacy of active doses of COMP360 (10mg or 25mg) compared with 1mg COMP360 in 233 patients suffering with TRD, across 22 trial sites in 10 countries in North America and Europe.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.3.2-4"></a>

###### Sites: registry record

> “This study has 25 locations”

Source: [ClinicalTrials.gov NCT03775200](https://clinicaltrials.gov/study/NCT03775200)

<a id="topic-3.1.3.2-5"></a>

###### Enrollment by country

| Country | 25 mg | 10 mg | 1 mg | Total |
| --- | --- | --- | --- | --- |
| United States | “32” | “32” | “32” | “96” |
| Netherlands | “17” | “16” | “17” | “50” |
| United Kingdom | “11” | “10” | “12” | “33” |
| Spain | “5” | “6” | “5” | “16” |
| Ireland | “3” | “3” | “5” | “11” |
| Denmark | “3” | “2” | “3” | “8” |
| Czechia | “3” | “2” | “2” | “7” |
| Canada | “2” | “2” | “2” | “6” |
| Germany | “2” | “2” | “0” | “4” |
| Portugal | “1” | “0” | “1” | “2” |

Source: [ClinicalTrials.gov NCT03775200 results](https://clinicaltrials.gov/study/NCT03775200?tab=results)

<a id="topic-3.1.3.2-6"></a>

###### Timing of topline announcement and publication

> “Data from the phase 2b trial was announced in November and December 2021, and presented at the American Psychiatric Association annual meeting in New Orleans in May 2022.”

Source: [COMPASS Pathways NEJM publication release (2022)](https://ir.compasspathways.com/News--Events-/news/news-details/2022/COMPASS-Pathways-announces-publication-of-phase-2b-study-of-COMP360-psilocybin-therapy-for-treatment-resistant-depression-in-The-New-England-Journal-of-Medicine/default.aspx)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Randomized, double-blind, dose-controlled design

> “In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control), along with psychological support.”

Source: [Goodwin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36322843/)

<a id="topic-3.1.3.3-2"></a>

###### Registered design details

| Item | Registry record |
| --- | --- |
| Phase | “Phase 2” |
| Allocation | “Randomized” |
| Intervention model | “Parallel Assignment” |
| Masking | “Quadruple” |
| Primary purpose | “Treatment” |

Source: [ClinicalTrials.gov NCT03775200](https://clinicaltrials.gov/study/NCT03775200)

<a id="topic-3.1.3.3-3"></a>

###### Protocol design and visit schedule

> “This is a Phase 2, international multicentre, randomised, fixed-dose, double-blind trial.”
> “Participants will be seen at the clinic for Screening (V1 plus a minimum of 3 safety visits), Baseline (V2, Day -1), Day 0 (V3, Dosing), Day 1 (V4), Week 1 (V5), Week 2 (V6), Week 3 (V7), and Week 12 (V10).”
> “Participants will also be contacted for follow-up at Week 6 (V8) and Week 9 (V9).”

Source: [COMPASS Pathways COMP001 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf)

<a id="topic-3.1.3.3-4"></a>

###### Preparation, administration, and follow-up sessions

> “Prior to administration, participants received at least one, and up to three, preparatory sessions with an assigned healthcare professional, in order to be informed and prepared for the COMP360 psilocybin session.”
> “Participants received two post-administration follow-up sessions with their healthcare professionals in which the psychedelic experience was discussed.”
> “Participants were followed for up to 12 weeks, with a visit the day after administration followed by weekly visits for the first three weeks, and visits every three weeks for the remaining nine weeks.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.3.3-5"></a>

###### Screening period and antidepressant taper

> “Those who meet the eligibility criteria will enter the screening period, which will last between 3 and 6 weeks.”
> “During the screening period, participants who are on antidepressant medications will be expected to complete the taper at least 2 weeks prior to Baseline (V2).”

Source: [COMPASS Pathways COMP001 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Registered eligibility criteria

| Item | Registry record |
| --- | --- |
| Inclusion | “Diagnosis of TRD” |
| Exclusion | “Other comorbidities” |
| Ages eligible | “18 Years and older” |
| Healthy volunteers | “No” |

Source: [ClinicalTrials.gov NCT03775200](https://clinicaltrials.gov/study/NCT03775200)

<a id="topic-3.1.3.4-2"></a>

###### Company definition of treatment-resistant depression

> “We define patients with TRD as those who meet Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, or DSM-5, diagnostic criteria for a single or recurrent episode of MDD without psychotic features, who have not responded to an adequate dose and duration of two, three, or four pharmacological treatments for the current episode of depression.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.3.4-3"></a>

###### Inclusion criteria: protocol

| Criterion | Quoted protocol text |
| --- | --- |
| Age | “18 years of age or older at Screening (V1).” |
| Diagnosis | “At least moderate MDD (single or recurrent episode as informed by DSM-5; if single episode, duration of ≥ 3 months and ≤ 2 years) based on medical records, clinical assessment and documented completion of the version 7.0.2 MINI.” |
| Symptom severity | “HAM-D-17 (17-item) score ≥ 18 at Screening (V1) and at Baseline (V2).” |
| Treatment resistance | “Failure to respond to an adequate dose and duration of 2, 3, or 4 pharmacological treatment for the current episode as determined through the MGH-ATRQ” |
| Augmentation | “Augmentation with an add-on treatment counts as a second treatment, provided it is approved for the adjunctive treatment of MDD in that country.” |
| Borderline personality screen | “McLean Screening Instrument for Borderline Personality Disorder < 7 at Screening (V1).” |
| Antidepressant discontinuation | “Have successfully discontinued all antidepressant medications at least 2 weeks prior to Baseline (V2).” |

Source: [COMPASS Pathways COMP001 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf)

<a id="topic-3.1.3.4-4"></a>

###### Exclusion criteria: protocol

| Criterion | Quoted protocol text |
| --- | --- |
| Psychiatric comorbidity | “Current or past history of schizophrenia, psychotic disorder (unless substance induced or due to a medical condition), bipolar disorder, delusional disorder, paranoid personality disorder, schizoaffective disorder, borderline personality disorder, or any serious psychiatric comorbidity as assessed by medical history and a structured clinical interview (version 7.0.2 MINI).” |
| Prior ECT or ketamine | “Prior electroconvulsive therapy and/or ketamine for current episode.” |
| Substance use | “Current (within the last year) alcohol or substance abuse as informed by DSM-5 at Screening (V1).” |
| Suicide risk | “Significant suicide risk as defined by (1) suicidal ideation as endorsed on items 4 or 5 on the C-SSRS within the past year, at Screening or at Baseline, or; (2) suicidal behaviors within the past year, or; (3) clinical assessment of significant suicidal risk during subject interview.” |
| Psychedelic exposure | “exposure to psilocybin within the past year and use of psychedelics, such as ayahuasca, during the current depressive episode” |
| Pregnancy | “Women who are pregnant, nursing, or planning a pregnancy.” |
| Cardiovascular | “Cardiovascular conditions: recent stroke (< 1 year from signing of ICF), recent myocardial infarction (< 1 year from signing of ICF), hypertension (blood pressure > 140/90 mmHg) or clinically significant arrhythmia within 1 year of signing the ICF.” |
| Diabetes | “Uncontrolled insulin-dependent diabetes.” |
| Seizures | “Seizure disorder.” |

Source: [COMPASS Pathways COMP001 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf)

<a id="topic-3.1.3.4-5"></a>

###### Prior psilocybin experience cap

> “The majority of participants will have no prior exposure to psilocybin or so-called magic mushrooms; however, to reflect the prevalence of experience in general population, we will allow up to 10% of participants with prior recreational experience with psilocybin or magic mushrooms.”

Source: [COMPASS Pathways COMP001 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Investigational product by arm

| Arm | Quoted protocol text |
| --- | --- |
| All arms | “Single 5-capsule oral psilocybin dose:” |
| 25 mg | “25 mg treatment: 5 × 5 mg capsules” |
| 10 mg | “10 mg treatment: 2 × 5 mg capsules and 3 × placebo capsules” |
| 1 mg | “1 mg treatment: 1 × 1 mg capsule and 4 × placebo capsules” |

Source: [COMPASS Pathways COMP001 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf)

<a id="topic-3.1.3.5-2"></a>

###### Administration session

> “The psilocybin administration session (V3, Day 0) will last approximately 6 hours and will be supported by a trained therapist.”

Source: [COMPASS Pathways COMP001 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf)

> “During the COMP360 psilocybin session, a single dose of COMP360 was administered to participants.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.3.5-3"></a>

###### Psychological support model

> “which randomized 233 adults with TRD in 1:1:1 ratio to a single fixed-dose (25 mg, 10 mg, or 1 mg) of COMP360 that was administered with a well-defined psychological support model that emphasizes safety and self-directed enquiry”
> “As part of the COMP360 treatment, psychological support was provided to ensure the participants’ physical and psychological safety and consisted of three phases: preparation, administration, and integration.”

Source: [Dougherty et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12226623/)

<a id="topic-3.1.3.5-4"></a>

###### Antidepressant washout before and after dosing

> “Participants who were on serotonergic medications were required to taper off their medicine at least two weeks prior to the baseline (Day -1) visit.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

> “All participants will be asked to remain off their antidepressant medications for at least 3 weeks following the psilocybin session until the primary endpoint assessment, or longer.”
> “These medications are not to be reintroduced to the participant until after V7 (Week 3).”

Source: [COMPASS Pathways COMP001 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf)

<a id="topic-3.1.3.5-5"></a>

###### Rescue medication

> “Rescue medications may be used during and after the psilocybin session.”
> “Benzodiazepine anxiolytics is the pharmacological intervention of choice in case of acute psychological distress”
> “Antipsychotic medications (eg, risperidone) should be available in the event that an adverse reaction escalates to unmanageable psychosis.”

Source: [COMPASS Pathways COMP001 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Montgomery-Åsberg Depression Rating Scale Total Score as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Primary endpoint definition

> “The primary end point was the change from baseline to week 3 in the total score on the Montgomery-Åsberg Depression Rating Scale (MADRS; range, 0 to 60, with higher scores indicating more severe depression).”

Source: [Goodwin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36322843/)

> “MADRS is a clinician-rated scale measuring depression symptom severity, consisting of 10 items, each scored from 0 (normal) to 6 (severe), for a total possible score of between 0 to 60; higher scores denote greater severity.”

Source: [ClinicalTrials.gov NCT03775200](https://clinicaltrials.gov/study/NCT03775200)

<a id="topic-3.1.3.6.1-2"></a>

###### Company rationale for the scale

> “MADRS, as assessed by independent raters in native language, is a widely accepted assessment of mood disorders.”
> “This variable was also being analyzed for change from baseline to Day 2, weeks 1, 6, 9 and 12.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.3.6.1-3"></a>

###### Independent remote blinded rating

> “MADRS evaluations will be performed by an independent remote rater who is blinded to the participant’s treatment assignment at Baseline, Day 1, and Weeks 1, 3, 6, 9, and 12 (V2, V4, V5, V7, V8, V9, and V10, respectively).”
> “The structure of the telephone-based interview will be controlled through the use of The Structured Interview Guide for the MADRS (SIGMA)”

Source: [COMPASS Pathways COMP001 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf)

> “The MADRS was assessed by independent raters who were remote from the trial site, and blind to intervention and study design, effectively creating a triple blind.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.3.6.1-4"></a>

###### Scale construction and sensitivity to change

> “The construction of a depression rating scale designed to be particularly sensitive to treatment effects is described.”
> “Its capacity to differentiate between responders and non-responders to antidepressant treatment was better than the HRS, indicating greater sensitivity to change.”

Source: [Montgomery and Asberg (1979)](https://pubmed.ncbi.nlm.nih.gov/444788/)

<a id="topic-3.1.3.6.1-5"></a>

###### Regulatory acceptance as a primary endpoint

> “Clinician-rated outcome measures are the current standard for assessing efficacy in”
> “To date, the FDA has accepted the following as primary endpoints in phase”
> “Montgomery Asberg Depression Rating Scale”

Source: [FDA (2018)](https://www.fda.gov/media/113988/download)

> “Acceptable scales to determine symptomatic improvement include the Hamilton Rating Scale of Depression (HDRS), preferably the 17-item scale, and the Montgomery-Asberg Depression Rating Scale (MADRS), however other validated scales might be acceptable as well.”
> “For rapid acting antidepressants it is anticipated that specific scales, other than the most commonly used MADRS, will be developed and validated, in order to be able to fully capture the rapid onset of effect.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

<a id="topic-3.1.3.6.1-6"></a>

###### Timing of the primary endpoint for a rapid-acting treatment

> “Efficacy generally should be demonstrated within 1 week for a rapid-acting”
> “Durability of effect beyond the initial response should be characterized.”

Source: [FDA (2018)](https://www.fda.gov/media/113988/download)

<a id="topic-3.1.3.6.1-7"></a>

###### Clinically meaningful change in treatment-resistant depression

> “Clinically meaningful changes in CGI‐S scores after 28 days corresponded to 6‐, 4‐, and 3‐point changes from baseline on the MADRS, SDS, and PHQ‐9, respectively.”
> “Similarly, a 2‐point CGI‐S score change (clinically substantial change) corresponded to a 12‐, 8‐, and 6‐point change on the MADRS, SDS, and PHQ‐9, respectively.”

Source: [Turkoz et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7986932/)

<a id="topic-3.1.3.6.1-8"></a>

###### Minimal important difference estimates

> “For both the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Beck Depression Inventory II (BDI-II), MID estimates range between 3 and 9 points, with estimates of 3-6 points likely being the most accurate.”

Source: [Hengartner and Plöderl (2022)](https://pubmed.ncbi.nlm.nih.gov/33593736/)

> “MCID estimates for MADRS ranged from 1.6 to 1.9.”

Source: [Duru and Fantino (2008)](https://pubmed.ncbi.nlm.nih.gov/18377706/)

<a id="topic-3.1.3.6.1-9"></a>

###### Response and remission thresholds

> “Secondary end points included response at week 3 (≥50% decrease from baseline in the MADRS total score), remission at week 3 (MADRS total score ≤10), and sustained response at 12 weeks (meeting response criteria at week 3 and all subsequent visits).”

Source: [Goodwin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36322843/)

> “Our results confirm the validity of the commonly used measures for response in MDD trials: a CGI-I score of 2 ('much improved') corresponded to a percentage MADRS reduction from baseline of 48-57%, and a CGI-I score of 1 ('very much improved') to a reduction of 80-84%.”

Source: [Leucht et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28068617/)

> “On the basis of a narrow definition of remission, which requires a complete absence of clinically significant symptoms of depression, the optimal MADRS cutoff was < or = 4. On the basis of a broader definition, the optimal cutoff was < or = 9.”

Source: [Zimmerman et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15003068/)

> “In MDD a 50% improvement of a patient on a usual rating scale is accepted as a clinically relevant response.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

<a id="topic-3.1.3.6.1-10"></a>

###### Key secondary endpoint hierarchy and multiplicity control

> “To control the overall Type I error rate a sequential test procedure will be applied across the primary and key secondary efficacy endpoints for both COMP360 doses (25 mg and 10 mg) following the hierarchy specified below, with all testing done at the 0.05 alpha level:”
> “Primary endpoint, change in MADRS total score from baseline to week 3 (25 mg vs 1 mg)”
> “Primary endpoint, change in MADRS total score from baseline to week 3 (10 mg vs 1 mg)”

Source: [COMPASS Pathways COMP001 statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/SAP_001.pdf)

<a id="topic-3.1.3.6.1-11"></a>

###### Time-to-event secondary endpoints in the protocol

> “Time to event measures: restart antidepressant medication for any reason, restart medication for continuing depressive symptoms, and relapse from a previously recovered state (clinical judgement, supported by the QIDS-SR-16).”

Source: [COMPASS Pathways COMP001 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Planned enrollment and power

> “216 participants will be randomised in a 1:1:1 ratio to receive 1 mg psilocybin, 10 mg psilocybin, or 25 mg psilocybin.”
> “The 6-point difference in average MADRS total score on a group level is supported by the pilot study with psilocybin”
> “and is within the range of potential differences that have been used to power other studies in major depression and TRD.”

Source: [COMPASS Pathways COMP001 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf)

> “For this primary analysis, a sample size of 216 randomised participants (72:72:72) will provide 90% power at the alpha = 0.05 level to detect a 6-point difference in average MADRS total score between the optimal therapeutic dose of COMP360 and COMP360 1 mg, assuming the common standard deviation (SD) is 11.0.”

Source: [COMPASS Pathways COMP001 statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/SAP_001.pdf)

<a id="topic-3.1.3.7.1-2"></a>

###### Actual enrollment: registry record

| Enrollment type | Participants |
| --- | --- |
| Actual | “233” |

Source: [ClinicalTrials.gov NCT03775200](https://clinicaltrials.gov/study/NCT03775200)

<a id="topic-3.1.3.7.1-3"></a>

###### Randomized participants by arm

> “A total of 79 participants were in the 25-mg group, 75 in the 10-mg group, and 79 in the 1-mg group.”

Source: [Goodwin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36322843/)

<a id="topic-3.1.3.7.1-4"></a>

###### Participants analyzed for the primary endpoint

| Analysis | 25 mg | 10 mg | 1 mg |
| --- | --- | --- | --- |
| Full analysis set (primary) | “79” | “75” | “79” |
| Per-protocol set (sensitivity) | “77” | “65” | “68” |

Source: [ClinicalTrials.gov NCT03775200 results](https://clinicaltrials.gov/study/NCT03775200?tab=results)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### Analysis set definitions

> “The Randomised Analysis Set: All randomised participants, whether or not they receive study drug.”
> “The Safety Analysis Set: All randomised participants who receive study drug.”
> “The Full Analysis Set (FAS): All participants randomised who receive study drug and have at least 1 post-dose efficacy assessment.”
> “The Per-Protocol (PP) Analysis Set: All participants in the FAS who do not have a protocol deviation that is thought to significantly affect the integrity of the participant’s efficacy data.”

Source: [COMPASS Pathways COMP001 statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/SAP_001.pdf)

<a id="topic-3.1.3.7.2-2"></a>

###### Changes to analysis sets from the protocol

> “modified Intent-to-Treat was removed”
> “Full Analysis Set definition updated to match the modified Intent-to-Treat definition”

Source: [COMPASS Pathways COMP001 statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/SAP_001.pdf)

<a id="topic-3.1.3.7.2-3"></a>

###### Primary and secondary estimands

> “The Hypothetical Strategy will be the primary estimand to best understand the clinical effects of COMP360 without the effects of participants taking new treatments for depression.”
> “The Treatment Policy will be the secondary estimand to understand the clinical effects of COMP360 versus inactive control including participants taking new treatment for depression if needed in both arms.”

Source: [COMPASS Pathways COMP001 statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/SAP_001.pdf)

<a id="topic-3.1.3.7.2-4"></a>

###### Primary analysis model in the protocol

> “The primary efficacy endpoint (change from Baseline in MADRS total score at Week 3) will be evaluated with a mixed-effects model for repeated measures analysis.”

Source: [COMPASS Pathways COMP001 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf)

<a id="topic-3.1.3.7.2-5"></a>

###### Analysis populations reported in the registry

> “The full analysis set includes all participants randomised who receive study drug and have at least 1 post-dose efficacy assessment.”
> “The per-protocol analysis set includes all participants in the Full Analysis Set who do not have a protocol deviation that is thought to significantly affect the integrity of the participant's efficacy data.”
> “The Safety Analysis Set included all randomised participants who received study drug.”

Source: [ClinicalTrials.gov NCT03775200 results](https://clinicaltrials.gov/study/NCT03775200?tab=results)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### Participant flow: registry results

| Status | 25 mg | 10 mg | 1 mg |
| --- | --- | --- | --- |
| Started | “79” | “75” | “79” |
| Completed | “74” | “66” | “69” |
| Not completed | “5” | “9” | “10” |

Source: [ClinicalTrials.gov NCT03775200 results](https://clinicaltrials.gov/study/NCT03775200?tab=results)

<a id="topic-3.1.3.8.1-2"></a>

###### Completion and withdrawals: company statement

> “Overall, 209 patients completed the study; there were five withdrawals from the 25mg group, nine from the 10mg, and 10 from the 1mg.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

###### Demographics: registry results

| Characteristic | 25 mg | 10 mg | 1 mg | Total |
| --- | --- | --- | --- | --- |
| Participants | “79” | “75” | “79” | “233” |
| Age, mean (SD), years | “40.2(12.19)” | “40.6(12.76)” | “38.7(11.71)” | “39.8(12.19)” |
| Age 65 years or older | “3” | “2” | “2” | “7” |
| Female | “35” | “34” | “43” | “112” |
| Male | “44” | “41” | “36” | “121” |
| White | “70” | “72” | “73” | “215” |
| Asian | “4” | “3” | “5” | “12” |
| Black or African American | “4” | “0” | “1” | “5” |

Source: [ClinicalTrials.gov NCT03775200 results](https://clinicaltrials.gov/study/NCT03775200?tab=results)

<a id="topic-3.1.3.8.2-2"></a>

###### Baseline depression severity

> “The mean MADRS total score at baseline was 32 or 33 in each group.”

Source: [Goodwin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36322843/)

<a id="topic-3.1.3.8.2-3"></a>

###### Prior psilocybin experience

> “94% of the patients had no prior experience with psilocybin.”

Source: [COMPASS Pathways NEJM publication release (2022)](https://ir.compasspathways.com/News--Events-/news/news-details/2022/COMPASS-Pathways-announces-publication-of-phase-2b-study-of-COMP360-psilocybin-therapy-for-treatment-resistant-depression-in-The-New-England-Journal-of-Medicine/default.aspx)

<a id="topic-3.1.3.8.2-4"></a>

###### Baseline suicidality

> “Two thirds of the patients had previous thoughts of wishing to be dead, as assessed by a suicidality scale completed during patient screening; this included all patients reporting one of these adverse events, meaning that patients who experienced these events during the trial had said in patient screening that they had had suicidal thoughts prior to the trial.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

> “Suicidality was comparable between groups at Baseline.”

Source: [Marwood et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39427449/)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### Primary endpoint: change in MADRS total score at Week 3

> “Least-squares mean changes from baseline to week 3 in the score were -12.0 for 25 mg, -7.9 for 10 mg, and -5.4 for 1 mg; the difference between the 25-mg group and 1-mg group was -6.6 (95% confidence interval [CI], -10.2 to -2.9; P<0.001) and between the 10-mg group and 1-mg group was -2.5 (95% CI, -6.2 to 1.2; P = 0.18).”

Source: [Goodwin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36322843/)

<a id="topic-3.1.3.8.3-2"></a>

###### Primary endpoint: company statement

> “The Phase 2b study met its primary endpoint.”
> “The 25mg group vs the 1mg group showed a -6.6 difference on the MADRS depression scale at week 3 (p<0.001).”
> “The 10mg vs 1mg dose did not show a statistically significant difference at week 3.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.3.8.3-3"></a>

###### Observed MADRS change at Week 3: registry results

| Analysis set | 25 mg | 10 mg | 1 mg |
| --- | --- | --- | --- |
| Full analysis set, mean (SD) | “-12(12.98)” | “-8.9(10.94)” | “-6.8(11.10)” |
| Per-protocol set, mean (SD) | “-12(12.98)” | “-8.9(11.11)” | “-6.7(11.18)” |

Source: [ClinicalTrials.gov NCT03775200 results](https://clinicaltrials.gov/study/NCT03775200?tab=results)

<a id="topic-3.1.3.8.3-4"></a>

###### Onset of effect at Day 2

> “The 25mg group demonstrated statistical significance on the MADRS efficacy endpoint on the day after the COMP360 psilocybin administration, day 2 (p=0.002).”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.3.8.3-5"></a>

###### Response, remission, and sustained response

> “In the 25-mg group, the incidences of response and remission at 3 weeks, but not sustained response at 12 weeks, were generally supportive of the primary results.”

Source: [Goodwin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36322843/)

> “After a single 25mg dose of COMP360 psilocybin, in combination with psychological support, 29.1% of participants with TRD were in remission by week 3 (p<0.002)”
> “Double the number of patients who received a 25mg dose had a sustained response at week 12, compared to those who received 1mg (20.3% of patients in the 25mg group vs 10.1% in the 1mg group)”

Source: [COMPASS Pathways NEJM publication release (2022)](https://ir.compasspathways.com/News--Events-/news/news-details/2022/COMPASS-Pathways-announces-publication-of-phase-2b-study-of-COMP360-psilocybin-therapy-for-treatment-resistant-depression-in-The-New-England-Journal-of-Medicine/default.aspx)

<a id="topic-3.1.3.8.3-6"></a>

###### Post hoc analysis: antidepressant discontinuation before dosing

> “Antidepressant drug discontinuation was not related to worsening of depression severity before Baseline.”
> “Psilocybin treatment efficacy and the subjective psychedelic experience did not appear to be compromised by antidepressant drug discontinuation.”

Source: [Marwood et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39427449/)

<a id="topic-3.1.3.8.3-7"></a>

###### Post hoc analysis: psychedelic experience and outcome

> “The mean intensity of psychedelic effects was dose-related, but distributions of scores for different doses overlapped considerably.”
> “At the 25 mg dose, 5D-ASC dimensions Oceanic Boundlessness (Pearson correlation coefficient r = -0.508) and Visual Restructuralization (r = -0.516), and EBI (r = -0·637) were the variables with the strongest correlation to the Week 3 change from Baseline in MADRS score.”

Source: [Goodwin et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39706482/)

<a id="topic-3.1.3.8.3-8"></a>

###### Post hoc analysis: therapeutic alliance

> “Change from Baseline to Week 3 MADRS scores showed weaker correlations with pre-dosing therapeutic alliance (-0.178) than with measures of the psychedelic experience: EBI (-0.637), Oceanic Boundlessness (-0.508), and Visual Restructuralization (-0.516).”
> “The effects of the alliance itself on therapeutic efficacy were either limited or absent.”

Source: [Goodwin et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41881122/)

<a id="topic-3.1.3.8.3-9"></a>

###### Post hoc analysis: pretreatment characteristics and the psychedelic experience

> “Dose was the strongest and most consistent predictor of the psychedelic experience.”
> “Some pretreatment characteristics contributed weakly to subjective experiences.”

Source: [Kirlić et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41362124/)

<a id="topic-3.1.3.8.3-10"></a>

###### Exploratory analysis: language-based prediction of response

> “Two multinomial logistic regression models were fit to predict responder status at week 3 and through week 12. Cross-validation of these models resulted in 85% and 88% accuracy and AUC values of 88% and 85%.”

Source: [Dougherty et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12226623/)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.3.8.4-1"></a>

###### Patient-reported measures assessed

> “Efficacy measures assessed patient-reported depression severity, anxiety, positive and negative affect, functioning and associated disability, quality of life, and cognitive function.”

Source: [Goodwin et al. (2023a)](https://pubmed.ncbi.nlm.nih.gov/36740140/)

<a id="topic-3.1.3.8.4-2"></a>

###### Week 3 patient-reported outcomes

> “At Week 3, psilocybin 25 mg, compared with 1 mg, was associated with greater improvements from Baseline total scores in all measures. The 10 mg dose produced smaller effects across these measures.”
> “Three weeks after dosing, psilocybin 25 mg and, to a lesser degree, 10 mg improved measures of patient-reported depression severity, anxiety, affect, and functioning.”

Source: [Goodwin et al. (2023a)](https://pubmed.ncbi.nlm.nih.gov/36740140/)

<a id="topic-3.1.3.8.4-3"></a>

###### Exploratory endpoints and multiplicity

> “Quality of life in participant EuroQoL (EQ)- 5 dimension-3 level scale (EQ-5D-3L) score change from Baseline to Week 3.”
> “The exploratory analyses for quality of life and wellbeing, functioning and associated disability, cognitive function, and anxiety are not hierarchical; there will be no correction for multiplicity in these analyses.”

Source: [COMPASS Pathways COMP001 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf)

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Overall adverse events

> “Adverse events occurred in 179 of 233 participants (77%) and included headache, nausea, and dizziness. Suicidal ideation or behavior or self-injury occurred in all dose groups.”

Source: [Goodwin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36322843/)

<a id="topic-3.1.3.8.5-2"></a>

###### Severity and timing of treatment-emergent adverse events

> “COMP360 was generally well tolerated, with more than 90% of treatment-emergent adverse events, or TEAEs, being mild or moderate in severity and greater than 77% of TEAEs occurring on the day of administration being resolved on the same day or the next day.”
> “179 patients reported at least one TEAE; the most common TEAEs across treatment groups (>10% overall incidence) were headache, nausea, fatigue, and insomnia.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.3.8.5-3"></a>

###### Serious adverse events through Week 12: registry results

| Event | 25 mg | 10 mg | 1 mg |
| --- | --- | --- | --- |
| Any serious adverse event | “5/79 (6.33%)” | “6/75 (8.00%)” | “1/79 (1.27%)” |
| Suicidal behaviour | “3/79 (3.80%)” | “0/75 (0.00%)” | “0/79 (0.00%)” |
| Intentional self-injury | “2/79 (2.53%)” | “2/75 (2.67%)” | “1/79 (1.27%)” |
| Suicidal ideation | “2/79 (2.53%)” | “2/75 (2.67%)” | “0/79 (0.00%)” |
| Drug withdrawal syndrome | “1/79 (1.27%)” | “0/75 (0.00%)” | “0/79 (0.00%)” |
| Depression | “0/79 (0.00%)” | “1/75 (1.33%)” | “0/79 (0.00%)” |
| Hospitalisation | “0/79 (0.00%)” | “1/75 (1.33%)” | “0/79 (0.00%)” |
| All-cause mortality | “0/79 (0.00%)” | “0/75 (0.00%)” | “0/79 (0.00%)” |

Source: [ClinicalTrials.gov NCT03775200 results](https://clinicaltrials.gov/study/NCT03775200?tab=results)

<a id="topic-3.1.3.8.5-4"></a>

###### Serious adverse events: company statement

> “There were 12 patients, 5 patients in the 25 mg group, 6 patients in the 10 mg group and 1 in the 1 mg group, who reported treatment-emergent serious adverse events, or TESAEs.”
> “These TESAEs included, among others, suicidal behavior, intentional self-injury, and suicidal ideation, which are regularly observed in a TRD patient population.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.3.8.5-5"></a>

###### Other adverse events with frequency of 5% or more: registry results

| Event | 25 mg | 10 mg | 1 mg |
| --- | --- | --- | --- |
| Any other adverse event | “60/79 (75.95%)” | “51/75 (68.00%)” | “50/79 (63.29%)” |
| Headache | “27/79 (34.18%)” | “16/75 (21.33%)” | “20/79 (25.32%)” |
| Nausea | “18/79 (22.78%)” | “7/75 (9.33%)” | “4/79 (5.06%)” |
| Fatigue | “12/79 (15.19%)” | “5/75 (6.67%)” | “7/79 (8.86%)” |
| Insomnia | “8/79 (10.13%)” | “11/75 (14.67%)” | “14/79 (17.72%)” |
| Anxiety | “7/79 (8.86%)” | “13/75 (17.33%)” | “3/79 (3.80%)” |
| Mood altered | “7/79 (8.86%)” | “3/75 (4.00%)” | “1/79 (1.27%)” |
| Dizziness | “6/79 (7.59%)” | “1/75 (1.33%)” | “1/79 (1.27%)” |
| Back pain | “6/79 (7.59%)” | “0/75 (0.00%)” | “3/79 (3.80%)” |
| Suicidal ideation | “5/79 (6.33%)” | “3/75 (4.00%)” | “4/79 (5.06%)” |
| Myalgia | “5/79 (6.33%)” | “2/75 (2.67%)” | “1/79 (1.27%)” |
| Panic reaction | “4/79 (5.06%)” | “1/75 (1.33%)” | “1/79 (1.27%)” |
| Euphoric mood | “4/79 (5.06%)” | “5/75 (6.67%)” | “4/79 (5.06%)” |
| Thinking abnormal | “0/79 (0.00%)” | “4/75 (5.33%)” | “0/79 (0.00%)” |

Source: [ClinicalTrials.gov NCT03775200 results](https://clinicaltrials.gov/study/NCT03775200?tab=results)

<a id="topic-3.1.3.8.5-6"></a>

###### Timing of suicidality events and dose-related events

> “On the day of COMP360 administration, headache, nausea, and dizziness were the most common adverse events where a dose-related increase in incidence was evident”
> “Suicidal ideation and intentional self-injury were seen in all treatment groups, as is common in TRD studies. Most cases occurred more than a week after the COMP360 psilocybin session. There was no mean worsening of suicidal ideation scores on the MADRS scale in any treatment group. Suicidal behaviours were reported at least one month after COMP360 administration for three non-responders in the 25mg arm”

Source: [COMPASS Pathways NEJM publication release (2022)](https://ir.compasspathways.com/News--Events-/news/news-details/2022/COMPASS-Pathways-announces-publication-of-phase-2b-study-of-COMP360-psilocybin-therapy-for-treatment-resistant-depression-in-The-New-England-Journal-of-Medicine/default.aspx)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary: functional unblinding, low-dose comparator without an active treatment, antidepressant washout, Week 3 primary endpoint

The authors state that interpretation is limited by the absence of an active comparator and the possibility of functional unblinding in participants who received a low dose, and that larger and longer trials, including comparison with existing treatments, are required. Published correspondence disputed the description of the trial as double-blind. The primary endpoint was at Week 3, and the authors state that in the 25 mg group, sustained response at 12 weeks was not generally supportive of the primary results. Participants tapered antidepressants at least two weeks before baseline and were asked to remain off them for at least 3 weeks after dosing; a commentary notes that many started other antidepressants after Week 3. The same commentary notes emergent suicidal ideation and behavior in the 25 mg and 10 mg groups and not in the 1 mg group, and the publication reports suicidal ideation or behavior or self-injury in all dose groups.

Source: [Goodwin et al. (2023a)](https://pubmed.ncbi.nlm.nih.gov/36740140/); [Goodwin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36322843/); [Østergaard and Hieronymus (2023)](https://www.nejm.org/doi/full/10.1056/NEJMc2215459); [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm); [COMPASS Pathways COMP001 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf); [Mann (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9873942/)

<a id="topic-3.1.3.9-2"></a>

###### Authors' stated limitations: comparator and trial size

> “Larger and longer trials, including comparison with existing treatments, are required to determine the efficacy and safety of psilocybin for this disorder.”

Source: [Goodwin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36322843/)

> “Interpretation of this trial is limited by the absence of an active comparator and the possibility of functional unblinding in participants who received a low dose of psilocybin.”

Source: [Goodwin et al. (2023a)](https://pubmed.ncbi.nlm.nih.gov/36740140/)

<a id="topic-3.1.3.9-3"></a>

###### Authors' stated limitations: secondary analyses

> “The existence of correlation does not establish causation and exploratory findings require further replication, preferably in larger independent samples.”

Source: [Goodwin et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39706482/)

> “Limitations of this study include that we were only able to analyze a cohort of 101 participants at 3 weeks and 90 individuals at 12 weeks.”

Source: [Dougherty et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12226623/)

<a id="topic-3.1.3.9-4"></a>

###### Functional unblinding: published correspondence

> “The authors refer to their trial as a double-blind trial.”
> “This is hardly true for the trial”

Source: [Østergaard and Hieronymus (2023)](https://www.nejm.org/doi/full/10.1056/NEJMc2215459)

<a id="topic-3.1.3.9-5"></a>

###### Functional unblinding: sponsor-authored response

> “The intensity of psychedelic experience overlaps widely across doses and mitigates the risk of unblinding to dose.”

Source: [Goodwin et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39706482/)

<a id="topic-3.1.3.9-6"></a>

###### Functional unblinding and expectancy in psychedelic trials

> “While psychedelic RCTs have generally shown promising results, with large effect sizes reported, we argue that treatment effect sizes in psychedelic RCTs are likely over-estimated due to de-blinding of participants and high levels of response expectancy.”

Source: [Muthukumaraswamy et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34038314/)

> “This increases the potential for bias due to functional unblinding of patients, therapists, monitors, or raters.”

Source: [FDA psychedelic drugs guidance (2026)](https://www.fda.gov/media/169694/download)

> “Positive expectancy might lead to overestimation bias while disappointment with treatment (negative expectancy) might lead to symptom worsening or safety issues (nocebo effect).”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

<a id="topic-3.1.3.9-7"></a>

###### Commentary: dose selection, psychedelic effects, and suicidality

> “The findings support use of drug plasma levels to optimize psilocybin doses and to analyze dose-dependent variance in clinical response, instead of using oral dose.”
> “Most side effects (nausea, headache) were comparable between the 10 mg and 25 mg dose groups, but surprisingly, the paper is silent about psychedelic effects even though it reports such effects lasted about 6 h after taking psilocybin.”
> “Of note, suicidal ideation and behavior history were comparable in all three dose groups prior to the study, but emergent suicidal ideation and behavior was observed in the 25 mg and 10 mg groups and not in the 1 mg group (employed as an active comparator instead of a placebo).”

Source: [Mann (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9873942/)

<a id="topic-3.1.3.9-8"></a>

###### Commentary: antidepressant restart after Week 3

> “Individuals who participated in the study were asked to stay off other psychotropic medications for the first 3 weeks and most complied.”
> “The 25 mg dose showed efficacy compared with 1 mg daily at 3 weeks, and this continued until 12 weeks, even though many patients started other antidepressants after week 3.”

Source: [Mann (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9873942/)

<a id="topic-3.1.3.9-9"></a>

###### Antidepressant washout before dosing

> “It has been suggested that the recent use and discontinuation of antidepressant drugs compromises the action of psilocybin.”
> “As evidence is only available from small or uncontrolled samples, this post hoc analysis investigated this using data from the largest, phase II, randomized controlled trial of psilocybin treatment to date.”

Source: [Marwood et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39427449/)

<a id="topic-3.1.3.9-10"></a>

###### Commentary on the therapeutic alliance analysis

> “While the authors conclude that alliance did not meaningfully contribute to treatment efficacy, we argue that this interpretation is not supported by the reported results, which are, in addition, shaped by methodological decisions that obscure relevant effects.”
> “Furthermore, we highlight unexplained deviations from the study protocol that warrant scrutiny.”

Source: [Wolff et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42903188/)

Additional sources: [Madras (2022)](https://www.nejm.org/doi/full/10.1056/NEJMe2210975)

<a id="heading-3.1.4"></a>

#### 3.1.4 COMP004

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Registered study purpose

> “The primary objective of this study is to assess the long-term efficacy of psilocybin with respect to use of new antidepressant treatment, hospitalisations for depression, suicidality, and depressive severity rated using the Montgomery and Asberg Depression Rating Scale (MADRS) over a total of 52 weeks (compared across the 1 mg, 10 mg and 25 mg psilocybin groups from COMP 001).”

Source: [ClinicalTrials.gov NCT04519957](https://clinicaltrials.gov/study/NCT04519957)

<a id="topic-3.1.4.1-2"></a>

###### Published study aim

> “Here, we report findings from COMP 004, a 52-week observational follow-up of patients from COMP 001 and COMP 003, a small open-label study of the coadministration of 25 mg COMP360 with continuing antidepressant treatment.”

Source: [Goodwin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40047545/)

<a id="topic-3.1.4.1-3"></a>

###### Role in the development program

> “The outcomes of the long-term follow-up study informed the design of our Phase 3 registrational program, including investigating whether a second administration of COMP360 may achieve improved durability, response and remission outcomes.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Study dates and identifiers

| Item | Registry record |
| --- | --- |
| Other study ID | “COMP004” |
| Study start (actual) | “2020-07-20” |
| Primary completion (actual) | “2022-08-11” |
| Study completion (actual) | “2022-08-11” |
| Last update posted | “2022-09-22” |

Source: [ClinicalTrials.gov NCT04519957](https://clinicaltrials.gov/study/NCT04519957)

<a id="topic-3.1.4.2-2"></a>

###### Sites

> “This study has 8 locations”

Source: [ClinicalTrials.gov NCT04519957](https://clinicaltrials.gov/study/NCT04519957)

<a id="topic-3.1.4.2-3"></a>

###### Data collection period

> “Data were collected from July 2020 to July 2022.”

Source: [Goodwin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40047545/)

<a id="topic-3.1.4.2-4"></a>

###### Publication

> “In March 2025, the results from our observational, 52-week follow-up study (COMP004) of 66 participants who took part in our Phase 2b trial were published in the Journal of Clinical Psychiatry.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Registered design

| Item | Registry record |
| --- | --- |
| Study type | “Observational” |
| Observational model | “Ecologic or Community” |
| Time perspective | “Prospective” |
| Official title | “Multicentre Study To Assess Safety And Efficacy Of Psilocybin In Patients With Treatment-Resistant Depression Following Completion Of COMP 001 And COMP 003 Trials (P-TRD LTFU)” |

Source: [ClinicalTrials.gov NCT04519957](https://clinicaltrials.gov/study/NCT04519957)

<a id="topic-3.1.4.3-2"></a>

###### Follow-up structure and duration

> “In this present study (COMP 004), the aim is to follow up participants from COMP 001 and COMP 003 in a long-term follow up study, with both remote and digital assessments”
> “Patients previously treated in COMP001 will be followed for approximately 40 weeks and patients previosuly treated in COMP003 will be followed for approximately 49 weeks giving a total follow up period of 52 weeks from psilocybin dosing.”

Source: [ClinicalTrials.gov NCT04519957](https://clinicaltrials.gov/study/NCT04519957)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Registered eligibility criteria

| Criterion | Quoted registry text |
| --- | --- |
| Consent | “Signed ICF” |
| Prior study completion | “Each participant having completed the final study visit of either COMP 001 or COMP 003” |
| Assessment capacity | “Ability to complete all protocol required assessment tools (including having access to the internet in order to complete the digital assessments) without any assistance or alteration to the copyrighted assessments, and to comply with all study visits” |
| Exclusion | “Subject has any condition, for which in the opinion of the investigator, participation would not be in the interest of the subject eg participation could compromise the wellbeing of the participant or prevent, limit, or confound the protocol-specified assessments” |
| Study population | “TRD patients who completed COMP001 or COMP003” |
| Ages eligible | “18 Years to 55 Years” |
| Sampling method | “Probability Sample” |

Source: [ClinicalTrials.gov NCT04519957](https://clinicaltrials.gov/study/NCT04519957)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Interventions received in the parent studies

> “to explore the long term efficacy and safety of the three different doses of psilocybin (1 mg, 10 mg, and 25 mg) administered to patients with TRD as a monotherapy in COMP 001 and 25 mg psilocybin administered as an adjunct to an SSRI in COMP 003”

Source: [ClinicalTrials.gov NCT04519957](https://clinicaltrials.gov/study/NCT04519957)

<a id="topic-3.1.4.5-2"></a>

###### No study drug administered during follow-up

> “Three participants reported experiencing a treatment emergent serious adverse event post-enrollment to COMP004, occurring more than 6 months after a single dose administration and all deemed unrelated to study drug.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Time to Depressive Event as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Primary endpoint definition

> “The primary efficacy endpoint was time to a prespecified depressive event over the 52 weeks following COMP360 administration in COMP 001 participants, presented as Kaplan-Meier estimates.”

Source: [Goodwin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40047545/)

> “The primary endpoint of this COMP004 study was the median time to a new depressive event.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.4.6.1-2"></a>

###### Registered outcome measures

| Outcome | Measure description | Time frame |
| --- | --- | --- |
| “Long-term efficacy of psilocybin” | “Use of new antidepressant treatment, hospitalisations for depression, suicidality, and depressive severity rated using the Montgomery and Asberg Depression Rating Scale (MADRS)” | “up to 52 weeks” |
| “Response, sustained response, remission and change in depression severity” | “Montgomery Asberg Depression Rating Scale (MADRS)” | “Up to 52 weeks” |
| “Psychosocial functioning and to predict durability of response to antidepressant treatment” | “Work and Social Adjustment Scale (WSAS) score change from Baseline of the prior study” | “up to 52 weeks” |
| “Functional impairment in work/school, social life, and family life.” | “Sheehan Disability Scale (SDS) score change from Baseline of the prior study” | “Up to 52 weeks” |
| “Safety of Psilocybin” | “Incidence and severity of Adverse Events (AEs) and Seroius Adverse Events (SAEs)” | “Up to 52 weeks” |

Source: [ClinicalTrials.gov NCT04519957](https://clinicaltrials.gov/study/NCT04519957)

<a id="topic-3.1.4.6.1-3"></a>

###### Regulatory expectations for durability after a single psychedelic dose

> “Therefore, sponsors should plan to evaluate the durability of response for their drug product and the safety and efficacy of repeat dosing.”
> “Sponsors should continue to follow subjects beyond the Week 12 endpoint to monitor for symptom recurrence or, potentially, the need for repeat dosing.”

Source: [FDA psychedelic drugs guidance (2026)](https://www.fda.gov/media/169694/download)

> “Endurance of effect needs to be demonstrated.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

<a id="topic-3.1.4.6.1-4"></a>

###### Time to relapse in regulatory maintenance designs

> “Because depression usually is a cyclical disease, maintenance studies of conventional”
> “antidepressants are actually assessments of the ability of the drug to reduce the rate of recurrence”

Source: [FDA (2018)](https://www.fda.gov/media/113988/download)

> “Due to the character of the disorder, longer trials are necessary to demonstrate that the acute effect is maintained during an episode (relapse prevention). For this, a randomised withdrawal study is the preferred design.”
> “The duration of 6 months is not strictly necessary when a time to event approach is chosen.”
> “In randomised withdrawal trials, efficacy usually is expressed as rate of patients worsening (relapsing) and/or time to this event.”
> “Worsening or relapse has to be defined in the protocol. Usually, a clinically relevant increase in symptoms scored on a validated rating scale is used.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

<a id="topic-3.1.4.6.1-5"></a>

###### Time to relapse as the primary endpoint in a treatment-resistant depression trial

> “Cumulative distribution of time to relapse during the maintenance phase among patients who achieved stable remission (primary efficacy end point) and those who achieved stable response without remission (secondary end point) was estimated by the Kaplan-Meier method.”
> “Relapse was defined as a MADRS total score of 22 or higher for 2 consecutive assessments separated by 5 to 15 days or hospitalization for worsening depression, suicide attempt, suicide prevention or completed suicide, or another clinically relevant event suggestive of relapse (assessed by a relapse adjudication committee).”

Source: [Daly et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6551577/)

<a id="topic-3.1.4.6.1-6"></a>

###### Clinical relevance of time-to-event endpoints in psychiatric conditions

> “The actual outcome in survival analysis is ‘time to event’, yet, in the mental health field, there has been little consideration of whether a temporary delay to relapse is clinically relevant in a condition that can last for decades.”
> “They inevitably lead to differences in time to relapse, even when there is little or no difference in the cumulative risk of relapse at final follow-up.”

Source: [Moncrieff et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9340015/)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Actual enrollment: registry record

| Enrollment type | Participants |
| --- | --- |
| Actual | “66” |

Source: [ClinicalTrials.gov NCT04519957](https://clinicaltrials.gov/study/NCT04519957)

<a id="topic-3.1.4.7.1-2"></a>

###### Participants by parent-study arm: company statement

> “Of the 66 participants, 22 participants were in the 25mg group, 19 participants were in the 10mg group, 17 participants were in the 1mg group and 8 participants were in the 25mg plus SSRI group.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.4.7.1-3"></a>

###### Participants analyzed for the primary endpoint

> “The pre-specified primary analysis was of the median time for such an event for all participants in our Phase 2b trial, not only those who enrolled in the COMP004 study.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.4.7.1-4"></a>

###### Planned enrollment

No evidence found.

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

###### Post hoc analysis set: participants who entered COMP004

> “A post hoc analysis included only participants that entered COMP 004.”

Source: [Goodwin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40047545/)

> “A post hoc analysis of the 58 participants who enrolled in the COMP004 from our Phase 2b trial revealed a substantial difference in median time to depressive event for those in the 25 mg group compared to the 10mg and 1mg groups”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

###### Participants entering follow-up

> “Sixty-six participants entered COMP 004 (COMP 001, n = 58 [25 mg group n = 22, 10 mg group n = 19, 1 mg group n = 17]; COMP 003, n = 8).”

Source: [Goodwin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40047545/)

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

###### Antidepressant use at entry

> “At COMP 004 entry, the 1 mg group had the highest number of participants on antidepressant medication (n = 10; 10 mg, n = 9; 25 mg, n = 6) and generally initiated treatment earlier.”

Source: [Goodwin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40047545/)

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

###### Median time to depressive event: published analysis

> “For all COMP 001 patients (n = 233), median time to depressive event was greater for the 25 mg group (92 days) compared to the 10 mg (83 days) and 1 mg (62 days) groups, with the majority of participants having had a depressive event by Week 12 (25 mg n = 37/75, 10 mg n = 38/79, 1 mg n = 44/75).”

Source: [Goodwin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40047545/)

<a id="topic-3.1.4.8.3-2"></a>

###### Median time to depressive event: annual report figure for the 10 mg group

> “The median time to a new depressive event was 92 days for the COMP360 25mg group compared to 86 days for the 10mg group and 62 days for the 1mg group.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.4.8.3-3"></a>

###### Median time to depressive event: post hoc analysis of enrolled participants

> “The post hoc supplementary analysis of those who enrolled in COMP 004 from COMP 001 exhibited the difference between groups more strikingly (25 mg, 189 days; 10 mg, 43 days; 1 mg, 21 days); however, only 10 participants experienced a depressive event post-COMP 004 enrollment (25 mg n = 6, 10 mg n = 3, 1 mg n = 1) from COMP 001 and none from COMP 003.”

Source: [Goodwin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40047545/)

<a id="topic-3.1.4.8.3-4"></a>

###### Median time to depressive event: quarterly results statement

> “Recent 52-week data from an observational follow-up study published on COMP360 demonstrated a durable treatment response and a median time to depressive event of 92 days (n=252) on a single 25mg administration and 189 days (n=58) for the 25mg subgroup that continued into the COMP004 long-term extension”

Source: [COMPASS Pathways first quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1816590/000162828025023427/q12025pressrelease.htm)

<a id="topic-3.1.4.8.3-5"></a>

###### New treatment for depression during follow-up

> “In addition, a lower proportion of participants started new treatments for depression in the 25mg”
> “and 10mg arm compared to the 1mg arm.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.4.8.3-6"></a>

###### Authors' conclusion

> “Over 52 weeks, a single administration of 25 mg psilocybin suggested longer maintenance of antidepressant effect than both 1 mg and 10 mg.”

Source: [Goodwin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40047545/)

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

Additional sources: [Goodwin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40047545/)

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

###### Adverse events after entry into follow-up

> “Few AEs were reported post-entry into COMP 004, with 1 AE of mild suicidal ideation in the 1 mg group deemed possibly related to study drug.”

Source: [Goodwin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40047545/)

<a id="topic-3.1.4.8.5-2"></a>

###### Serious, ongoing, and suicidality adverse events: company statement

> “With respect to adverse events, twenty-seven or 40.9% of participants had an adverse event that was ongoing as of, or started, after week 12.”
> “Suicidality was recorded as an adverse event across all arms with two in each of the 25mg group and the 10mg group, and one in the 1mg group.”
> “COMP360 was generally well tolerated.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary: observational design, selected subgroup, few events, post hoc analysis

COMP004 was an observational follow-up that enrolled 66 participants who had completed COMP001 or COMP003, 58 of them from COMP001. The prespecified primary analysis covered all COMP001 participants, and the analysis restricted to enrolled participants was post hoc and based on 10 depressive events after enrollment. At entry, more participants in the 1 mg group were taking antidepressant medication (10, compared with 9 in the 10 mg and 6 in the 25 mg group). The published and Form 10-K medians for the 10 mg group differ (83 and 86 days). The authors state that larger long-term studies are required, and FDA guidance describes blinded long-term follow-up with prespecified retreatment criteria as the most informative design.

Source: [ClinicalTrials.gov NCT04519957](https://clinicaltrials.gov/study/NCT04519957); [Goodwin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40047545/); [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm); [FDA psychedelic drugs guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="topic-3.1.4.9-2"></a>

###### Authors' stated limitations: few events and need for larger studies

> “Larger long-term studies are required to confirm these findings and provide clarity on the longer-term effects of psilocybin.”

Source: [Goodwin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40047545/)

<a id="topic-3.1.4.9-3"></a>

###### Unblinded observational follow-up

> “The most informative clinical trial design would incorporate blinded long-term follow-up (typically 12 months) with prespecified criteria for retreatment.”
> “These criteria should take into account symptom ratings as well as whether the participant seeks additional treatment outside the study.”

Source: [FDA psychedelic drugs guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="topic-3.1.4.9-4"></a>

###### Limited evidence on durability and retreatment

> “The experience and the available information on the sustainability of the action and the long-term effects, both desirable and undesirable of psychedelics and the efficacy of re-treatment are very limited.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

<a id="heading-3.1.5"></a>

#### 3.1.5 COMP003

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

###### Safety, tolerability, and efficacy of COMP360 adjunctive to an SSRI

> “This phase II, exploratory, international, fixed-dose, open-label study explored the safety, tolerability, and efficacy of a synthetic form of psilocybin (investigational drug COMP360) adjunct to a selective serotonin reuptake inhibitor in participants with TRD.”
> “With the development of psilocybin specifically as a treatment for TRD, it is important to test the impact of chronic antidepressant treatment on the antidepressant effects of psilocybin.”
> “This outcome will inform whether it is necessary to withdraw people from antidepressant drugs prior to administering psilocybin for a safe or therapeutic effect.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

###### Study period and sites in Ireland and the United States

> “This was a phase II, exploratory, fixed-dose, open-label study conducted between August 2020 and September 2021.”
> “The protocol was approved by ethics committees at two sites located in Ireland and the United States (US): the Clinical Research Ethics Committee of the Cork Teaching Hospitals (CREC), and the Advarra Center for IRB Intelligence (CIRBI).”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.2-2"></a>

###### Registry dates and locations

| Field | Registry entry |
| --- | --- |
| Study start (actual) | “2020-08-10” |
| Primary completion (actual) | “2021-10-14” |
| Study completion (actual) | “2021-10-14” |
| United States site | “Kadima Neuropsychiatry Institute” |
| Ireland site | “Sheaf House, Tallaght Hospital” |

Source: [ClinicalTrials.gov NCT04739865](https://clinicaltrials.gov/study/NCT04739865)

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Open-label, single-arm, fixed-dose design

> “This trial explored the safety and efficacy of a single dose of 25 mg of the investigational drug COMP360, a proprietary pharmaceutical-grade synthetic psilocybin formulation, optimized for stability and purity, adjunct to an antidepressant drug in participants experiencing a current episode of treatment-resistant MDD (EudraCT number: 2018 002377; Clinicaltrials.gov identifier: NCT04739865).”
> “COMP360 was supplied by the sponsor, COMPASS Pathfinder Ltd (a subsidiary of COMPASS Pathways plc), London, UK.”
> “The sponsor supervised the study which was conducted by a contract research organization (Worldwide Clinical Trials, Nottingham, UK, and North Carolina, US).”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.3-2"></a>

###### Screening, administration, and follow-up periods

> “Eligible participants entered the screening period and attended the clinic weekly for three weeks prior to the psilocybin administration session.”
> “Participants were followed up for three weeks to monitor safety and efficacy.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.3-3"></a>

###### Recruitment alongside the phase 2b trial

> “Participants entered this study having been previously pre-screened for our phase IIb clinical trial (COMP 001), which was not an open label study, and the current trial (COMP 003) simultaneously.”
> “In COMP 001, 428 patients were screened and 233 were found to be eligible and underwent randomization having successfully withdrawn from any antidepressant drug as required by the protocol.”
> “Patients unable or unwilling to complete medication withdrawal at the two participating sites, or those who had a preference to be screened for COMP 003 instead, were considered for this study.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### Inclusion criteria: treatment-resistant episode of major depressive disorder

> “This study recruited adults aged 18 years or older who were outpatients and referred by practitioners from specialized psychiatric services or word of mouth from primary care services.”
> “Participants were experiencing TRD, defined by meeting the Diagnostic and Statistical Manual of Mental Disorders (5th edition) criteria of single or recurrent episode of MDD (if first single episode, duration >3 months ≤2 years was required) without psychotic features and with at least moderate symptom severity (Hamilton Depression Rating Scale, 17 item [HAM-D-17] >18) at Screening and Baseline, and having failed to respond to an adequate dose and duration (>8 weeks) of two to four pharmacological treatments for the current episode, including their current SSRI”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.4-2"></a>

###### Inclusion criteria: stable treatment with a single SSRI

> “Participants were taking a locally approved therapeutic dose of a single SSRI with at least 75% adherence for a minimum of six weeks prior to taking part and were asked to continue this treatment for the duration of the study.”
> “Permitted SSRIs included citalopram, escitalopram, fluoxetine, paroxetine, sertraline, vilazodone, and vortioxetine.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.4-3"></a>

###### Exclusion criteria: psychiatric comorbidity, suicide risk, and other antidepressants

> “Participants taking multiple antidepressant therapies were excluded.”
> “Participants experiencing a major comorbid psychiatric disorder or suicide risk were excluded based on clinical assessment, medical records, the Mini International Neuropsychiatric Interview (version 7.0.2), the McLean screening instrument for borderline personality disorder, and the Columbia-Suicide Severity Rating Scale (C-SSRS)”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.4-4"></a>

###### Exclusion criteria in the registry record

> “Prior electroconvulsive therapy and/or ketamine for current episode.”
> “Ongoing use of an antidepressant medication, including augmentation or combination therapies, other than a single SSRI”
> “Significant suicide risk as defined C-SSRS within the past year”
> “Cardiovascular conditions”
> “Seizure disorder.”

Source: [ClinicalTrials.gov NCT04739865](https://clinicaltrials.gov/study/NCT04739865)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Single 25 mg dose during a monitored session

> “The administration session (Day 1) consisted of a single administration of psilocybin 25 mg which could be administered to up to six participants in different rooms simultaneously.”
> “Each participant was accompanied by a lead therapist, with whom they had completed preparation, for the six- to eight-hour session to ensure physical and psychological safety and encourage the participant to remain attentive to the natural unfolding of their subjective experience, while avoiding active guidance.”
> “An assisting therapist was available within the vicinity to step in at any time if the lead therapist needed to leave or additional support was required, and a study psychiatrist was on site.”
> “Blood pressure was monitored continuously using a finger cuff device.”
> “Participants wore eyeshades and headphones with a specifically designed playlist of music to assist in directing their attention internally.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.5-2"></a>

###### Preparation and integration sessions

> “Preparation for the psilocybin experience was conducted by a therapist who was trained by the sponsor through a specially devised program”
> “Preparation took place over three sessions, during which the therapist built trust with the participant, explained the trial design and procedures, provided psychoeducation, and helped to prepare the participant for the psilocybin experience.”
> “At Day 2 and Week 1 following administration, participants completed an integration session with their lead therapist who encouraged them to derive their own solutions and insights from the psilocybin experience.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.5-3"></a>

###### Continued SSRI treatment and simultaneous sessions

> “All participants continued their SSRI medication throughout the follow-up period and to the end of the study (Week 3); two participants on escitalopram increased their dose (10–20 mg) during the study.”
> “Two psilocybin administration sessions (Day 1) involved simultaneous administration, where two participants were administrated at the same time (in separate rooms) in each session.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using Montgomery-Åsberg Depression Rating Scale Total Score as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

###### Primary endpoint definition and scale range

> “The primary efficacy end point was the change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from Baseline (Day -1) to three weeks post-psilocybin administration (Week 3)”
> “Total scores in the MADRS range from 0-60, with higher scores indicating greater severity of depression.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.6.1-2"></a>

###### Remote blinded independent rating

> “The MADRS was administered by a remote, blinded independent rater, following the structured interview guide”
> “at Baseline (Day -1), Day 2 and Weeks 1, 2, and 3 to ensure standardization of administration and questions (service was provided by Worldwide Clinical Trials).”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.6.1-3"></a>

###### Secondary endpoints: response, remission, and clinician global ratings

> “Key secondary end points included the proportion of participants with a response (defined as a ≥50% improvement in MADRS total score from Baseline) and remission (defined as a MADRS total score ≤10) at Week 3, change from Baseline in Clinical Global Impression–Severity (CGI-S) score at Week 3”
> “The CGI-S is a 7-point rating scale of severity based on clinical judgment.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### No formal sample size calculation

> “No formal sample size calculations were performed for this study.”
> “Nineteen participants were dosed and the mean Baseline MADRS total score was 31.7 (SD = 5.77).”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.7.1-2"></a>

###### Registry enrollment

| Field | Registry entry |
| --- | --- |
| Enrollment (actual) | “19” |

Source: [ClinicalTrials.gov NCT04739865](https://clinicaltrials.gov/study/NCT04739865)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

###### Safety, full analysis, and per-protocol sets

> “Safety analyses were performed on the safety analysis set which included all participants who received psilocybin.”
> “Efficacy analyses were performed on the full analysis set which included all participants who received psilocybin and had at least one post-Baseline efficacy assessment.”
> “All enrolled participants were included in the safety and full analysis sets and one participant was excluded from the per- protocol analysis set due to violation of exclusion criterion two: Prior electroconvulsive therapy and/or ketamine for current episode”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.7.2-2"></a>

###### Descriptive analysis and missing data

> “There was no imputation for missing efficacy data and the observed data were used in statistical analyses.”
> “The primary efficacy end point (change from Baseline to Week 3 in the MADRS total score) was evaluated with the use of descriptive summaries using statistics for continuous variables.”
> “Similarly, the secondary and exploratory efficacy end points were also summarized descriptively.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

###### Enrolled, dosed, and completed

> “Nineteen out of 24 enrolled participants with TRD were dosed and completed the study - there were no post-treatment withdrawals.”
> “The stable and ongoing SSRIs included sertraline, escitalopram, fluoxetine, vilazodone, paroxetine, and citalopram”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

###### Demographic and clinical characteristics, safety analysis set

| Characteristic | COMP360 25 mg + SSRI (N = 19) |
| --- | --- |
| Female, n (%) | “13 (68.4)” |
| Age, years, mean (SD) | “42.2 (10.80)” |
| Race, White, n (%) | “15 (78.9)” |
| Body mass index, kg/m2, mean (SD) | “26.26 (6.521)” |
| Duration of current episode 1 year to <2 years, n (%) | “13 (68.4)” |
| Duration of current episode >2 years, n (%) | “3 (15.8)” |
| Failed treatments in current episode: 2, n (%) | “12 (63.2)” |
| Failed treatments in current episode: 3 or 4, n (%) | “7 (36.8)” |
| Ongoing sertraline, n (%) [min dose, max dose] | “6 (31.6) [50 mg, 200 mg]” |
| Ongoing escitalopram, n (%) [min dose, max dose] | “6 (31.6) [5 mg, 20 mg]” |
| Ongoing fluoxetine, n (%) [min dose, max dose] | “3 (15.8%) [20 mg, 80 mg]” |
| Ongoing vilazodone, n (%) [min dose, max dose] | “2 (10.5%) [20 mg, 40 mg]” |
| Ongoing paroxetine, n (%) [dose] | “1 (5.3%) [60 mg]” |
| Ongoing citalopram, n (%) [dose] | “1 (5.3%) [20 mg]” |
| Duration of SSRI treatment prior to Baseline, months, mean (SD) | “14.68 (13.213)” |
| MADRS total score, mean (SD) | “31.7 (5.77)” |
| MADRS moderate (20 to 30), n (%) | “7 (36.8)” |

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.8.2-2"></a>

###### Depression severity and episode duration at baseline

> “The length of current episode of depression was greater than one year for 84.2% of participants, and 36.8% had experienced 3 or 4 treatment failures.”
> “At Baseline the MADRS total score was classified as severe (total score ≥31) for 57.9% of participants and the mean MADRS total score was 31.7 (SD = 5.77)”
> “At Baseline the mean CGI-S score was 4.3 (SD = 0.99) which falls into the ‘moderately ill’ range (score = 4).”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

###### Primary endpoint: MADRS change from baseline at Week 3

> “The mean MADRS total score at Week 3 was 16.8 (95% confidence interval [CI], 11.2–22.4) which equated to a clinically meaningful mean change from Baseline of −14.9 (95% CI, −20.7 to −9.2).”
> “This improvement was apparent at Day 2 and maintained throughout the three-week follow-up”
> “The results from per-protocol analysis of the primary end point were consistent with the full analysis set.”
> “A reduction in every item in the MADRS was apparent from Baseline to Week 3”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.8.3-2"></a>

###### MADRS response and remission

> “Response (≥50% reduction from Baseline MADRS total score) at Week 3 was evident in eight (42.1%) participants and was sustained throughout the follow-up period for 63.2% at Day 2, and 57.9% at Weeks 1 and 2.”
> “The same 42.1% of participants who were responders at Week 3 were also remitters (MADRS total score of ≤10) at Week 3.”
> “Remission rates remained high throughout the follow-up period for 52.6% at Day 2, 47.4% at Week 1, and 42.1% at Week 2”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.8.3-3"></a>

###### Clinician global impression of severity and improvement

> “The mean CGI-S score at Week 3 was 2.9 (SD = 1.84) which equates to a −1.3 (SD = 1.29) change from Baseline.”
> “Proportion of responders on the CGI-S were 42.1% at Day 2, 63.2% at Week 1, 57.9% at Week 2, and 52.6% at Week 3”
> “Fourteen participants (73.7%) were considered at least minimally improved (CGI-I score ≤3) by clinicians from Baseline to Week 3 and seven participants (36.8%) were considered responders (score or 1 or 2) at Week 3.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.8.3-4"></a>

###### Authors' comparison with the phase 2b trial

> “in fact, the response and remission rates were higher in the current study (42% response and remission rates at Week 3 verses 37% and 29%, respectively).”
> “This indicates that antidepressant drug withdrawal is not a prerequisite for a therapeutic response to psilocybin in this patient group, despite most previous trials including withdrawal as a standard procedure”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.8.3-5"></a>

###### Acute psychedelic experience on the Five-Dimensional Altered States of Consciousness questionnaire

> “Alterations of consciousness on the 5D-ASC were observed in every dimension including visual restructuralization, oceanic boundlessness, reduction of vigilance, and to a lesser extent anxious ego dissolution and auditory alterations”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.5.8.4-1"></a>

###### Health-related quality of life: EQ-5D-3L and EQ-VAS

> “Participants’ EQ-5D-3L mean total score at Baseline was 0.51 (SD = 0.333) and improved by an average of 0.18 (SD = 0.310) by Week 3.”
> “The EQ-VAS mean score at Baseline was 49.0 (SD = 17.45) and improved by an average of 13.7 (SD = 18.09) by Week 3.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.8.4-2"></a>

###### Self-reported depression: QIDS-SR-16

> “The QIDS-SR-16 mean total score at Baseline was 16.5 (SD = 5.04), indicating severe depression, and decreased by an average of 6.9 (SD = 6.05) by Week 3 where the mean total score indicated mild depression.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.8.4-3"></a>

###### Anxiety and affect: GAD-7 and PANAS

> “The GAD-7 mean total score at Baseline was 12.9 (SD = 5.94) and decreased by an average of 4.1 (SD = 4.90) by Week 3, which is considered a clinically meaningful improvement in anxiety symptoms”
> “The mean Baseline score for positive affect was 19.3 (SD = 7.22) and increased by an average of 8.1 (SD = 10.58) by Day 2, and mean Baseline score for negative affect was 24.3 (SD = 10.26) and decreased by an average of 7.5 (SD = 6.79) by Day 2”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

###### Treatment-emergent adverse events from Day 1 to Week 3, safety analysis set

| Period and event | Participants, n (%) | Events |
| --- | --- | --- |
| Overall: any TEAE | “12 (63.2)” | “17” |
| Overall: any severe TEAE | “2 (10.5)” | “2” |
| Overall: any serious TEAE | “0” | “0” |
| Day 1: any TEAE | “9 (47.4)” | “11” |
| Day 1: headache | “4 (21.1)” | “4” |
| Day 1: blood pressure increased | “3 (15.8)” | “3” |
| Day 1: dizziness | “1 (5.3)” | “1” |
| Day 1: dry mouth | “1 (5.3)” | “1” |
| Day 1: fall | “1 (5.3)” | “1” |
| Day 1: skin abrasion | “1 (5.3)” | “1” |
| After Day 1 to Week 3: any TEAE | “4 (21.1)” | “6” |
| After Day 1 to Week 3: headache | “2 (10.5)” | “2” |
| After Day 1 to Week 3: depression | “1 (5.3)” | “1” |
| After Day 1 to Week 3: diarrhea | “1 (5.3)” | “1” |
| After Day 1 to Week 3: palpitations | “1 (5.3)” | “1” |
| After Day 1 to Week 3: vertigo | “1 (5.3)” | “1” |

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.8.5-2"></a>

###### Onset, duration, and headache

> “Seventeen TEAEs were reported for 12 participants (63.2%), none of which were considered serious, or led to study withdrawal”
> “Eleven of these TEAEs, which were experienced in nine participants (47.4%), had an onset of Day 1 (psilocybin administration day), and eight resolved on the same day.”
> “The most common TEAE reported was headache (six events; six participants [31.6%]) which had an onset of Day 1 (n = 4) or Day 2 (n = 2) which were predominantly transient, reported as mild and moderate in five and one participants, respectively, and resolved on their own or with standard medication (paracetamol and ibuprofen) on the same day or day after.”
> “All TEAEs resolved before the end of the study (Week 3), and none had a duration exceeding seven days.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.8.5-3"></a>

###### Blood pressure increase treated with clonidine

> “Three participants had a TEAE of blood pressure increased which were considered related or possibly related to study treatment, two were severe and treated with clonidine.”
> “One of these patients experienced chest heaviness and headache (also relieved by clonidine).”
> “There were no specific parameters for administering clonidine and it was down to investigator discretion.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.8.5-4"></a>

###### Suicidal ideation and behavior

> “There were no reports of active suicidal ideation with plan or intent to act, attempts, or self-injurious behavior at Baseline or during the study and follow-up period”
> “During the follow-up period, one participant who was disappointed by their lack of response and quality of psychedelic experience invoked concern regarding their mental state during a conversation with their non-study therapist, which prompted the therapist to initiate an involuntary assessment of the participant at a local emergency department.”
> “After evaluation by a psychiatrist in the emergency department, the participant was deemed to not be a danger to themselves and not in need of hospital admission.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.8.5-5"></a>

###### Laboratory tests and electrocardiograms

> “There were no clinically meaningful shifts from Baseline in clinical laboratory tests.”
> “No participant had treatment-emergent clinically important ECG values or increases in QTcF interval from Baseline.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary: open-label single-arm design, small sample, short follow-up, blood pressure measurement, sponsor analysis

The authors state that the study was limited by its small size, open-label design and absence of a comparator, a sample that was not demographically diverse, and the exclusion of participants with high suicide risk or current hospitalization, and that the open-label design may have influenced participant expectations. Nineteen participants were dosed, no formal sample size calculation was performed, efficacy was summarized descriptively, and follow-up lasted three weeks. Blood pressure elevations were recorded with a finger cuff system that was not accurately calibrated. The sponsor performed the data review, interpretation, and post hoc analyses, and several authors are current or past employees of COMPASS Pathfinder. The authors state that the findings need confirmation in a larger, double-blind, comparator-controlled study.

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.9-2"></a>

###### Authors' stated limitations

> “The present study was limited by its small size, open-label design and absence of a comparator, the lack of a demographically diverse sample, and the exclusion of participants with high suicide risk or current hospitalization.”
> “It is possible that the open-label design influenced participant bias and expectations towards the study treatment, and definitive comparisons with studies that included a withdrawal from SSRIs is not necessarily valid.”
> “The findings will need to be confirmed in a larger, double-blind, comparator-controlled study.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.9-3"></a>

###### Blood pressure measurement

> “Unfortunately, we cannot give an accurate measure of the blood pressure elevation that undoubtedly occurred, because the finger cuff system was not accurately calibrated.”
> “but these specific instances were recorded with a system which may not have been properly calibrated and were not checked by conventional cuff auscultation.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.9-4"></a>

###### Follow-up duration

> “Future research should examine whether the outcomes of psilocybin as a monotherapy or as an adjunct to SSRIs remain comparable in a longer term follow up.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.9-5"></a>

###### Sponsor role in analysis and interpretation

> “Review of the data, interpretation, and post-hoc statistical analyses and were performed by the sponsor.”
> “GMG, MC, LM, SM, HS, CS, SCS, JT, SW, and EM are current or past employees of COMPASS Pathfinder.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="heading-3.1.6"></a>

#### 3.1.6 PsiDeR

<a id="heading-3.1.6.1"></a>

##### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

###### Feasibility of a placebo-controlled randomized design

> “We examined the feasibility of administering a single 25-mg dose of psilocybin or placebo with psychological support in a randomized controlled trial design with 6 weeks of follow-up.”
> “The present trial built upon this pilot, exploring the feasibility of a randomized controlled trial (RCT) design that included a placebo.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.1-2"></a>

###### Primary objective in the protocol

> “The primary objective is to evaluate the feasibility of a randomised, controlled trial design, in which a single dose of psilocybin 25 mg PO versus placebo, is given to adult participants with treatment resistant MDD (TRD), under psychologically supportive conditions, with 6 weeks of follow-up, by measuring recruitment rates, dropout rates and by estimating the variance of the primary outcome measure (Montgomery Asberg Depression Rating Scale (MADRS)) to inform on the design of a phase 3 trial.”

Source: [Rucker et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8638462/)

<a id="heading-3.1.6.2"></a>

##### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

###### Recruitment period and setting

> “Between 21 June 2021 and 3 July 2024, 75 potential participants consented and were screened for eligibility.”
> “Study visits were carried out initially at King’s College Hospital Clinical Research Facility and, subsequently, a refurbished community mental healthcare and research setting in the local community.”
> “Halfway through recruitment, we moved to a refurbished community mental health team setting in a residential area, close to the local hospital.”
> “Recruitment to this trial was severely delayed by the impact of the COVID-19 pandemic, although the trial did recruit to target.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.2-2"></a>

###### Registry dates and location

| Field | Registry entry |
| --- | --- |
| Study start (actual) | “2021-06-21” |
| Primary completion (actual) | “2024-12-18” |
| Study completion (actual) | “2024-12-18” |
| Location | “Clinical Research Facility, King's College Hospital” |

Source: [ClinicalTrials.gov NCT04959253](https://clinicaltrials.gov/study/NCT04959253)

<a id="topic-3.1.6.2-3"></a>

###### Planned trial period in the protocol

> “The trial is taking place between September 2020 and September 2023 in a single centre in London, UK.”
> “Because of the impact of the COVID-19 pandemic, the recruitment period may be extended, subject to necessary approvals.”

Source: [Rucker et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8638462/)

<a id="heading-3.1.6.3"></a>

##### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

###### Single-site, double-blind, placebo-controlled feasibility trial

> “This was a parallel-group, two arm, double-blind, randomized, placebo-controlled phase 2 feasibility trial undertaken at one NHS site in the UK (South London and Maudsley NHS Foundation Trust).”
> “An open-label extension was also offered to all participants, lasting a further 12 weeks after the 6-week RCT follow-up period.”
> “The sponsor of the trial was the South London and Maudsley NHS Foundation Trust and King’s College London.”
> “COMP360 psilocybin—a proprietary, pharmaceutical-grade synthetic psilocybin formulation—and matching placebo capsules were supplied by COMPASS Pathfinder Ltd., a subsidiary of COMPASS Pathways plc, which had no role in the design, conduct or analysis of the study.”
> “This trial was funded by the National Institute for Health and Care Research (NIHR) Clinician Scientist Programme (CS-2017-17-007).”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.3-2"></a>

###### Randomization by minimization and masking

> “Participants were randomized (1:1) to receive 25-mg psilocybin or placebo, with the sequence generated using minimization by sex (male, female), age (25−59, ≥60) and past psilocybin use (yes, no), by a web-based service hosted by the King’s Clinical Trials Unit (KCTU) and concealed from the trial team.”
> “Participants, researchers and the senior statistician (B.C.) were masked to treatment allocation until database lock.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.3-3"></a>

###### Choice of an inactive placebo

> “An inactive placebo control allows for a better characterization of safety signals in psychedelic trials and does not adversely affect feasibility aims; hence, it was chosen for this trial”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

> “In discussion with the funders of this trial, we decided to use a true placebo control to measure the difference in AE rate and the variance in the primary depression outcome measure without the difficulties implied by an active control.”

Source: [Rucker et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8638462/)

<a id="heading-3.1.6.4"></a>

##### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

###### Inclusion criteria: age, depression severity, and prior treatment

> “Eligibility criteria for participants included age 25−80 years, fluency in English, meeting DSM-5 criteria for a current episode of MDD, a 17-item Hamilton Depression Rating Scale (HAM-D-17)”
> “score of ≥14 and an inadequate response to ≥2 therapeutic antidepressant trials or ≥1 antidepressant trial and ≥1 psychotherapy trial.”
> “There was no upper limit on the number or type of previous treatments permitted.”
> “For those aged ≥60 years, the first episode of depression must have started prior to their 60th birthday.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.4-2"></a>

###### Exclusion criteria

> “Exclusion criteria included a DSM-5 diagnosis of bipolar disorder, psychotic disorder, drug or alcohol dependence syndrome, personality disorder or dementia; suicide attempt in the past year; any clinically significant medical diagnoses or biochemical or electrocardiographic abnormalities deemed incompatible with psilocybin treatment; personal circumstances or behavior judged to be incompatible with establishment of rapport or safe exposure to psilocybin; women of childbearing potential not using adequate contraception; women who were pregnant or breastfeeding; those unable to give informed consent; those enrolled in another drug trial; and hypersensitivity to the investigational medicinal product, any of the excipients or placebo.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="heading-3.1.6.5"></a>

##### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

###### Single 25 mg dose of COMP360 or matched placebo

> “COMP360 psilocybin and placebo were administered as five capsules, matched for appearance, weight, color, texture and smell.”
> “Participants self-administered either 25-mg COMP360 psilocybin or placebo via oral administration.”
> “Participants were accompanied by a therapist and chaperone for approximately 6 hours within a quiet room with a bed and adjustable lighting within the research facility.”
> “Participants were given an optional eye mask and earphones through which they listened to a curated playlist of music.”
> “A trial doctor determined suitability for discharge at the end of the day.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.5-2"></a>

###### Withdrawal of antidepressants and psychological preparation

> “Participants determined eligible at screening (V1) entered a screening and preparation phase (lasting 1−8 weeks), during which they were withdrawn from antidepressant, antipsychotic or mood-stabilizing drugs and had sessions of psychological preparation and psychoeducation with a trial therapist.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.5-3"></a>

###### Integration therapy and open-label extension

> “For 6 weeks after the dosing visit, participants met with the study team to complete follow-up assessments and engage in time-limited integration therapy (1 day (V4), 1 week (V5), 3 weeks (V6) and 6 weeks (V7) after dosing).”
> “As part of the extended design of this trial, at 6-week follow-up all eligible participants were invited to take part in a 12-week open-label extension, the results of which will be published elsewhere.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="heading-3.1.6.6"></a>

##### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

###### 3.1.6.6.1 Rationale for Using Recruitment and Retention Rates as the Primary Endpoint

<a id="topic-3.1.6.6.1-1"></a>

###### Primary feasibility outcomes

> “Primary outcomes were measures of feasibility: recruitment rates, dropout rates and an estimate of the variance of the MADRS”
> “The study was designed as a feasibility study to estimate the dropout rate (20%) with a 95% CI of ±10.1% (9.9−30.1%).”
> “No hypothesis testing was undertaken.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.6.1-2"></a>

###### Rationale in the protocol: acceptability of a placebo-controlled design and variance for a future efficacy trial

> “However, this study was not blinded and did not have a placebo control group.”
> “Furthermore, it could not be determined from the open label design whether a randomised, placebo-controlled design investigating psilocybin would be acceptable to patients with TRD.”
> “A further purpose of this trial was to estimate the variance of the primary outcome measure between groups to inform a power calculation for a future efficacy trial.”
> “Allows a robust measurement of the variance in the primary outcome measure between groups to inform an efficacy trial.”

Source: [Rucker et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8638462/)

<a id="topic-3.1.6.6.1-3"></a>

###### Feasibility parameters reported

> “To evaluate recruitment and other feasibility parameters, the following are reported alongside 95% CIs: proportion eligible out of number screened; proportion randomized out of number consented; proportion completing at least the MADRS at each follow-up visit out of number randomized (overall and by arm); proportion attending the dosing visit out of number randomized (overall and by arm); and proportion receiving all five capsules/tablets out of number randomized (overall and by arm).”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.6.1-4"></a>

###### Depression outcome: MADRS by blinded independent raters at Week 3

> “The primary outcome measure for depression is the Montgomery Asberg Depression Rating Scale collected by blinded, independent raters.”
> “The primary endpoint is at 3 weeks, and the total follow-up is 6 weeks.”

Source: [Rucker et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8638462/)

<a id="topic-3.1.6.6.1-5"></a>

###### Secondary clinical outcomes

> “Secondary outcomes at weeks 1, 3 and 6 follow-up included MADRS total scores; proportions of participants in each group who met criteria for clinician-rated response to treatment (defined as a ≥50% decrease in MADRS score from baseline) and remission (defined as a MADRS score ≤10)”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="heading-3.1.6.7"></a>

##### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

###### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

###### Target sample size and its basis

> “The target sample size was 60 participants.”
> “All 60 participants were included in primary feasibility analyses.”
> “One participant withdrew in the placebo arm before contributing follow-up MADRS data and was, thus, excluded from mixed models.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

> “Since the study is exploratory, formal sample size calculations were not undertaken.”
> “The sample size selected was informed by published work that models processes of parameter estimates for continuous measures from early phase trials.”
> “This is considered sufficient to test the intervention and provide adequately reliable estimates of recruitment rate and loss to follow-up.”

Source: [Rucker et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8638462/)

<a id="heading-3.1.6.7.2"></a>

###### 3.1.6.7.2 Description of Analysis Sets

<a id="topic-3.1.6.7.2-1"></a>

###### Intention-to-treat analysis and mixed models

> “Analyses were intention to treat: all participants were analyzed as randomized.”
> “For secondary continuous clinical outcomes, the adjusted mean difference between arms was estimated in mixed-effects linear regression models.”
> “Follow-up values were fit simultaneously and predicted by the fixed effects of trial arm, baseline assessment, minimization factors (sex, age group, prior psilocybin use), time (categorical) and an arm × time interaction term to allow estimates of the treatment effect at each follow-up point.”
> “Secondary binary outcomes were analyzed using mixed-effects logistic regression models with random intercept at the participant level and adjusting for the fixed effects, as stated previously.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.7.2-2"></a>

###### Missing data

> “No multiple imputation was done for missing follow-up measurements.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="heading-3.1.6.8"></a>

##### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

###### 3.1.6.8.1 Participant Disposition

<a id="topic-3.1.6.8.1-1"></a>

###### Screening, randomization, and withdrawal

> “Sixty participants were randomized to either psilocybin or placebo arms; 30 participants were allocated to each arm”
> “Of 75 participants consented and screened, 62 were eligible (83%, 95% confidence interval (CI): 72−90%), and 60 were randomized (80%, 95% CI: 69−88%).”
> “All randomized participants attended the dosing visit, and 59 of 60 participants completed the MADRS at each timepoint, as the only missing observation was the one participant in the placebo arm who had withdrawn prior to week 1.”
> “One participant withdrew from the placebo arm; the participant no longer wished to participate for personal reasons.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="heading-3.1.6.8.2"></a>

###### 3.1.6.8.2 Baseline Characteristics

<a id="topic-3.1.6.8.2-1"></a>

###### Minimization factors and baseline demographics by arm

| Characteristic | Placebo (N = 30) | Psilocybin (N = 30) | Overall (N = 60) |
| --- | --- | --- | --- |
| Female, n (%) | “15 (50%)” | “15 (50%)” | “30 (50%)” |
| Age group 60 or older, n (%) | “3 (10%)” | “3 (10%)” | “6 (10%)” |
| Past psilocybin use, n (%) | “5 (17%)” | “4 (13%)” | “9 (15%)” |
| Age at randomization, median (IQR) | “40.2 (33.7−52.0)” | “41.7 (38.6−57.0)” | “40.8 (35.2−52.3)” |
| HAM-D-17 score, median (IQR) | “17.0 (15.0−21.0)” | “18.5 (16.0−21.0)” | “18.0 (15.0−21.0)” |
| Ethnicity White, n (%) | “24 (80%)” | “21 (70%)” | “45 (75%)” |
| Postgraduate degree, n (%) | “14 (47%)” | “11 (37%)” | “25 (42%)” |
| Full-time employed, n (%) | “11 (37%)” | “15 (50%)” | “26 (43%)” |
| First-degree family history of depression, n (%) | “15 (50%)” | “18 (60%)” | “33 (55%)” |
| Years spent with feelings of significant depression, mean (s.d.) | “19.2 (10.3)” | “20.9 (10.2)” | “20.0 (10.2)” |
| Maudsley Staging Method score at screening, median (IQR) | “8.0 (7.0−9.0)” | “8.0 (7.0−10.0)” | “8.0 (7.0−9.5)” |

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.8.2-2"></a>

###### Treatment resistance and chronicity

> “Median Maudsley Staging Method (MSM) scores at screening indicated that most participants scored within the moderate range for treatment resistance, with a chronic course of illness.”
> “On average, patients in this trial had been ill for 20 years and showed moderate levels of treatment resistance.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="heading-3.1.6.8.3"></a>

###### 3.1.6.8.3 Efficacy Results

<a id="topic-3.1.6.8.3-1"></a>

###### Primary feasibility outcomes

| Feasibility parameter | Numbers | Proportion (95% CI) |
| --- | --- | --- |
| Participation rate (enrolled / approached) | “75 / 165” | “46% (38−53%)” |
| Eligibility rate (eligible / consented to screening) | “62 / 75” | “83% (72−90%)” |
| Randomization rate (randomized / consented) | “60 / 75” | “80% (69−88%)” |
| Dosing visit attendance, overall | “60 / 60” | “100% (94%)” |
| Week 3 MADRS completion, placebo | “29 / 30” | “97% (83−100%)” |
| Week 3 MADRS completion, psilocybin | “30 / 30” | “100% (88%)” |
| Week 6 MADRS completion, overall | “59 / 60” | “98% (91−100%)” |

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

> “No success metrics were set, but eligibility and randomization rates were high.”
> “The 97.5% one-sided CI (with an upper bound of infinity) is given if the proportion was 100%.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.8.3-2"></a>

###### MADRS adjusted mean difference between arms

| MADRS timepoint (n = 59) | Mean difference (95% CI) | Cohen's d (95% CI) |
| --- | --- | --- |
| Week 1 | “−11.44 (−15.89 to −6.98)” | “−1.87 (−2.59 to −1.14)” |
| Week 3 | “−10.41 (−14.86 to −5.95)” | “−1.7 (−2.42 to −0.97)” |
| Week 6 | “−12.92 (−17.37 to −8.47)” | “−2.11 (−2.83 to −1.38)” |

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

> “At week 3, the between-group difference in the MADRS was −10.41 (95% CI: −14.86 to −5.95), indicating a clinically significant improvement in depression in the psilocybin arm compared to the placebo arm.”
> “The between-group difference in the MADRS at week 3 was sustained at week 6, with an adjusted mean difference of −12.92 points (95% CI: −17.37 to −8.47).”
> “Cohen’s d is the mean difference between arms divided by pooled baseline standard deviation.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.8.3-3"></a>

###### MADRS response and remission

> “At week 3, 1 (3%) participant in the placebo arm and 13 (43%) participants in the psilocybin arm met the cutoff for MADRS response, and 1 (3%) in the placebo arm and 12 (40%) in the psilocybin arm met the cutoff for MADRS remission.”
> “These figures were sustained at week 6; however MADRS response increased to 15 (50%) participants in the psilocybin arm.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="heading-3.1.6.8.4"></a>

###### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.6.8.4-1"></a>

###### Adjusted mean differences in patient-reported outcomes

| Scale and timepoint | Mean difference (95% CI) | Cohen's d (95% CI) |
| --- | --- | --- |
| QIDS-SR-16, Week 3 | “−5.48 (−7.85 to −3.12)” | “−1.19 (−1.7 to −0.67)” |
| QIDS-SR-16, Week 6 | “−5.63 (−8.00 to −3.27)” | “−1.22 (−1.73 to −0.71)” |
| GAD-7, Week 3 | “−4.85 (−6.96 to −2.74)” | “−1.00 (−1.44 to −0.57)” |
| GAD-7, Week 6 | “−4.54 (−6.64 to −2.44)” | “−0.94 (−1.37 to −0.50)” |
| EQ-5D-5L VAS, Week 3 | “12.46 (3.39−21.54)” | “0.62 (0.17−1.07)” |
| EQ-5D-5L VAS, Week 6 | “10.69 (1.63−19.75)” | “0.53 (0.08−0.98)” |
| WSAS, Week 3 | “−8.20 (−12.09 to −4.30)” | “−1.26 (−1.86 to −0.66)” |
| WSAS, Week 6 | “−9.22 (−13.08 to −5.36)” | “−1.42 (−2.02 to −0.83)” |
| M3VAS, Week 3 | “45.33 (19.69−70.96)” | “1.17 (0.51−1.83)” |
| M3VAS, Week 6 | “36.42 (10.80−62.04)” | “0.94 (0.28−1.60)” |
| WEMWBS, Week 3 | “10.48 (6.57−14.40)” | “1.76 (1.10−2.42)” |
| WEMWBS, Week 6 | “9.44 (5.55−13.32)” | “1.59 (0.93−2.24)” |

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.8.4-2"></a>

###### Self-reported depression response and remission

> “At week 3, no participants in the placebo arm met criteria for Quick Inventory of Depressive Symptomatology Self-Report 16-item version (QIDS-SR-16) response compared to 15 (50%) in the psilocybin arm.”
> “At week 6, one (4%) participant in the placebo arm and 13 (43%) participants in the psilocybin arm met QIDS-SR-16 response.”
> “One participant (4%) in the placebo arm and 12 (40%) participants in the psilocybin arm met the cutoff for QIDS-SR-16 remission at week 3 compared to two (7%) in the placebo arm and 10 (33%) in the psilocybin arm at week 6.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.8.4-3"></a>

###### Anxiety, health state, functioning, and wellbeing

> “at week 6, 5 of 30 (17%) psilocybin participants had GAD-7 scores ≥10 compared with 18 out of 29 (62%) placebo participants.”
> “Self-reported depression severity was improved in the psilocybin arm compared to placebo at all follow-up timepoints, as were ratings of anxiety, overall health state, psychopathology and mental wellbeing.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="heading-3.1.6.8.5"></a>

###### 3.1.6.8.5 Safety Results

<a id="topic-3.1.6.8.5-1"></a>

###### Nonserious adverse events during the randomized phase (randomization to Week 6)

| Category | Placebo (123 events; 28 reporters) | Psilocybin (164 events; 30 reporters) | Overall (287 events; 58 reporters) |
| --- | --- | --- | --- |
| Neurological, events (reporters) | “32 (17)” | “53 (26)” | “85 (43)” |
| Mood/psychological, events (reporters) | “13 (9)” | “30 (18)” | “43 (27)” |
| Respiratory infection, events (reporters) | “24 (16)” | “12 (11)” | “36 (27)” |
| Gastrointestinal, events (reporters) | “8 (6)” | “15 (12)” | “23 (18)” |
| Musculoskeletal/pain, events (reporters) | “13 (11)” | “14 (9)” | “27 (20)” |
| Medication or substance related, events (reporters) | “5 (5)” | “10 (9)” | “15 (14)” |
| General fatigue/tiredness, events (reporters) | “4 (4)” | “8 (8)” | “12 (12)” |
| Related to study medication, n (%) | “2 (2%)” | “29 (18%)” | “31 (11%)” |
| Possibly related, n (%) | “16 (13%)” | “56 (34%)” | “72 (25%)” |
| Mild intensity, n (%) | “77 (63%)” | “111 (68%)” | “188 (66%)” |
| Moderate intensity, n (%) | “45 (37%)” | “48 (29%)” | “93 (32%)” |
| Severe intensity, n (%) | “1 (1%)” | “5 (3%)” | “6 (2%)” |
| Adverse events of special interest, n (%) | “0 (0%)” | “0 (0%)” | “0 (0%)” |

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.8.5-2"></a>

###### Serious adverse events and relatedness

> “In total, 287 nonserious AEs (123 in the placebo arm, 164 in the psilocybin arm) were recorded in the RCT phase”
> “Four SAEs (one in the placebo arm, three in the psilocybin arm) were recorded: three during the open-label phase and one during the RCT phase”
> “Over half of nonserious AEs (184 out of 287, 64%) were not related to study medication, and all but one SAE was deemed not related to study medication.”
> “The remaining event, which occurred in the placebo arm, was deemed as possibly related.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.8.5-3"></a>

###### Suicidality and mania

> “Psilocybin administration was well tolerated: AEs were mostly mild in severity and resolved by the end of the trial, and clinical safety scales measuring suicidality and mania did not show substantial changes across time.”
> “In the present study, the proportion of patients reporting suicidal ideation on the Columbia−Suicide Severity Rating Scale (C−SSRS) was similar at baseline and at week 3 and week 6 follow-up, after an initial reduction at day 1 and week 1.”
> “Proportions also appeared similar across arms.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="heading-3.1.6.9"></a>

##### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

###### Summary: functional unblinding, inactive placebo with little placebo response, feasibility design, single site, sample composition

PsiDeR was a single-site feasibility trial of 60 participants with 6 weeks of follow-up and no hypothesis testing. Blinding was assessed in a subsample of 23 participants after a measure was introduced part-way through the trial: 13 of 13 (100%) in the psilocybin arm and 7 of 10 (70%) in the placebo arm correctly guessed their allocation, and the authors state that “expectancy effects in both groups likely account for some of the between-group difference observed”. The placebo arm did not show meaningful reductions in MADRS or QIDS-SR scores, and the authors note that active placebos or subperceptual doses may be more appropriate for efficacy trials. The sample was highly educated, recruitment targets were not met for Black, African, Caribbean or Black British participants, and about half of participants used facilities opened under a later financial agreement with COMPASS Pathways.

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.9-2"></a>

###### Functional unblinding and expectancy

> “Blinding was not upheld, with 100% of participants who received psilocybin and 70% of participants who received placebo correctly guessing their allocation.”
> “Thus, expectancy effects in both groups likely account for some of the between-group difference observed.”
> “Functional unblinding due to the subjective effects of psilocybin is an obvious limitation of this trial, as it is with all trials of drugs that have noticeable effects, as well as many psychological and behavioral interventions.”
> “However, we used raters who were independent of the trial team to measure the primary outcome in this trial, and participants were asked not to discuss their beliefs about their allocation with the raters.”
> “Despite this, the limited assessment of blinding is a weakness of this trial.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.9-3"></a>

###### Blinding assessed in a subsample

> “The adequacy of participant blinding was assessed using self-report visual analog scales of group allocation confidence, introduced part-way through the trial and, therefore, collected in only a subsample of participants.”
> “Of the 23 participants who were asked, n = 13 out of 13 (100%) in the psilocybin arm and n = 7 out of 10 (70%) in the placebo arm correctly guessed their treatment allocation.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.9-4"></a>

###### Absence of placebo response and choice of control

> “However, a part of this effect is likely attributable to a lack of response or remission in the placebo arm, with total MADRS and QIDS-SR scores not showing meaningful reductions across time.”
> “However, other trial designs (that is, active placebos or subperceptual doses of the study drug) may be more appropriate for efficacy trials and will be considered in the design of a future trial”
> “found more modest effect sizes comparing 1-mg to 25-mg psilocybin at week 3 than in the present trial.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.9-5"></a>

###### Sample composition and generalizability

> “We largely met our recruitment targets in all ethnic groups, apart from in Black, African, Caribbean or Black British participants.”
> “We note that our sample population is highly educated, with much higher proportions of participants with university degrees than in the general population.”
> “Together, these results suggest that a single dose of psilocybin may reduce depressive symptoms in MDD and TRD, although larger, and longer, scale studies are required to confirm the nature and durability of these effects.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.9-6"></a>

###### Single centre and rater independence in the protocol

> “As this is a single-centre study, the findings are unlikely to be generalisable beyond the trial setting.”
> “While raters of the primary outcome are independent of the study team, they are not independent of the institution undertaking the research.”

Source: [Rucker et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8638462/)

<a id="topic-3.1.6.9-7"></a>

###### Relationship between the trial facilities and COMPASS Pathways

> “Although COMPASS Pathways did not financially support this study, a separate financial agreement 4 years subsequent to this study being funded resulted in the opening of the Centre for Mental Health Research and Innovation, the facilities of which were used (without cost) for about half of the participants in this study.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="heading-3.1.7"></a>

#### 3.1.7 EudraCT 2018-000978-30

<a id="heading-3.1.7.1"></a>

##### 3.1.7.1 Objective

<a id="topic-3.1.7.1-1"></a>

###### Safety of simultaneous administration and effects on cognition

> “The aim of this study was to explore the safety of simultaneous administration of psilocybin to healthy participants in the largest randomised controlled trial of psilocybin to date.”
> “This study aimed to evaluate the safety and feasibility of simultaneous administration of single doses of either 10 or 25 mg doses of psilocybin compared with placebo in healthy participants, administered in a supervised setting with one-to-one psychological support, and to assess the short- and long-term effects of psilocybin on key domains of cognitive functioning.”
> “It is important to study the safety and feasibility of this model of simultaneous administration as it could be a more effective, time- and cost-efficient model of treatment delivery, meaning more patients could potentially benefit from this treatment, if approved.”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="heading-3.1.7.2"></a>

##### 3.1.7.2 Location and Study Date

<a id="topic-3.1.7.2-1"></a>

###### Single site in London, August 2018 to July 2019

> “The first participant’s first visit date was August 17, 2018, and the last participant’s last visit date was July 19, 2019.”
> “the NIHR/Wellcome Trust Clinical Research Facility at King’s College Hospital, where this study was undertaken.”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="heading-3.1.7.3"></a>

##### 3.1.7.3 Study Design

<a id="topic-3.1.7.3-1"></a>

###### Phase 1, randomized, double-blind, placebo-controlled design

> “This was a phase 1, randomised, double-blind, placebo-controlled, between-groups study to evaluate the effects of single 10 and 25 mg doses of psilocybin compared with placebo in healthy participants, conducted at the Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK, sponsored by COMPASS Pathways (EudraCT number: 2018-000978-30).”
> “Participants were followed up for 12 weeks after study drug administration”
> “The study was funded and sponsored by COMPASS Pathways, London, UK.”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="topic-3.1.7.3-2"></a>

###### Stratified randomization with individual allocation within shared sessions

> “Participants were stratified by sex and age (18–35 years old; >35 years old) and randomised in a 1:1:1 ratio using blocked randomisation”
> “Participants were randomised on an individual basis and therefore participants in the same dosing session could be allocated to different treatment groups.”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="heading-3.1.7.4"></a>

##### 3.1.7.4 Eligibility Criteria

<a id="topic-3.1.7.4-1"></a>

###### Healthy adults without recent psilocybin use

> “The study recruited healthy participants (male or female; aged 18−65 years at screening) with no psilocybin experience within 1 year prior to enrolment; the study aimed to recruit up to 90 participants who met eligibility criteria at the screening visit (visit 1; day -56 to day -2).”
> “Participants were recruited via online advertisements and word of mouth.”
> “Inclusion criteria, psychiatric exclusion criteria (including current/history of psychiatric disorders, current/recent psychiatric medications, or other psilocybin-incompatible psychiatric or psychological conditions, as judged by the investigator), and medical exclusion criteria are listed in the Supplementary Methods.”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="heading-3.1.7.5"></a>

##### 3.1.7.5 Treatment

<a id="topic-3.1.7.5-1"></a>

###### Single oral dose of COMP360 10 mg or 25 mg, or placebo, as five capsules

> “The study drug was administered simultaneously to up to six participants as a single 5-capsule oral dose (psilocybin 10 mg: 2 × 5 mg psilocybin capsules plus 3 × placebo capsules; psilocybin 25 mg: 5 × 5 mg psilocybin capsules; placebo: 5 × placebo capsules).”
> “COMP360 psilocybin was administered in this study, which is COMPASS Pathways’ proprietary pharmaceutical-grade synthetic psilocybin formulation that has been optimised for stability and purity.”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="topic-3.1.7.5-2"></a>

###### Group preparation, simultaneous administration session, and integration

> “During this visit, participants attended a 2-h group preparatory session (involving all participants to be dosed the following day, a lead therapist and assisting therapists) and had a short (5–15 min) individual discussion with their assigned assisting therapist.”
> “Administration sessions generally lasted ~6–8 h, with psychological support available throughout from specially trained assisting therapists, who were supervised by a lead therapist.”
> “The simultaneous dosing involved each participant having a private space, for example, a bed separated by curtains within the same room, so they could focus on their own experience with minimal distractions, especially as participants were encouraged to wear eyeshades, earplugs and/or earphones for the duration of the administration session.”
> “Participants were subsequently discharged and asked to return the following day (day 1; visit 4) for safety assessments and a discussion with their allocated therapist about the subjective experience during the administration session (integration session).”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="heading-3.1.7.6"></a>

##### 3.1.7.6 Study Outcomes

<a id="heading-3.1.7.6.1"></a>

###### 3.1.7.6.1 Rationale for Using CANTAB Cognitive Measures as the Primary Endpoint

<a id="topic-3.1.7.6.1-1"></a>

###### Rationale for studying cognitive and emotional processing

> “Psilocybin’s effects on cognitive function have not been widely or systematically studied.”
> “Neural correlates of cognitive and emotional processing are considered important therapeutic targets in the development of novel treatments for treatment-resistant depression and other mental disorders.”
> “Given this unmet need for improved treatment of social and emotional functioning deficits, a better understanding of the short- and long-term effects of psilocybin on emotional processing and social cognition is required.”
> “Furthermore, it has not yet been investigated whether the beneficial effects of psilocybin may also benefit general cognitive abilities.”
> “Given the potential for psilocybin as a treatment for a range of conditions, studying its effects on cognition is important.”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="topic-3.1.7.6.1-2"></a>

###### Primary efficacy endpoints: CANTAB measures and social cognition scales

> “The primary efficacy endpoints were short-term change from baseline (day -1) to day 8 in cognitive measures of attention, spatial and working memory and executive function”
> “short-term change from baseline to day 8 in social cognition, emotional processing scales (comprising the Pictorial Empathy Test (PET); Reading the Mind in the Eyes Test (RMET); Scale of Social Responsibility (SSR); Social Value Orientation (SVO); and Toronto Empathy Questionnaire (TEQ)”
> “change from baseline to day 29 in the individual cognitive functioning assessments previously outlined; and long-term change from baseline to day 85 in social cognition, emotional processing scales.”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="topic-3.1.7.6.1-3"></a>

###### CANTAB global composite score as a safety endpoint

> “Safety was assessed via endpoints which included cognitive function, assessed by CANTAB global composite score, and treatment-emergent adverse event (TEAE) monitoring.”
> “Cognitive function was measured by the Cambridge Neuropsychological Test Automated Battery (CANTAB) global composite score change from baseline (day -1) to day 8 and 29, calculated from Z scores for each CANTAB measure (Paired Associates Learning-Total Errors Adjusted (PAL-TEA; a measure of episodic memory); Spatial Working Memory-Between Errors (SWM-BE; working memory); SWM-Strategy (SWM-S; executive function and planning); and Rapid Visual Information Processing A-prime (RVP-A’; sustained attention); a higher CANTAB global composite score indicates better cognitive function).”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="topic-3.1.7.6.1-4"></a>

###### Familiarization session to limit practice effects

> “At screening, participants underwent CANTAB assessments as part of a familiarisation session; this was included in the descriptive statistics but was excluded from statistical modelling.”
> “The purpose of familiarisation was to ensure that all the participants had a chance to practice the tests prior to the collection of the baseline data.”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="topic-3.1.7.6.1-5"></a>

###### Secondary efficacy endpoints

> “Secondary efficacy endpoints included dose-related differences in the cognitive effects of psilocybin at baseline, day 8 and day 29, measured by the CANTAB assessments RVP-Aʹ, SWM-BE, SWM-S, PAL-TEA; dose-related differences in the psychological effects of psilocybin at baseline, day 8 and day 85, measured by the social cognition, emotional processing scales; differences in the cognitive effects of psilocybin between psilocybin-naïve and -experienced participants at baseline, day 8 and day 29, measured by the CANTAB global composite score; and differences in PANAS after study drug administration on day 1.”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="heading-3.1.7.7"></a>

##### 3.1.7.7 Statistical Analysis Description

<a id="heading-3.1.7.7.1"></a>

###### 3.1.7.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.7.7.1-1"></a>

###### Planned sample of up to 90 participants

> “A sample size of up to 90 participants (30 per treatment group) was chosen to allow reasonable assessment of each of the planned endpoints.”
> “This study was exploratory and therefore not adequately powered to detect statistical significance; as such p values are not reported.”
> “Of these, 30 participants were randomised to receive 25 mg psilocybin, 30–10 mg psilocybin and 29 to placebo; 33 (37.1%) participants had prior psilocybin experience.”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="heading-3.1.7.7.2"></a>

###### 3.1.7.7.2 Description of Analysis Sets

<a id="topic-3.1.7.7.2-1"></a>

###### Safety, modified intent-to-treat, and per-protocol populations

> “The Safety Population comprised all randomised participants who received study drug and was used for all summaries of participant accountability, demographic and baseline data, and safety information, including AE incidence and cognition endpoint analyses.”
> “The modified Intent-to-Treat (mITT) Population comprised all participants in the Safety Population who had at least one post-dose assessment.”
> “This population was used for emotional processing endpoint analyses.”
> “The Per-Protocol (PP) Population comprised all participants in the Safety Population who did not have a major protocol deviation that was thought to significantly affect the integrity of the participant’s data.”
> “This population was used for the CANTAB primary endpoint analyses.”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="topic-3.1.7.7.2-2"></a>

###### Mixed model for repeated measures

> “The MMRM method utilises the observed data efficiently, handling missing data automatically, based on the assumption that data are missing at random, thus minimising bias in the estimates of treatment effect.”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="heading-3.1.7.8"></a>

##### 3.1.7.8 Results

<a id="heading-3.1.7.8.1"></a>

###### 3.1.7.8.1 Participant Disposition

<a id="topic-3.1.7.8.1-1"></a>

###### Randomized, dosed, and completed

> “The study randomised 89 healthy participants (mean age, 36.1 years; 41 females, 48 males)”
> “All participants randomised to both psilocybin arms completed the study; four (13.8%) placebo-treated participants did not complete all study visits (three were lost to follow-up; one was withdrawn following a protocol deviation).”
> “Twenty-five administration sessions were completed, with up to six participants dosed simultaneously per session (there were 2 sessions with one participant each, 3 with two, 5 with three, 11 with four, 2 with five and 2 with six).”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="heading-3.1.7.8.2"></a>

###### 3.1.7.8.2 Baseline Characteristics

<a id="topic-3.1.7.8.2-1"></a>

###### Participant demographics, safety population

| Characteristic | Psilocybin 25 mg (N = 30) | Psilocybin 10 mg (N = 30) | Placebo (N = 29) | Overall (N = 89) |
| --- | --- | --- | --- | --- |
| Male, n (%) | “16 (53.3)” | “16 (53.3)” | “16 (55.2)” | “48 (53.9)” |
| Female, n (%) | “14 (46.7)” | “14 (46.7)” | “13 (44.8)” | “41 (46.1)” |
| White, n (%) | “25 (83.3)” | “27 (90.0)” | “20 (69.0)” | “72 (80.9)” |
| Age at consent, years, mean (SD) | “36.6 (10.29)” | “36.1 (9.25)” | “35.6 (7.69)” | “36.1 (9.06)” |
| BMI, kg/m2, mean (SD) | “22.9 (3.75)” | “23.0 (2.90)” | “23.7 (3.20)” | “23.2 (3.29)” |
| Undergraduate or higher national diploma, n (%) | “9 (30.0)” | “11 (36.7)” | “10 (34.5)” | “30 (33.7)” |
| Master’s or postgraduate diploma, n (%) | “16 (53.3)” | “16 (53.3)” | “15 (51.7)” | “47 (52.8)” |
| PhD, n (%) | “3 (10.0)” | “2 (6.7)” | “4 (13.8)” | “9 (10.1)” |
| Prior psilocybin experience, n (%) | “11 (36.7)” | “15 (50.0)” | “7 (24.1)” | “33 (37.1)” |

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="heading-3.1.7.8.3"></a>

###### 3.1.7.8.3 Efficacy Results

<a id="topic-3.1.7.8.3-1"></a>

###### CANTAB measures: least squares mean difference from placebo

| CANTAB measure and dose | Day 8, LS mean (95% CI) difference from placebo | Day 29, LS mean (95% CI) difference from placebo |
| --- | --- | --- |
| Global composite, 10 mg | “−0.1960 (−0.39172, −0.00024)” | “0.0364 (−0.21234, 0.28505)” |
| Global composite, 25 mg | “−0.1167 (−0.31228, 0.07898)” | “0.1519 (−0.09846, 0.40219)” |
| PAL-TEA, 10 mg | “2.5 (−0.57, 5.65)” | “−2.4 (−6.48, 1.59)” |
| PAL-TEA, 25 mg | “−0.5 (−3.60, 2.60)” | “−2.5 (−6.59, 1.52)” |
| SWM-BE, 10 mg | “1.5 (−1.27, 4.27)” | “1.7 (−0.56, 4.02)” |
| SWM-BE, 25 mg | “1.7 (−1.02, 4.51)” | “0.5 (−1.83, 2.77)” |
| SWM-S, 10 mg | “0.4 (−0.46, 1.26)” | “0.2 (−0.78, 1.16)” |
| SWM-S, 25 mg | “0.3 (−0.59, 1.12)” | “−0.4 (−1.35, 0.60)” |
| RVP-A’, 10 mg | “−0.0017 (−0.00984, 0.00651)” | “0.0103 (−0.00464, 0.02524)” |
| RVP-A’, 25 mg | “−0.0053 (−0.01348, 0.00286)” | “0.0099 (−0.00519, 0.02490)” |

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

> “For PAL-TEA, SWM-BE and SWM-S, lower scores denote better performance.”
> “For RVP-A’ and CANTAB composite, higher scores denote better performance.”
> “There were no clinically relevant between-group differences in CANTAB global composite score, CANTAB cognitive domain scores, or emotional processing scale scores.”
> “On the CANTAB composite score, performance was worse than placebo for the 10 mg psilocybin group at day 8.”
> “However, this result is due in part to the larger improvement in performance from baseline by the placebo group at day 8.”
> “For the 10 mg psilocybin group, performance increased again by day 29 to a level similar to placebo suggesting no adverse effects of the 10 mg psilocybin dose compared with placebo.”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="topic-3.1.7.8.3-2"></a>

###### Social cognition and emotional processing scales: least squares mean difference from placebo

| Scale and dose | Day 8, LS mean (95% CI) difference from placebo | Day 85, LS mean (95% CI) difference from placebo |
| --- | --- | --- |
| PET, 10 mg | “−0.1 (−0.39, 0.15)” | “−0.1 (−0.39, 0.15)” |
| PET, 25 mg | “0.2 (−0.11, 0.42)” | “0.1 (−0.12, 0.41)” |
| RMET, 10 mg | “0.1 (−1.43, 1.69)” | “0.2 (−1.53, 1.95)” |
| RMET, 25 mg | “0.2 (−1.44, 1.74)” | “0.5 (−1.29, 2.28)” |
| SSR Global, 10 mg | “1.2 (−2.16, 4.56)” | “0.3 (−2.83, 3.49)” |
| SSR Global, 25 mg | “2.8 (−0.50, 6.18)” | “2.2 (−0.94, 5.29)” |
| SVO Angle, 10 mg | “3.4 (−0.05, 6.85)” | “3.4 (−0.16, 6.97)” |
| SVO Angle, 25 mg | “2.1 (−1.32, 5.58)” | “2.4 (−1.16, 6.06)” |
| TEQ, 10 mg | “0.1 (−0.16, 0.31)” | “0.1 (−0.15, 0.34)” |
| TEQ, 25 mg | “0.2 (−0.08, 0.38)” | “0.1 (−0.13, 0.36)” |

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

> “There was no difference between either psilocybin group and placebo in any social cognition and emotional processing scale (PET, RMET, SSR, SVO, or TEQ) scores at day 8 or day 85, relative to baseline”
> “These findings suggest that psilocybin does not exert any detrimental effect on the social cognition and emotional functions assessed.”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="heading-3.1.7.8.4"></a>

###### 3.1.7.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.7.8.4-1"></a>

###### Positive and negative affect after dosing

> “The placebo group showed a trend for a reduction in positive affect score from baseline to post-dose (least squares (LS) mean change = -5.0), which was not observed in either psilocybin group”
> “Conversely, the 25 mg psilocybin group showed a trend for an increase in LS mean negative affect score from baseline of 1.3, compared with no change in the 10 mg psilocybin and placebo groups.”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="heading-3.1.7.8.5"></a>

###### 3.1.7.8.5 Safety Results

<a id="topic-3.1.7.8.5-1"></a>

###### Most frequent treatment-emergent adverse events and events of special interest, safety population

| TEAE (MedDRA preferred term) | 25 mg, n (%) | 25 mg, events | 10 mg, n (%) | 10 mg, events | Placebo, n (%) | Placebo, events |
| --- | --- | --- | --- | --- | --- | --- |
| Hallucination, visual | “21 (70.0)” | “22” | “18 (60.0)” | “20” | “2 (6.9)” | “2” |
| Illusion | “18 (60.0)” | “26” | “19 (63.3)” | “25” | “4 (13.8)” | “5” |
| Mood altered | “15 (50.0)” | “25” | “13 (43.3)” | “23” | “6 (20.7)” | “9” |
| Headache | “15 (50.0)” | “16” | “9 (30.0)” | “12” | “5 (17.2)” | “5” |
| Fatigue | “8 (26.7)” | “8” | “9 (30.0)” | “10” | “3 (10.3)” | “3” |
| Euphoric mood | “7 (23.3)” | “8” | “7 (23.3)” | “7” | “0” | “0” |
| Tension headache | “6 (20.0)” | “6” | “3 (10.0)” | “3” | “3 (10.3)” | “3” |
| Time perception altered | “6 (20.0)” | “6” | “2 (6.7)” | “2” | “3 (10.3)” | “3” |
| Emotional disorder | “5 (16.7)” | “6” | “2 (6.7)” | “2” | “0” | “0” |
| Somatic hallucination | “5 (16.7)” | “6” | “8 (26.7)” | “8” | “4 (13.8)” | “5” |
| Affect lability | “3 (10.0)” | “3” | “5 (16.7)” | “5” | “1 (3.4)” | “1” |
| Any TEAE of special interest | “26 (86.7)” | “80” | “25 (83.3)” | “81” | “10 (34.5)” | “19” |
| Substance-induced psychotic disorder | “1 (3.3)” | “1” | “0” | “0” | “0” | “0” |

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="topic-3.1.7.8.5-2"></a>

###### Overall incidence, relatedness, and duration

> “In total, 511 TEAEs were reported during the 12-week study: 217 in the 25 mg psilocybin arm (reported by 29 (96.7%) participants), 203 in the 10 mg psilocybin arm (reported by 29 (96.7%) participants) and 91 in the placebo arm (reported by 26 (89.7%) participants).”
> “Of these, 208, 188 and 77 were deemed by the investigator to be potentially related to study treatment in the 25 mg, 10 mg and placebo arms, respectively.”
> “There were no serious TEAEs and no AEs led to withdrawal from the study.”
> “Across all AEs reported in all treatment arms throughout the 12 week study, 67% started and resolved on the administration day; the median duration of AEs was 1.0 day.”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="topic-3.1.7.8.5-3"></a>

###### Anxiety and substance-induced psychotic disorder on the day of dosing

> “Four participants reported AEs of anxiety on the day of study drug administration (25 mg psilocybin, n = 2 (6.7%); 10 mg psilocybin, n = 1 (3.3%); placebo, n = 1 (3.4%))”
> “An AE of substance induced psychotic disorder was reported for a participant who became behaviourally disinhibited during the acute drug experience.”
> “After a medical assessment, 2.5 mg oromucosal midazolam was administered.”
> “The participant recovered with no sequelae and was discharged 11 h after receiving the study intervention.”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="topic-3.1.7.8.5-4"></a>

###### Suicidality on the Sheehan Suicidality Tracking Scale

> “At baseline, all participants recorded an SSTS score of 0.”
> “During follow-up, no participants in the 25 mg psilocybin arm recorded an SSTS score > 0; however, one participant in the 10 mg psilocybin arm recorded a highest score of 1 during follow-up (reported at the day 29 visit).”
> “This participant reported a TEAE of suicidal thoughts (one event), which started and resolved on day 19, was mild in severity and was deemed by the investigator to be possibly related to study drug.”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="topic-3.1.7.8.5-5"></a>

###### Laboratory tests and vital signs

> “There were four clinically significant clinical laboratory assessment findings, which were recorded as AEs (none of which prevented the participant from entering or continuing in the study).”
> “There were no clinically significant findings in vital signs.”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="heading-3.1.7.9"></a>

##### 3.1.7.9 Study Limitations

<a id="topic-3.1.7.9-1"></a>

###### Summary: healthy participants, exploratory sample size, blinding not assessed, practice effects, sponsor involvement

The study enrolled 89 healthy participants who were typically highly educated, and 37% of the sample had previous psilocybin experience; the authors state that these factors and the small sample size could have limited generalisability and that the findings warrant investigation in clinical populations. The sample size was not powered to detect statistically significant differences, and p values were not reported. Blinding efficacy was not assessed, and the authors state that participants may have been able to determine their assigned treatment group. Practice effects could have influenced results, and outcomes were measured at day 8 and at day 29 or 85. The study was funded and sponsored by COMPASS Pathways, and several authors are employees or former employees of the company.

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="topic-3.1.7.9-2"></a>

###### Exploratory design without power for efficacy comparisons

> “however, our sample size was not powered to detect statistically significant differences in psilocybin efficacy between groups.”
> “Instead, this was an exploratory evaluation of the efficacy and safety of psilocybin compared with placebo; caution should therefore be taken when interpreting these results.”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="topic-3.1.7.9-3"></a>

###### Healthy, highly educated, psilocybin-experienced sample

> “The fact that participants were typically highly educated, and the small sample size, could have limited the generalisability of results.”
> “These findings warrant further investigation in clinical populations.”
> “With thirty-five participants reporting previous use of psilocybin in this study, the proportion of participants with prior experience is greater than expected in the general population, thus additional caution should be taken when generalising these results to other populations.”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="topic-3.1.7.9-4"></a>

###### Blinding not assessed

> “The efficacy of the blinding was not assessed in this study and therefore we cannot rule out the potential that guessing the treatment assignment influenced results.”
> “Given psilocybin’s psychedelic effects, combined with the fact that 37% of the total sample had previous experience using psilocybin, it is possible that these participants may have been able to determine their assigned treatment group.”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="topic-3.1.7.9-5"></a>

###### Practice effects and assessment timepoints

> “It is possible that practice effects could have influenced results.”
> “The current study measured the short-term effects of psilocybin at day 8, and longer-term effects at day 29 or 85.”
> “Future research would benefit from collecting outcomes at later time points post-dosing to gain a broader understanding of more long-term effects, and also acutely, either immediately after or during psilocybin administration.”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="topic-3.1.7.9-6"></a>

###### Sponsor involvement

> “ML-J, LM, SM, FS, SS, SW, HE and EM are employees or former employees of COMPASS Pathways plc.”
> “This assistance was funded by COMPASS Pathways plc, London, UK.”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
